Mannkind, Game-Chancer in Sachen Diabetik? - 500 Beiträge pro Seite (Seite 12)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 1
Gesamt: 593.804
Gesamt: 593.804
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: NNFN
3,8440
EUR
-1,94 %
-0,0760 EUR
Letzter Kurs 09:30:40 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,9000 | +59,66 | |
0,6000 | +57,48 | |
1,9200 | +23,87 | |
5,4500 | +19,00 | |
5,8800 | +17,60 |
Wertpapier | Kurs | Perf. % |
---|---|---|
4,3600 | -13,49 | |
1,6900 | -14,50 | |
2,8150 | -15,21 | |
2,2900 | -17,63 | |
2,2600 | -30,25 |
TRx 641
so wird das nix
so wird das nix
Leider
Jedoch meht usd als letze woche
Jedoch meht usd als letze woche
Leider
Jedoch mehr usd als letze woche
Jedoch mehr usd als letze woche
Bleibt zu hoffen das die Internet Werbung und die Plakete noch ein wenig treiben oder die "Big News" am 07.08 verkündet werden.... sonst könnte es eng werden
5000/5000
Zeichenbeschränkung: 5000
MannKind Corporation gibt die Finanzergebnisse des zweiten Quartals 2019 und die jüngsten geschäftlichen Höhepunkte bekannt
Telefonkonferenz beginnt heute um 17:00 Uhr (MEZ)
Gesamtumsatz im 2. Quartal 2019 von 15,0 Mio. USD; + 285% gegenüber dem zweiten Quartal 2018
Afrezza erzielte im zweiten Quartal 2019 einen Nettoumsatz von 6,1 Mio. USD. + 62% gegenüber dem zweiten Quartal 2018
Der Umsatz im Bereich Collaboration and Services belief sich im 2. Quartal 2019 auf 8,9 Millionen US-Dollar
Afrezza in Brasilien zugelassen
Abschluss einer exklusiven Marketing- und Vertriebsvereinbarung mit AMSL für Australien
Abgeschlossene Fremdkapitalfinanzierung, die die bisherige gesicherte Fremdkapitalfazilität ersetzt und nicht verwässerndes Kapital in Höhe von bis zu 75 Mio. USD bereitstellt
WESTLAKE VILLAGE, Kalifornien, 7. August 2019 (GLOBE NEWSWIRE) - Die MannKind Corporation (NASDAQ: MNKD) hat heute die Finanzergebnisse für das am 30. Juni 2019 endende Quartal und das erste Halbjahr bekannt gegeben.
"Wir setzen unsere Geschäftsstrategie für Afrezza fort, die zu einem Produktwachstum von 62% gegenüber dem zweiten Quartal 2018 führte", sagte Michael Castagna, Vorstandsvorsitzender der MannKind Corporation. „Unser Partner in Brasilien, Biomm, hat die Marktzulassung für Afrezza erhalten und wird voraussichtlich in der zweiten Hälfte dieses Jahres eingeführt. Währenddessen gewinnt unsere Partnerschaft mit United Therapeutics weiter an Stärke, als wir im Juli den Abschluss des Baus einer neuen hochwirksamen Fertigungssuite in unserem Werk in Danbury feierten. “
Ergebnisse des zweiten Quartals 2019
Der Gesamtumsatz belief sich im zweiten Quartal 2019 auf 15,0 Mio. USD, was einem Nettoumsatz von 6,1 Mio. USD für Afrezza und einem Umsatz für Zusammenarbeit und Dienstleistungen von 8,9 Mio. USD entspricht. Der Nettoumsatz von Afrezza stieg um 62% gegenüber 3,8 Mio. USD im zweiten Quartal 2018, was hauptsächlich auf die höhere Produktnachfrage, eine günstigere Mischung aus Afrezza-Patronen und dem günstigeren Preis zurückzuführen ist. Der Umsatz mit Zusammenarbeit und Dienstleistungen stieg im Vergleich zum zweiten Quartal 2018 um 8,9 Millionen US-Dollar. Dies ist auf die Lizenz- und Forschungsvereinbarungen zurückzuführen, die im September 2018 mit United Therapeutics unterzeichnet wurden.
Der Bruttogewinn von Afrezza belief sich im zweiten Quartal 2019 auf 1,7 Mio. USD, was einer Steigerung von 3,1 Mio. USD oder 230% gegenüber einem Bruttoverlust von 1,3 Mio. USD im gleichen Zeitraum des Jahres 2018 entspricht. Dies ist hauptsächlich auf einen Anstieg des Nettoumsatzes von 2,3 Mio. USD zurückzuführen. Ein Rückgang des realisierten Währungsverlusts im Zusammenhang mit einem Devisenkontrakt um 0,4 Mio. USD und ein Rückgang der Abschreibungen auf Vorräte um 0,2 Mio. USD, der teilweise durch höhere Kosten aufgrund höherer Umsätze ausgeglichen wurde.
Die Aufwendungen für Forschung und Entwicklung (F & E) beliefen sich im zweiten Quartal 2019 auf USD 1,6 Mio. gegenüber USD 3,0 Mio. im zweiten Quartal 2018. Dieser Rückgang um 45% war hauptsächlich auf einen Rückgang der Ausgaben für klinische Studien um USD 0,5 Mio. und des Personals um USD 0,5 Mio. zurückzuführen Kosten.
Die Vertriebs-, allgemeinen und Verwaltungskosten (VVG-Kosten) beliefen sich im zweiten Quartal 2019 auf 16,6 Mio. USD gegenüber 21,7 Mio. USD im zweiten Quartal 2018. Dieser Rückgang von 5,1 Mio. USD oder 24% war hauptsächlich auf einen Rückgang des Personalaufwands um 2,3 Mio. USD zurückzuführen Kosten, ein Rückgang der Honorare um 1,3 Mio. USD und ein Rückgang der Marketingausgaben um 1,0 Mio. USD.
Der Zinsaufwand für Schuldverschreibungen (Verpflichtungen zur Finanzierung von Krediten und vorrangige Wandelanleihen) belief sich im zweiten Quartal 2019 auf 0,6 Mio. USD gegenüber 1,7 Mio. USD im zweiten Quartal 2018. Dieser Rückgang von 1,1 Mio. USD war hauptsächlich auf eine Verringerung der Verbindlichkeiten zurückzuführen.
Der Nettoverlust für das zweite Quartal 2019 betrug 12,4 Mio. USD oder 0,07 USD pro Aktie, verglichen mit einem Nettoverlust von 22,7 Mio. USD im zweiten Quartal 2018 oder 0,16 USD pro Aktie. Der Rückgang ist hauptsächlich auf die gestiegenen Gesamterlöse aus der höheren kommerziellen Nachfrage von Afrezza sowie aus unseren Lizenz- und Forschungsvereinbarungen mit United Therapeutics zurückzuführen.
Sechs Monate zum 30. Juni 2019
Der Gesamtumsatz belief sich in den sechs Monaten zum 30. Juni 2019 auf 32,5 Millionen US-Dollar, was einen Nettoumsatz von 11,1 Millionen US-Dollar für Zusammenarbeit und Dienstleistungen von 21,3 Millionen US-Dollar widerspiegelt. Der Nettoumsatz von Afrezza stieg um 56% gegenüber 7,2 Mio. USD im Halbjahr zum 30. Juni 2018, hauptsächlich aufgrund der höheren Produktnachfrage, einer günstigeren Mischung aus Afrezza-Patronen und dem günstigeren Preis. Der Umsatz mit Zusammenarbeit und Dienstleistungen stieg im Vergleich zum Halbjahr zum 30. Juni 2018 um 21,2 Millionen US-Dollar. Dies ist auf die Lizenz- und Forschungsvereinbarungen zurückzuführen, die im September 2018 mit United Therapeutics unterzeichnet wurden.
Der Bruttogewinn von Afrezza belief sich in den sechs Monaten zum 30. Juni 2019 auf 2,8 Mio. USD. Dies entspricht einer Steigerung von 4,7 Mio. USD oder 243% gegenüber einem Bruttoverlust von 1,9 Mio. USD im gleichen Zeitraum 2018, was hauptsächlich auf einen Anstieg des Nettoumsatzes von 4,0 Mio. USD zurückzuführen ist Ein Rückgang der Abschreibungen auf Vorräte um 0,8 Mio. USD, der teilweise durch höhere Kosten aufgrund höherer Umsätze ausgeglichen wurde.
Die F & E-Aufwendungen für das am 30. Juni 2019 endende Halbjahr beliefen sich auf 3,3 Mio. USD gegenüber 5,6 Mio. USD für das am 30. Juni 2018 endende Halbjahr. Dieser Rückgang um 41% war in erster Linie auf einen Rückgang der Personalkosten um 1,0 Mio. USD und des Personalaufwands um 0,7 Mio. USD zurückzuführen Ausgaben für klinische Studien.
Die VVG-Kosten für das am 30. Juni 2019 und am 30. Juni 2018 endende Halbjahr betrugen jeweils 42,3 Mio. USD
Zeichenbeschränkung: 5000
MannKind Corporation gibt die Finanzergebnisse des zweiten Quartals 2019 und die jüngsten geschäftlichen Höhepunkte bekannt
Telefonkonferenz beginnt heute um 17:00 Uhr (MEZ)
Gesamtumsatz im 2. Quartal 2019 von 15,0 Mio. USD; + 285% gegenüber dem zweiten Quartal 2018
Afrezza erzielte im zweiten Quartal 2019 einen Nettoumsatz von 6,1 Mio. USD. + 62% gegenüber dem zweiten Quartal 2018
Der Umsatz im Bereich Collaboration and Services belief sich im 2. Quartal 2019 auf 8,9 Millionen US-Dollar
Afrezza in Brasilien zugelassen
Abschluss einer exklusiven Marketing- und Vertriebsvereinbarung mit AMSL für Australien
Abgeschlossene Fremdkapitalfinanzierung, die die bisherige gesicherte Fremdkapitalfazilität ersetzt und nicht verwässerndes Kapital in Höhe von bis zu 75 Mio. USD bereitstellt
WESTLAKE VILLAGE, Kalifornien, 7. August 2019 (GLOBE NEWSWIRE) - Die MannKind Corporation (NASDAQ: MNKD) hat heute die Finanzergebnisse für das am 30. Juni 2019 endende Quartal und das erste Halbjahr bekannt gegeben.
"Wir setzen unsere Geschäftsstrategie für Afrezza fort, die zu einem Produktwachstum von 62% gegenüber dem zweiten Quartal 2018 führte", sagte Michael Castagna, Vorstandsvorsitzender der MannKind Corporation. „Unser Partner in Brasilien, Biomm, hat die Marktzulassung für Afrezza erhalten und wird voraussichtlich in der zweiten Hälfte dieses Jahres eingeführt. Währenddessen gewinnt unsere Partnerschaft mit United Therapeutics weiter an Stärke, als wir im Juli den Abschluss des Baus einer neuen hochwirksamen Fertigungssuite in unserem Werk in Danbury feierten. “
Ergebnisse des zweiten Quartals 2019
Der Gesamtumsatz belief sich im zweiten Quartal 2019 auf 15,0 Mio. USD, was einem Nettoumsatz von 6,1 Mio. USD für Afrezza und einem Umsatz für Zusammenarbeit und Dienstleistungen von 8,9 Mio. USD entspricht. Der Nettoumsatz von Afrezza stieg um 62% gegenüber 3,8 Mio. USD im zweiten Quartal 2018, was hauptsächlich auf die höhere Produktnachfrage, eine günstigere Mischung aus Afrezza-Patronen und dem günstigeren Preis zurückzuführen ist. Der Umsatz mit Zusammenarbeit und Dienstleistungen stieg im Vergleich zum zweiten Quartal 2018 um 8,9 Millionen US-Dollar. Dies ist auf die Lizenz- und Forschungsvereinbarungen zurückzuführen, die im September 2018 mit United Therapeutics unterzeichnet wurden.
Der Bruttogewinn von Afrezza belief sich im zweiten Quartal 2019 auf 1,7 Mio. USD, was einer Steigerung von 3,1 Mio. USD oder 230% gegenüber einem Bruttoverlust von 1,3 Mio. USD im gleichen Zeitraum des Jahres 2018 entspricht. Dies ist hauptsächlich auf einen Anstieg des Nettoumsatzes von 2,3 Mio. USD zurückzuführen. Ein Rückgang des realisierten Währungsverlusts im Zusammenhang mit einem Devisenkontrakt um 0,4 Mio. USD und ein Rückgang der Abschreibungen auf Vorräte um 0,2 Mio. USD, der teilweise durch höhere Kosten aufgrund höherer Umsätze ausgeglichen wurde.
Die Aufwendungen für Forschung und Entwicklung (F & E) beliefen sich im zweiten Quartal 2019 auf USD 1,6 Mio. gegenüber USD 3,0 Mio. im zweiten Quartal 2018. Dieser Rückgang um 45% war hauptsächlich auf einen Rückgang der Ausgaben für klinische Studien um USD 0,5 Mio. und des Personals um USD 0,5 Mio. zurückzuführen Kosten.
Die Vertriebs-, allgemeinen und Verwaltungskosten (VVG-Kosten) beliefen sich im zweiten Quartal 2019 auf 16,6 Mio. USD gegenüber 21,7 Mio. USD im zweiten Quartal 2018. Dieser Rückgang von 5,1 Mio. USD oder 24% war hauptsächlich auf einen Rückgang des Personalaufwands um 2,3 Mio. USD zurückzuführen Kosten, ein Rückgang der Honorare um 1,3 Mio. USD und ein Rückgang der Marketingausgaben um 1,0 Mio. USD.
Der Zinsaufwand für Schuldverschreibungen (Verpflichtungen zur Finanzierung von Krediten und vorrangige Wandelanleihen) belief sich im zweiten Quartal 2019 auf 0,6 Mio. USD gegenüber 1,7 Mio. USD im zweiten Quartal 2018. Dieser Rückgang von 1,1 Mio. USD war hauptsächlich auf eine Verringerung der Verbindlichkeiten zurückzuführen.
Der Nettoverlust für das zweite Quartal 2019 betrug 12,4 Mio. USD oder 0,07 USD pro Aktie, verglichen mit einem Nettoverlust von 22,7 Mio. USD im zweiten Quartal 2018 oder 0,16 USD pro Aktie. Der Rückgang ist hauptsächlich auf die gestiegenen Gesamterlöse aus der höheren kommerziellen Nachfrage von Afrezza sowie aus unseren Lizenz- und Forschungsvereinbarungen mit United Therapeutics zurückzuführen.
Sechs Monate zum 30. Juni 2019
Der Gesamtumsatz belief sich in den sechs Monaten zum 30. Juni 2019 auf 32,5 Millionen US-Dollar, was einen Nettoumsatz von 11,1 Millionen US-Dollar für Zusammenarbeit und Dienstleistungen von 21,3 Millionen US-Dollar widerspiegelt. Der Nettoumsatz von Afrezza stieg um 56% gegenüber 7,2 Mio. USD im Halbjahr zum 30. Juni 2018, hauptsächlich aufgrund der höheren Produktnachfrage, einer günstigeren Mischung aus Afrezza-Patronen und dem günstigeren Preis. Der Umsatz mit Zusammenarbeit und Dienstleistungen stieg im Vergleich zum Halbjahr zum 30. Juni 2018 um 21,2 Millionen US-Dollar. Dies ist auf die Lizenz- und Forschungsvereinbarungen zurückzuführen, die im September 2018 mit United Therapeutics unterzeichnet wurden.
Der Bruttogewinn von Afrezza belief sich in den sechs Monaten zum 30. Juni 2019 auf 2,8 Mio. USD. Dies entspricht einer Steigerung von 4,7 Mio. USD oder 243% gegenüber einem Bruttoverlust von 1,9 Mio. USD im gleichen Zeitraum 2018, was hauptsächlich auf einen Anstieg des Nettoumsatzes von 4,0 Mio. USD zurückzuführen ist Ein Rückgang der Abschreibungen auf Vorräte um 0,8 Mio. USD, der teilweise durch höhere Kosten aufgrund höherer Umsätze ausgeglichen wurde.
Die F & E-Aufwendungen für das am 30. Juni 2019 endende Halbjahr beliefen sich auf 3,3 Mio. USD gegenüber 5,6 Mio. USD für das am 30. Juni 2018 endende Halbjahr. Dieser Rückgang um 41% war in erster Linie auf einen Rückgang der Personalkosten um 1,0 Mio. USD und des Personalaufwands um 0,7 Mio. USD zurückzuführen Ausgaben für klinische Studien.
Die VVG-Kosten für das am 30. Juni 2019 und am 30. Juni 2018 endende Halbjahr betrugen jeweils 42,3 Mio. USD
Hört sich doch gut an, oder nicht?
ja , seh ich auch so
wenn jetzt noch Absatzzahlen in den USA steigen , Brasilien und Australien dazu kommen sollte es aufwärts gehen
wenn jetzt noch Absatzzahlen in den USA steigen , Brasilien und Australien dazu kommen sollte es aufwärts gehen
Antwort auf Beitrag Nr.: 61.203.551 von liquidx am 08.08.19 08:11:13in jedem Fall viel besser als erwartet und endlich einmal gewinn gemacht..das beste q-ergebnis seit langem...meiner meinung nach sollte heute ein dickes plus drin sein
2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018
º 2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018
º 2Q 2019 Collaboration and Services Revenue was $8.9 million
Afrezza approved in Brazil
Entered into exclusive marketing and distribution agreement with AMSL for Australia
Completed debt financing, which replaces previous secured debt facility and provides up to $75 million in non-dilutive capital
Genial, Bankrott vom Tisch, shorts müssen andere Lügen ausdenken, meine Kursziel 5 US Dollar in 6-12 Monaten!
º 2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018
º 2Q 2019 Collaboration and Services Revenue was $8.9 million
Afrezza approved in Brazil
Entered into exclusive marketing and distribution agreement with AMSL for Australia
Completed debt financing, which replaces previous secured debt facility and provides up to $75 million in non-dilutive capital
Genial, Bankrott vom Tisch, shorts müssen andere Lügen ausdenken, meine Kursziel 5 US Dollar in 6-12 Monaten!
langsam- ganz langsam aufwärts
wann käme denn eine KE
wenn überhaupt
wann käme denn eine KE
wenn überhaupt
Antwort auf Beitrag Nr.: 61.205.003 von price-of-success am 08.08.19 10:32:12Abwarten, Mannkind schoß vor 2 Jahren in 2 Monaten von 1 auf 6-7 Dollar, jetzt sind die Fundamentaldaten um Klassen besser, es fehlt nur noch der Zündfunke, z.B. das zusätzliche unbekannte Molekül von UTHR zur Einlizensierung, dann geht`s ab!
ja.
damals war es vor einer KE. meine ich.bisserl gepumpt eben
unterm Strich geht es jetzt ersmal weiter
und morgen ist
TGIF
damals war es vor einer KE. meine ich.bisserl gepumpt eben
unterm Strich geht es jetzt ersmal weiter
und morgen ist
TGIF
Antwort auf Beitrag Nr.: 61.205.003 von price-of-success am 08.08.19 10:32:12KE ist vom Tisch die haben mit der Umstrukturierung genug Kohle und wollen nicht weiter verwässern!
Antwort auf Beitrag Nr.: 61.205.201 von Magnetfeldfredy am 08.08.19 10:49:44verstehe nicht, warum es nicht gleich ordenrtlichen kaufdruck gibt
Liegt an den shorts imo
Im Minus, ich fass es nicht...😣
Was muß denn noch passieren, die Zahlen sind doch wirklich nicht von schlechten Eltern...😯
Diese Shorties...🤬
Was muß denn noch passieren, die Zahlen sind doch wirklich nicht von schlechten Eltern...😯
Diese Shorties...🤬
Das ist Teil des Spiels FUD streuen, genialer Q2 Bericht und gleich Kurs drücken, schaut Euch das Volumen an 700000 Stück werden benötigt um den Kurs zu deckeln, gestern nur das Doppelte am Gesamtvolumen, es brodelt, der richtige Zündfunke und es knallt, Bankrott vom Tisch 60 % Steigerungsraten, Top Pipline.......
Sie sollen verrecken die Drecksshorts!
Sie sollen verrecken die Drecksshorts!
Antwort auf Beitrag Nr.: 61.208.090 von Magnetfeldfredy am 08.08.19 15:54:30ganz ehrlich..ich glaube nicht daran, daß es an den shorts liegt..wenn genug käufer da wären
gäbe es doch einen short-squeeze..die shorts müssten dann covern, wenn allerdings nicht genug
kaufdruck aufkommt ist es natürlich einfach...beschämende und bittere kursentwicklung, normalrweise müssten wir bei 1,50 oder höher stehen..regt mich auch total auf
gäbe es doch einen short-squeeze..die shorts müssten dann covern, wenn allerdings nicht genug
kaufdruck aufkommt ist es natürlich einfach...beschämende und bittere kursentwicklung, normalrweise müssten wir bei 1,50 oder höher stehen..regt mich auch total auf
Die Longies werden bis zur Halskrause eingedeckt sein und wollen oder können nicht mehr gross nachlegen. Neue Interessenten schauen sich das Trauerspiel an trotz guten News geht's runter. Also halten die auch erstmal die Füße still und die Shorties deckeln mit ständigem Druck.
Hatte heute echt mit nem Sprung gerechnet... Pustekuchen
Hatte heute echt mit nem Sprung gerechnet... Pustekuchen
Stay long and strong, wie bei meinen Amarin von 1 auf 17,2 US Dollar!
Nach einer Stunde Handel haben wir fast das Volumen vom ganzen gestrigen Tag, die Shorts haben ganz schön zu tun, Leerverkäufe, naked shorts und auch big Pharma ist bei diesem Spiel dabei um Afrezza ja nicht hochkommen zu lassen, da kann Brasilien ein ganz anderes Spiel werden und zur erhofften Umsatz/Gewinnsteigerung beitragen, im Okober wird Afrezza offiziell eingeführt!
Antwort auf Beitrag Nr.: 61.208.477 von Magnetfeldfredy am 08.08.19 16:33:49https://www.afrezza.com/
Der Kurs käst mich echt an..Schlimm ist, daß es super Ergebnisse waren im Vgl zum Vorjahr
und wir schmieren trotzdem ab..Gar nicht auszudenken, wenn eine KE ausgerufen worden wäre oder es ein schlechtes Ergebis gekommen wäre..Dann wären wir vermutlich 15% im Minus, so nur -3%...Verkehrte Welt
und wir schmieren trotzdem ab..Gar nicht auszudenken, wenn eine KE ausgerufen worden wäre oder es ein schlechtes Ergebis gekommen wäre..Dann wären wir vermutlich 15% im Minus, so nur -3%...Verkehrte Welt
Trx 772 stand grad bei stockwits… deutlich mehr als letzte Woche
nicht schlecht
nicht schlecht
Wie geil ist das denn......
Meine 800 ante portas
Meine 800 ante portas
Wann geben die shorts auf
Ab 800 trx
Ab 900. trx
Ab 1000. trx
Oder werfen die blick auf die finanzzahlen und entscheiden
Ab
1,1 mio
1;5. mio
2, mio
Pro monat zu decken?
Mir scheint dass bei positiven news weiter geshortet wird um einen anstieg zu verhindern
Nur umso höher und steiler geht es dann nach oben
Und
Steigerung zur letzten woche sind 131 trx
Imo
Nächste woche in my dreams dann 901. trx..
Freue mich darauf.
Dyor
Ab 800 trx
Ab 900. trx
Ab 1000. trx
Oder werfen die blick auf die finanzzahlen und entscheiden
Ab
1,1 mio
1;5. mio
2, mio
Pro monat zu decken?
Mir scheint dass bei positiven news weiter geshortet wird um einen anstieg zu verhindern
Nur umso höher und steiler geht es dann nach oben
Und
Steigerung zur letzten woche sind 131 trx
Imo
Nächste woche in my dreams dann 901. trx..
Freue mich darauf.
Dyor
Ende des Monats sollten wir die 1000 überspringen....
Gestern und vorgestern hatten die Shorties schon gut zu tun im den Kurs unten zu halten.
Mit steigenden Trx Zahlen wird ihnen das immer schwerer fallen
Gestern und vorgestern hatten die Shorties schon gut zu tun im den Kurs unten zu halten.
Mit steigenden Trx Zahlen wird ihnen das immer schwerer fallen
Fehler
Pro monat zu decken?
Muss heissen. Pro woche
Pro monat zu decken?
Muss heissen. Pro woche
Antwort auf Beitrag Nr.: 61.216.526 von price-of-success am 09.08.19 16:07:08und ab Oktober kommt Brasilien noch dazu
Evtl noch die eine oder andere Meldung sollte dem Kurs doch helfen, hoffe ich
Evtl noch die eine oder andere Meldung sollte dem Kurs doch helfen, hoffe ich
irgendwann bricht der " Bann"
sind die verschreibungszahlen so schwach wegen Versichrungsfragen und Angst der Endos vor Klagen?
sagte meine Frau heute beiläufig
sind die verschreibungszahlen so schwach wegen Versichrungsfragen und Angst der Endos vor Klagen?
sagte meine Frau heute beiläufig
Antwort auf Beitrag Nr.: 61.215.644 von Kleingeldinvestor am 09.08.19 14:22:22Was sind denn TRX zahlen???
Antwort auf Beitrag Nr.: 61.217.117 von price-of-success am 09.08.19 17:03:47TRX 772 rest auf stocktwits- was just nicht geht
Week ending 8/2
TRx: 772 vs. 641
NRx: 331 vs. 285
Rev$: 1.19M vs. 1.05M
(Refills: 441 vs. 356)
from stocktwits today
TRx: 772 vs. 641
NRx: 331 vs. 285
Rev$: 1.19M vs. 1.05M
(Refills: 441 vs. 356)
from stocktwits today
vielleicht geht es wirklich mal los, bin jetzt seit Jahren Aktionär und es ist nur Frust, trotz gutem Produkt ...
Antwort auf Beitrag Nr.: 61.217.117 von price-of-success am 09.08.19 17:03:47
oder es gibt von den "Piekser-Vertretern" derzeit ein schönes Goodie fürs verschreiben
Zitat von price-of-success: irgendwann bricht der " Bann"
sind die verschreibungszahlen so schwach wegen Versichrungsfragen und Angst der Endos vor Klagen?
sagte meine Frau heute beiläufig
oder es gibt von den "Piekser-Vertretern" derzeit ein schönes Goodie fürs verschreiben
sieht so aus... https://stocktwits.com/symbol/MNKD
Würde mal Zeit, der Kurs ist ja mehr als zum Kotzen!
Antwort auf Beitrag Nr.: 61.273.338 von Magnetfeldfredy am 16.08.19 10:19:30Bin mal auf die Zahlen nachher gespannt
TRx 622
NRx 249
Rifills 373
NRx 249
Rifills 373
So wird das nix
Antwort auf Beitrag Nr.: 61.274.940 von Muckimann66 am 16.08.19 12:32:11ohwe
Wenn heut sonst nix kommt geht's aber mal deutlich unter 1$
Wenn heut sonst nix kommt geht's aber mal deutlich unter 1$
vielleicht war letzte Woche Ostern, Weihnachten und Thanksgiving - daher so wenig Verkäufe ?
Ist schon ätzend wie langsam das alles vorwärts geht
Ist schon ätzend wie langsam das alles vorwärts geht
2 Schritte vor, einen zurück!
Durchschnittliches Volumen und kaum Kursbewegung im Amiland
Die Shorties zeigen sich großzügig und halten den Kurs über 1 $
Denke sie wollen sich ihren "Spielball" nicht selber wegnehmen ?
Die Shorties zeigen sich großzügig und halten den Kurs über 1 $
Denke sie wollen sich ihren "Spielball" nicht selber wegnehmen ?
Steile Thesen ...
Veröffentlicht MNKD eigentlich NICHT die Anzahl der Patienten,
die Afrezza länger als 1 Jahr, 2 Jahre etc. nehmen?
Antwort auf Beitrag Nr.: 61.282.599 von tippse am 17.08.19 19:09:27 Ich hoffe er macht einen Denkfehler, ansonsten wäre das ja wirklich schlimm - nur 6% die auf afrezza bleiben
das hatte ich neulich schonmal gesehen....
gibt wirklich zu denken, meine Euphorie legt sich auch langsam. Sollte sie nochmal einen Sprung machen überlege ich auszusteigen
gibt wirklich zu denken, meine Euphorie legt sich auch langsam. Sollte sie nochmal einen Sprung machen überlege ich auszusteigen
Potentielle Katalysatoren für die nahe Zukunft, lassen mich sicher nicht aussteigen:
lots of imminent potential catalysts for a massive move per the most recent CC:
-TreT Phase III and milestone
-UTHR decision on new, mystery “consumer, mass market” molecule
-Brazil Afrezza shipment
-RLS update
-Epi?
lots of imminent potential catalysts for a massive move per the most recent CC:
-TreT Phase III and milestone
-UTHR decision on new, mystery “consumer, mass market” molecule
-Brazil Afrezza shipment
-RLS update
-Epi?
Antwort auf Beitrag Nr.: 61.295.875 von Magnetfeldfredy am 20.08.19 08:13:55...drück dir die daumen, aber ewig kann man auch nicht ausharren.
Schade hatte von Mannkind grosse erwartet, aber das Management hat komplett versagt, aber ganzer linie.
Schade hatte von Mannkind grosse erwartet, aber das Management hat komplett versagt, aber ganzer linie.
Antwort auf Beitrag Nr.: 61.302.430 von sir1 am 20.08.19 19:03:26.......nur noch aetzend
Hoffe MC haut die Tage noch ne Nachricht raus um den $ zu halten..
beim nächsten Hupps bin ich erstmal raus hier
beim nächsten Hupps bin ich erstmal raus hier
TRX 705.... nicht berauschend
Aber 1,2 Millionen US Dollar revenues pro Woche mit 75 Vetrieblern, wenn da ein großer Pharmakonzern mit über 1000 Vertrieblern einsteigt gehts up.........
Trx 750
Letzte woche
1,11 mio
Zähe sache
Zahlen stocktwits heute
Letzte woche
1,11 mio
Zähe sache
Zahlen stocktwits heute
von 705 auf 750 nicht schlecht, das wird noch!
Nochmals aus www.stocktwits.com:
Scripts week ending 8/30/2019
TRx 750 vs. 705
NRx 349 vs. 327
Rev $1.11 Ml vs. $1.2 Ml
(Refills) 401 vs. 378
Expect dip for next weeks #’s (Labor Day)
Scripts week ending 8/30/2019
TRx 750 vs. 705
NRx 349 vs. 327
Rev $1.11 Ml vs. $1.2 Ml
(Refills) 401 vs. 378
Expect dip for next weeks #’s (Labor Day)
Leute
Ich hoffe so auf 800
Ich hoffe so auf 800
Ob 800 oder 700, hier zählt der Langfristerfolg und der wird kommen mit lächerlichen 80 Vetrieblern 1,2 Millionen Umsatz US Dollar pro Woche schaffen, Hut ab, das ist erst der Anfang meiner Meinung nach.
Es wird im nächsten Jahr eine entscheidende Labelverbesserung geben (Black Box Warnung wird aufgehoben)und Afrezza durchstarten,
2 Millionen pro Woche Umsatz prognostiziere ich in einem Jahr dazu neue Technosphere Verträge und Mannkind bei 5 US Dollar!
Es wird im nächsten Jahr eine entscheidende Labelverbesserung geben (Black Box Warnung wird aufgehoben)und Afrezza durchstarten,
2 Millionen pro Woche Umsatz prognostiziere ich in einem Jahr dazu neue Technosphere Verträge und Mannkind bei 5 US Dollar!
Antwort auf Beitrag Nr.: 61.380.200 von Magnetfeldfredy am 30.08.19 16:48:44
Mögest du recht haben!
Andererseits: das hatten wir ja bereits mit durchschlagendem Erfolg - nach unten!
Insofern sollte man aufpassen, was man sich wünscht...
Wünsche Mannkind trotzdem viel Erfolg! Wie auch immer!
Einen Grund zum Wiedereinstieg sehe ich (leider) noch nicht.
Grüßle
Randfontein
Kurzzeitgedächtnis
Zitat von Magnetfeldfredy: Aber 1,2 Millionen US Dollar revenues pro Woche mit 75 Vetrieblern, wenn da ein großer Pharmakonzern mit über 1000 Vertrieblern einsteigt gehts up.........
Mögest du recht haben!
Andererseits: das hatten wir ja bereits mit durchschlagendem Erfolg - nach unten!
Insofern sollte man aufpassen, was man sich wünscht...
Wünsche Mannkind trotzdem viel Erfolg! Wie auch immer!
Einen Grund zum Wiedereinstieg sehe ich (leider) noch nicht.
Grüßle
Randfontein
Antwort auf Beitrag Nr.: 61.438.490 von Randfontein am 08.09.19 21:48:05Abwarten, Sanofi hat MannKind mit Afrezza nach dem CEO Wechsel boykottiert, und MannKind ist kein ohne Trick Pony mehr, UTHR Deal mit imminent upddates🤠
Hast recht bei den trx geht es mir um psychologische wirkung als zeichen dafür es geht aufwärts
Mehr bedeutung hat natürlich das zahlenwerk
Irgendwann werden shorts nervös
Imo
Mehr bedeutung hat natürlich das zahlenwerk
Irgendwann werden shorts nervös
Imo
Knapp 1,40$, so hoch wie seit Mai nicht mehr...und keiner ist mehr hier?! 😋😉
Antwort auf Beitrag Nr.: 61.461.683 von Stoxtrayder am 11.09.19 19:14:58ich bin da, seit Jahren, und freue mich nach langer Zeit mal wieder.
Bin aber skeptisch, ob es hält ...
Bin aber skeptisch, ob es hält ...
Gibt es einen besonderen Grund für den Anstieg?
Hat jemand Infos?
Hat jemand Infos?
Antwort auf Beitrag Nr.: 61.462.181 von Apollonius am 11.09.19 20:18:15hab nichts gefunden, daher denke ich ja, ev. ein Strohfeuer.
Aber solange es steigt, will ich nicht meckern ...
Aber solange es steigt, will ich nicht meckern ...
Shortie-Strohfeuer...?! 😜
Ich kann’s jedenfalls schon ein wenig riechen, ihr auch?! 😏
Jetzt noch ein wenig Spiritus in Form von guten News und wir stehen bei 2$ und mehr... 🔥
Ich kann’s jedenfalls schon ein wenig riechen, ihr auch?! 😏
Jetzt noch ein wenig Spiritus in Form von guten News und wir stehen bei 2$ und mehr... 🔥
Mannkind is so kraß unterbewertet, das beste ultra rapid actin mealtime insulin, Afrezza, ohne Nadeln, die Technosphere Technologie, Umschuldung gelungen......alles unter 2-3 Dollar ist ein Witz!
Antwort auf Beitrag Nr.: 61.462.835 von Magnetfeldfredy am 11.09.19 21:37:23https://alphastocknews.com/mannkind-mnkd-stock-pops-on-unite…
MannKind (MNKD) Stock Pops On United Therapeutics News
By
Joshua Rodriguez -
September 11, 2019 0
MannKind MNKD Stock News
MannKind Corporation (NASDAQ: MNKD) is headed up in the market this morning, trading on gains of more than 8%. However, I believe that once the reason for the gains really hits the mainstream, we’re going to see quite a bit more movement.
If you do some digging, you’ll see that the company hasn’t issued any press releases or SEC filings. In fact, the company hasn’t released anything, but it’s partner, United Therapeutics (NASDAQ: UTHR), has. Here’s what’s happening:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
UTHR News Sends MNKD Stock Up
In a press release issued this morning, United Therapeutics Corporation said that the FDA has accepted the New Drug Application for Trevyent for review. It is hoped that the drug will be approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). So, what does this have to do with MannKind?
A while ago, MNKD and UTHR announced an agreement. Under the terms of the agreement, United Therapeutics would test the company’s Technosphere technology to create an inhalable powder version of Trevyent.
Importantly, the clinical trial, assessing the inhalable version of Trevyent was expected to begin in August of this year, according to ClinicalTrials.gov. While we haven’t heard any news associated with the trial initiation, this is likely around the corner.
Considering the fact that the FDA has accepted the NDA for Trevyent, UTHR is well on its way to earning an approval. Should the drug be approved, for the inhaled version of it to receive approval, MNKD and UTHR will only need to show that the drug is safely and effectively deliverable through this vehicle, setting the stage for MannKind to earn milestone and royalty payments associated with it.
Investors Haven’t Caught Up To The News
Because MannKind had nothing to do with the news issued today, it seems as though investors haven’t quite caught up. Those searching are finding little to nothing as a reason for the gains.
Nonetheless, when the masses see that a NDA was acceped by the FDA surrounding a drug that MNKD and UTHR are working on together. Should an approval take place, the opportunity here is going to be massive. So, keep an eye and try to beat the masses to the jump.
By
Joshua Rodriguez -
September 11, 2019 0
MannKind MNKD Stock News
MannKind Corporation (NASDAQ: MNKD) is headed up in the market this morning, trading on gains of more than 8%. However, I believe that once the reason for the gains really hits the mainstream, we’re going to see quite a bit more movement.
If you do some digging, you’ll see that the company hasn’t issued any press releases or SEC filings. In fact, the company hasn’t released anything, but it’s partner, United Therapeutics (NASDAQ: UTHR), has. Here’s what’s happening:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
UTHR News Sends MNKD Stock Up
In a press release issued this morning, United Therapeutics Corporation said that the FDA has accepted the New Drug Application for Trevyent for review. It is hoped that the drug will be approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). So, what does this have to do with MannKind?
A while ago, MNKD and UTHR announced an agreement. Under the terms of the agreement, United Therapeutics would test the company’s Technosphere technology to create an inhalable powder version of Trevyent.
Importantly, the clinical trial, assessing the inhalable version of Trevyent was expected to begin in August of this year, according to ClinicalTrials.gov. While we haven’t heard any news associated with the trial initiation, this is likely around the corner.
Considering the fact that the FDA has accepted the NDA for Trevyent, UTHR is well on its way to earning an approval. Should the drug be approved, for the inhaled version of it to receive approval, MNKD and UTHR will only need to show that the drug is safely and effectively deliverable through this vehicle, setting the stage for MannKind to earn milestone and royalty payments associated with it.
Investors Haven’t Caught Up To The News
Because MannKind had nothing to do with the news issued today, it seems as though investors haven’t quite caught up. Those searching are finding little to nothing as a reason for the gains.
Nonetheless, when the masses see that a NDA was acceped by the FDA surrounding a drug that MNKD and UTHR are working on together. Should an approval take place, the opportunity here is going to be massive. So, keep an eye and try to beat the masses to the jump.
Antwort auf Beitrag Nr.: 61.463.057 von Magnetfeldfredy am 11.09.19 22:09:30Hört sich doch gut an der Bericht, wenn das klappt gehts steil oder???
Die nächsten Milestones von UTHR sind dadurch gesichert und bei Zulassung niedrige zweistellige Prozente vom Umsatz, das könnte eine Cash-cow werden mit bis zur 50 Millionen pro Jahr für Mannkind!
Antwort auf Beitrag Nr.: 61.464.161 von Magnetfeldfredy am 12.09.19 07:45:20.....whats going on MANNKIND...................wer kauft, wer wird gegrillt.....
gibt doch keine neuen news, umsatzzahlen weiter verhalten ??????????????????????????????????????????????????????????????😤😤😤😤😤😤😤😤😤🤢🤔🤣😎🤔
gibt doch keine neuen news, umsatzzahlen weiter verhalten ??????????????????????????????????????????????????????????????😤😤😤😤😤😤😤😤😤🤢🤔🤣😎🤔
1,50$-Marke heute schon mal angetastet...
Das sind Witzkurse, wartet bis ein nächster großer Partner für die Technosphere Technologie ala UTHR kommt, dann gibt den short squezzzzzzzzzzzzzzzzzzzzeeeeeeeeeeeeeeeeeee!
TRx 615
NRx 268
Refillls 347
Von stockwits
NRx 268
Refillls 347
Von stockwits
neil36
Sep 13th, 12:44 pm
$MNKD
$1674 per script — the revenue per script is still in an up trend. Year ago revenue per script was $1325.
Labor Day week revenue this year ($1.03m) is up 52% over last year ($677k)
TRx 615 for $1.03 million
NRx 268
Refills 347
Sep 13th, 12:44 pm
$MNKD
$1674 per script — the revenue per script is still in an up trend. Year ago revenue per script was $1325.
Labor Day week revenue this year ($1.03m) is up 52% over last year ($677k)
TRx 615 for $1.03 million
NRx 268
Refills 347
Gar nicht so schlecht mit den paar Vertrieblern!
Wird schon mal sehen ob die scripts in den nächsten Wochen steigen, bin optimistisch ( schon seit Jahren) 😁
Antwort auf Beitrag Nr.: 61.477.346 von Muckimann66 am 13.09.19 13:15:00....eine zockerbude, spielball von wem auch immer.......
....einfach nur bull shit
....einfach nur bull shit
Ohne Worte
Ich seit fast einem Jahrzehnt als Gründer dieses Threads.
Antwort auf Beitrag Nr.: 61.483.013 von Magnetfeldfredy am 14.09.19 09:09:52....eigentlich kann man sich hier nur besaufen.......wenn der alte das noch mitbekommen würde, wie die Firma langsam gegen die Wand gefahren wird......trauig, trauig,
Deine Meinung, nicht meine, abwarten.........
Antwort auf Beitrag Nr.: 61.492.844 von sir1 am 16.09.19 13:12:22
Bin hier ja bekannt skeptisch,
aber die Foristen hier haben es echt nicht verdient, so angemacht zu werden.
Auch wenn ich deine Reaktion nachvollziehen kann.
So richtig vorwärts bringt dein Kommentar keinen - investiert oder nicht...
Schneide zum Frustabau doch lieber meine Büsche
Zitat von sir1: ....eigentlich kann man sich hier nur besaufen.......wenn der alte das noch mitbekommen würde, wie die Firma langsam gegen die Wand gefahren wird......trauig, trauig,
Bin hier ja bekannt skeptisch,
aber die Foristen hier haben es echt nicht verdient, so angemacht zu werden.
Auch wenn ich deine Reaktion nachvollziehen kann.
So richtig vorwärts bringt dein Kommentar keinen - investiert oder nicht...
Schneide zum Frustabau doch lieber meine Büsche
Antwort auf Beitrag Nr.: 61.494.884 von Randfontein am 16.09.19 17:01:12Wie kann man mit einem so einzigartigem Produkt keinen Durchbruch am Markt schaffen?
Antwort auf Beitrag Nr.: 61.509.224 von sir1 am 18.09.19 10:52:43Die große Pleite war die Zusammenarbeit mit Sanofi, bzw. der CEO, weiß den Namen nicht mehr wollte voll auf Afrezza setzen und wurde kurz nach der Zusammenarbeit mit Mannkind entlassen!
Der neue CEO von Sanofi war der Exubera Manager, Exubera floppte und Afrezza war von Anfang an unter dem neuen CEO zum Scheitern verurteilt!
Es ist nicht einfach gegen big pharma zu Bestehen, Novo...., aber trotz vieler Managerfehler macht Mannkind pro Woche 1 Million revenues und das wird bald mehr werden, Qualität setzt sich durch!
Die Technosphere Technologie hat uns mit dem UTHR 105 Millionen Deal vom Bankrott bewahrt, mehr Deals werden dort folgen und Afrezza wird den Druchbruch im Laufe der Zeit schaffen, 1-2 Jahre!
Kursziel 5-10 US Dollar in den nächsten 2 Jahren!
Der neue CEO von Sanofi war der Exubera Manager, Exubera floppte und Afrezza war von Anfang an unter dem neuen CEO zum Scheitern verurteilt!
Es ist nicht einfach gegen big pharma zu Bestehen, Novo...., aber trotz vieler Managerfehler macht Mannkind pro Woche 1 Million revenues und das wird bald mehr werden, Qualität setzt sich durch!
Die Technosphere Technologie hat uns mit dem UTHR 105 Millionen Deal vom Bankrott bewahrt, mehr Deals werden dort folgen und Afrezza wird den Druchbruch im Laufe der Zeit schaffen, 1-2 Jahre!
Kursziel 5-10 US Dollar in den nächsten 2 Jahren!
Antwort auf Beitrag Nr.: 61.512.245 von Magnetfeldfredy am 18.09.19 15:49:02Genau so wird es kommen hast recht.
Afrezza überlegen:
MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
GlobeNewswire•September 19, 2019
WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain.
Oral Abstract 183: Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog
MannKind investigators reported data1 from more than 500 patients with type 1 diabetes comparing Afrezza to rapid-acting injected insulin analog (insulin aspart) therapy to assess glucose control, mealtime glucose changes, Afrezza dosing, and rates of hypoglycemia over a one-year period.
Oral Abstract Presentation Highlights:
When compared to injected insulin aspart, Afrezza provided significantly better glucose control in the first two hours following a standardized meal.
Titration of Afrezza to approximately 1.5 to 2 times the unit dose of injected insulin aspart resulted in significantly lower post-meal glucose excursions and was associated with lower rates of overall and level 2 hypoglycemia—an observation that was particularly evident in the late (>2 hour) post-meal period.
Dr. Anne Peters, Clinical Professor of Medicine at the Keck School of Medicine at USC and Director of the USC Westside Center for Diabetes Care noted that “the improved post-meal glucose levels and lower rates of low blood sugars seen in this study of individuals with type 1 diabetes support my growing clinical experience. The presentation of these data provides further evidence that proper dosing of Afrezza has the potential to safely and effectively keep more patients within the target glucose range at meal times.”
These data provide additional evidence supporting the safe and effective use of Afrezza in type 1 diabetes patients and offer insight into the dosing of this ultra rapid-acting insulin as compared to a traditional rapid-acting injected insulin analog.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s quarterly report on Form 10-Q for the quarter ended June 30, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contact:
Rose Alinaya
Investor Relations
818-661-5000
ir@mannkindcorp.com
Appendix – Presentation Information
(1) Oral Presentation: Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog
Presenter: David M. Kendall, M.D.
Presentation No: 183
Date/Time: Thursday, September 19, 2019; 2:30 PM
Contact:
MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
GlobeNewswire•September 19, 2019
WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain.
Oral Abstract 183: Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog
MannKind investigators reported data1 from more than 500 patients with type 1 diabetes comparing Afrezza to rapid-acting injected insulin analog (insulin aspart) therapy to assess glucose control, mealtime glucose changes, Afrezza dosing, and rates of hypoglycemia over a one-year period.
Oral Abstract Presentation Highlights:
When compared to injected insulin aspart, Afrezza provided significantly better glucose control in the first two hours following a standardized meal.
Titration of Afrezza to approximately 1.5 to 2 times the unit dose of injected insulin aspart resulted in significantly lower post-meal glucose excursions and was associated with lower rates of overall and level 2 hypoglycemia—an observation that was particularly evident in the late (>2 hour) post-meal period.
Dr. Anne Peters, Clinical Professor of Medicine at the Keck School of Medicine at USC and Director of the USC Westside Center for Diabetes Care noted that “the improved post-meal glucose levels and lower rates of low blood sugars seen in this study of individuals with type 1 diabetes support my growing clinical experience. The presentation of these data provides further evidence that proper dosing of Afrezza has the potential to safely and effectively keep more patients within the target glucose range at meal times.”
These data provide additional evidence supporting the safe and effective use of Afrezza in type 1 diabetes patients and offer insight into the dosing of this ultra rapid-acting insulin as compared to a traditional rapid-acting injected insulin analog.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s quarterly report on Form 10-Q for the quarter ended June 30, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contact:
Rose Alinaya
Investor Relations
818-661-5000
ir@mannkindcorp.com
Appendix – Presentation Information
(1) Oral Presentation: Technosphere Insulin Provides Better Early Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog
Presenter: David M. Kendall, M.D.
Presentation No: 183
Date/Time: Thursday, September 19, 2019; 2:30 PM
Contact:
TRx 703
NRx 314
Refillls 389
Stocktwits
NRx 314
Refillls 389
Stocktwits
Danke. Wo bleibt bloss trx 800.....
Da bin ich auch mal gespannt. Vielleicht nächstes Jahr???
Antwort auf Beitrag Nr.: 61.521.986 von Magnetfeldfredy am 19.09.19 15:09:47....ist doch nix neues, dass Insulin schneller wirkt oder..
Falsch, mit Afrezza haben die Diabetiker nicht nur eine schnellere Lösung sondern auch eine optimale, keine Hypos......
Wir brauchen einen neuen big pharma Partner sonst dümpel wir trotz allen guten Nachrichten weiter dahin.......
Wir brauchen einen neuen big pharma Partner sonst dümpel wir trotz allen guten Nachrichten weiter dahin.......
Antwort auf Beitrag Nr.: 61.533.578 von Magnetfeldfredy am 20.09.19 18:26:17...2004 boersengang .....und jetzt 2019 und immer noch mau, mau
15 JAHRE and for what
15 JAHRE and for what
Heute übrt 800?..
Antwort auf Beitrag Nr.: 61.579.887 von price-of-success am 27.09.19 04:37:24Ob mehr oder weniger als 800 Treatments wird keine Rolle spielen, es wird immer zu wenig sein. Ohne Partner wird das nichts
Ich hoffte zumindest auf kleine fortschritte beim trx um eine richtung zu erkennen
Oh mann wie frustrierend
Bedarf es an mehr pharmavertetern..
Oh mann wie frustrierend
Bedarf es an mehr pharmavertetern..
Antwort auf Beitrag Nr.: 61.587.255 von price-of-success am 27.09.19 22:13:0715 years for what........MANNKIND
KILL the Management
KILL the Management
881..... buuuuuuummmmm
Über 30 % Steigerung, super, Wochenrevenues bald bei 1,5 Millionen, das könnte bald mit der zu erwartentenden Brasilienlieferung den von mir propezeiten Short-Squeeeeeeeeeeeeeeezzzzzzzze
auslösen, go Mannkind go, fuck the shorts!
auslösen, go Mannkind go, fuck the shorts!
Wunderbar. Cool. Fast 900. wie geht das
Bald werden shorts nervöser und covern
Geil so geil
Irre gute Zahlen
Bald werden shorts nervöser und covern
Geil so geil
Irre gute Zahlen
Wunderbar. Cool. Fast 900. wie geht das
Bald werden shorts nervöser und covern
Geil so geil
Irre gute Zahlen
Das sind summa summarum ca 3 mehr pro aussendienstler
Bald werden shorts nervöser und covern
Geil so geil
Irre gute Zahlen
Das sind summa summarum ca 3 mehr pro aussendienstler
Antwort auf Beitrag Nr.: 61.623.720 von Magnetfeldfredy am 04.10.19 11:22:06Gut Ding braucht Weile, ist halt so.!
SUPER Zahlen hoffe es geht weiter so, mal sehen wie es nächste Woche aussieht
Wie lässt sich ergründen bei es sich um us scripts handelt und nich zb brasilien dabei ist
Die Kampagne wirkt, Afrezza ist zudem das beste und schnellste Meal-Time Insulin!
Mannkind ist nicht mehr von der Pleite bedroht, die Umschuldung lässt die shorts diese Karte nicht mehr spielen, die Verschreibungen steigen an, wenn auch immer wieder mit Rücksetzern, dazu die Technosphere Platform mit dem 105 Millionen US $ UTHR Deal, das ist eine 5 US Dollar Aktie!
Wir bräuchten noch einen weiteren Trigger, z.B. das innhalierbare EPI wird zu ähnlichen Bedingungen auslizensiert, dann gehts schnell, yes we hope!
Wir bräuchten noch einen weiteren Trigger, z.B. das innhalierbare EPI wird zu ähnlichen Bedingungen auslizensiert, dann gehts schnell, yes we hope!
Die ultra-longies hätten es mal verdient, wäre schön, wenn die Story noch ein happy-end bekommt
Jahrelanger stress verdient belohnung
genau, und es sieht nicht allzu schlecht aus, auch das Volumen ist ordentlich.
@: have a nice week-end!
@: have a nice week-end!
Antwort auf Beitrag Nr.: 61.627.695 von questionmark am 04.10.19 19:30:54Las heute anzahl shot aktien. 38.000.000
Kann das stimmen.dann wäre ordentlich potential für anstieg vorhanden
Kann das stimmen.dann wäre ordentlich potential für anstieg vorhanden
Short. Aktien
Na ja, die shorts sind noch lange nicht am Ende, wie man gestern sah, dier große Anstieg ist wieder verpufft, aber was zählt ist der immense Anstieg der Verschreibungen für Afrezza und der ist entscheidend und wird, wenn`s so weitergeht, zu deutlichen Kurssteigerungen führen!
Erklärung des immensen Scriptanstiegs:
lungbiotech
Oct 5th, 11:07 pm
$MNKD Reposting MC explanation on scripts increase:
‘Yes we retrained our reps on some key areas for improving our marketing messages over past two weeks and focused them even more on priority accounts. We see when they come out of the field for vacation or training scripts slow and when they are out there they grow. Afrezza is very responsive to promotion.
We have pretty much a full team now so Q4 should show you what MannKind can do with a fully focused field team executing the right message at the the right frequency.’
Das läßt hoffen!
lungbiotech
Oct 5th, 11:07 pm
$MNKD Reposting MC explanation on scripts increase:
‘Yes we retrained our reps on some key areas for improving our marketing messages over past two weeks and focused them even more on priority accounts. We see when they come out of the field for vacation or training scripts slow and when they are out there they grow. Afrezza is very responsive to promotion.
We have pretty much a full team now so Q4 should show you what MannKind can do with a fully focused field team executing the right message at the the right frequency.’
Das läßt hoffen!
trotzdem wird es kumulativ nicht deutlich mehr, man müsste doch annehmen, dass die user dabei bleiben, das ist Sache der Diabetologen, die pts bei der Stange zu halten, und das funktioniert nicht so gut.
Die reps sollten die neuen Verschreibungen boosten, das hilft aber nur wenig, wenn die pts nicht dauerhaft dabei bleiben.
Die Diskussion gab es doch neulich schon mal, gab es da Erklärungen ?
Die reps sollten die neuen Verschreibungen boosten, das hilft aber nur wenig, wenn die pts nicht dauerhaft dabei bleiben.
Die Diskussion gab es doch neulich schon mal, gab es da Erklärungen ?
Antwort auf Beitrag Nr.: 61.632.600 von questionmark am 06.10.19 10:08:12Wenn die Patienten einen Mehrwert bei diesem Präparat erkennen, dann werden sie es auch dauerhaft nutzen.
Mehr braucht man da nicht rein interpretieren, das kann dann auch kein Arzt schön reden.
Mehr braucht man da nicht rein interpretieren, das kann dann auch kein Arzt schön reden.
Werbung wird immer besser!
Antwort auf Beitrag Nr.: 61.633.878 von Magnetfeldfredy am 06.10.19 18:18:02Ja, es hat eine Menge Vorteile gegenüber der Spritzenversion---sollte sich also langfristig durchsetzen 🙂
Antwort auf Beitrag Nr.: 61.635.642 von pegasusorion am 07.10.19 09:10:14-...du hast recht mit deinem Kommentar........lannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnngfristig,.....aber nicht unendlich
🤠😎😎😎😎😎💡💩🏧
🤠😎😎😎😎😎💡💩🏧
Bin ja mal gespannt was für Zahlen heute kommen, bleibt es bei über 800 oder geht es noch höher
Ich hoffe. Endlich 1000 trx
Fürchte eher 700. oder ähnlich wg quartalsende?..
Fürchte eher 700. oder ähnlich wg quartalsende?..
ja ich denke auch um die 700 ( hoffe natürlich auf mehr)
sollte es bei ca 700 bleiben wird der Kurs deutlich nachgeben. Das wären dann wiederum Nachkauf- oder Einstiegskurse.
Also bleibe ich entspannt und harre den Dingen die da kommen.
sollte es bei ca 700 bleiben wird der Kurs deutlich nachgeben. Das wären dann wiederum Nachkauf- oder Einstiegskurse.
Also bleibe ich entspannt und harre den Dingen die da kommen.
TRX$ 1.312m$ (1.412m$)
TRX 758 (881)
NRX 360 (462)
Refills 398 (419)
TRX 758 (881)
NRX 360 (462)
Refills 398 (419)
warum der starke anstieg letzte woche auf 881
was war der Grund uns warum läßt sich das nicht wiederholen?
was war der Grund uns warum läßt sich das nicht wiederholen?
Ich verfolge Mannkind schon lange und bin immer wieder überrascht, warum es nicht wirklich klappt. Sie haben doch ein wirklich gutes Produkt und sind auch keine OTC Klitsche. Aber es gibt immer wieder Dinge wie "MannKind- Conflicts And Misperception Over Bioavailability And The Correct Status For The Clinical Trial For Tre-T Has Created Self-Inflected Confusion"....und so gibt es zwar ein "Buy" aber verbunden mit hohem Risiko. Sehe ich ähnlich. Irgendwann ja, aber irgendwann braucht eine Zahl, sonst geht irgendwann nix mehr
Habs vergessen - übersetzt von https://seekingalpha.com/article/4296437-mannkind-conflicts-…
Obwohl Mannkinds Partner United Therapeutics erklärte, dass sein PAH-Kandidat für die klinischen Tests der Phase 3 bereit sei, startete er überraschenderweise eine Phase-1b-Studie.
Es besteht die Gefahr von Investorenverwirrung darüber, wie viel Prozent der Afrezza die Lunge des Patienten erreichen.
Nachdem ich die Gelegenheit genutzt habe, MannKind direkt zu kontaktieren und eine Antwort erhalten habe, habe ich mir neue Meinungen über die MannKind-Geschichte gebildet, die ich hier mitteilen werde.
Das berühmte Zitat von Apollo 13 umschreiben - Äh! Mannkind Investoren, Sie haben ein Problem
Obwohl Mannkinds Partner United Therapeutics erklärte, dass sein PAH-Kandidat für die klinischen Tests der Phase 3 bereit sei, startete er überraschenderweise eine Phase-1b-Studie.
Es besteht die Gefahr von Investorenverwirrung darüber, wie viel Prozent der Afrezza die Lunge des Patienten erreichen.
Nachdem ich die Gelegenheit genutzt habe, MannKind direkt zu kontaktieren und eine Antwort erhalten habe, habe ich mir neue Meinungen über die MannKind-Geschichte gebildet, die ich hier mitteilen werde.
Das berühmte Zitat von Apollo 13 umschreiben - Äh! Mannkind Investoren, Sie haben ein Problem
75 % der kunden stoppen die verwendung von afrezza steht im artikel
das ist extrem hoch- frage
warum??
und
das neue therapeutics product kommt erst in 2022? den part verstehe ich nicht
mannkind. do we have a problem?? haben die 39 millionen shorts doch recht??
das ist extrem hoch- frage
warum??
und
das neue therapeutics product kommt erst in 2022? den part verstehe ich nicht
mannkind. do we have a problem?? haben die 39 millionen shorts doch recht??
Antwort auf Beitrag Nr.: 61.711.356 von price-of-success am 17.10.19 10:23:45Könnte mit den Problemen der THC-Inh. Produkten in den USA zu tun haben, die gerade für Probleme sorgen???
Sind aber 2 völlig verschiedene Paar Schuhe, genauso E-Zigaretten das Liquid hat damit auch nix zu tun oder?
Sind aber 2 völlig verschiedene Paar Schuhe, genauso E-Zigaretten das Liquid hat damit auch nix zu tun oder?
An alle Basher.....das Warten wird sich lohnen, wir werden bald 1000 Rezepte pro Woche haben und 1,5 Millionen revenues pro Woche!
die Zahlen sagen schon eindeutig, dass viele wieder abspringen, und es wäre interessant die Gründe zu erfahren.
die neuen Verschreibungen zu den Wieder-Verschreibungen müsste doch ein ganz anderes Verhältnis haben, 1:10 oder so mindestens
die neuen Verschreibungen zu den Wieder-Verschreibungen müsste doch ein ganz anderes Verhältnis haben, 1:10 oder so mindestens
Da heute Freitag ist. Trx für letzte Woche jemand??
16:17 MannKind initiated at Cantor Fitzgerald Cantor Fitzgerald starts MannKind at Overweight as Afrezza uptake gains traction. As previously reported, Cantor Fitzgerald analyst Brandon Folkes initiated coverage of MannKind (MNKD) with an Overweight rating and $3.00 price target. Initial expectations for Afrezza, the company's inhaled insulin, were unrealistic, but he believes expectations have been adequately reset, Folkes said. Since receiving Afrezza back from Sanofi (SNY), uptake has been steadily gaining traction, the analyst added.
Read more at:
https://thefly.com/landingPageNews.php?id=2980962
Read more at:
https://thefly.com/landingPageNews.php?id=2980962
From Proboards:
week ending 10/18:
TRX 712 (767)
NRX 369 (394)
Refills 343 (373)
TRx $1.164mn$ (1.318mn$)
week ending 10/18:
TRX 712 (767)
NRX 369 (394)
Refills 343 (373)
TRx $1.164mn$ (1.318mn$)
wird einfach net besser bzw viel zu langsam...
ohne positive News wird das nix....
ohne positive News wird das nix....
Das war eine 4 Tage Woche
In voller 5 tage woche hätten es ergo 890 werden können
Denke das Problem sind die "Refills"... die Kunden scheinen nicht zufrieden zu sein und das ist kein gutes Zeichen.
Na ja..unter 1,10€ werd ich wieder einsteigen... traden kann man die immer.. News sind überfällig und dann bei 1,30 bis 1,40 wider raus
Na ja..unter 1,10€ werd ich wieder einsteigen... traden kann man die immer.. News sind überfällig und dann bei 1,30 bis 1,40 wider raus
Antwort auf Beitrag Nr.: 61.774.355 von Kleingeldinvestor am 27.10.19 08:25:22Denke ich auch, und würde gerne wissen, was der Grund ist, wenn es mit der Technologie zusammenhängt, hätte das Auswirkungen auch auf andere Indikationen
Wenn zB das Inhalieren als unangenehm empfunden würde, wäre das ein Problem
Wenn zB das Inhalieren als unangenehm empfunden würde, wäre das ein Problem
Stimmt.. eine Aufgabe für MKND
Herausfinden warum soooo viele den Gebrauch stoppen und diese Probleme abstellen
Herausfinden warum soooo viele den Gebrauch stoppen und diese Probleme abstellen
Antwort auf Beitrag Nr.: 61.774.862 von Kleingeldinvestor am 27.10.19 10:42:56Ich fürchte, das wissen Sie, wissen aber nicht, was dagegen zu tun ist
Kann ja nicht sein, dass sie kein Feedback eingeholt haben von Alex User an
Kann ja nicht sein, dass sie kein Feedback eingeholt haben von Alex User an
Antwort auf Beitrag Nr.: 61.774.978 von questionmark am 27.10.19 11:05:28sowieso das Problem im Unternehmen
keine Kommunikation immer wieder das gleiche bla bla…
wird schon... Geduld..es wartet Großes bla bla
Kein Wort zum Stand in Brasilien nur ein Beispiel.
Deshalb sag ich ja... einfach traden
keine Kommunikation immer wieder das gleiche bla bla…
wird schon... Geduld..es wartet Großes bla bla
Kein Wort zum Stand in Brasilien nur ein Beispiel.
Deshalb sag ich ja... einfach traden
Das ist ein Auszug von der UTHR Pressekonferenz, die Zusammenarbeit scheint gut voranzuschreiten, ich denke am 6.11.2019 beim Mankkind CC hören wir mehr!
TRX 766(was 712)
NRX 360(369)
Refills 406(343)
TRX$ 1.346m (1.164m
Refills verbessern sich deutlich !!!
NRX 360(369)
Refills 406(343)
TRX$ 1.346m (1.164m
Refills verbessern sich deutlich !!!
Refills sind der Schlüssel imo für einen nachhaltigen erfolg
UND.
Wird mnkd in 2019
1000. Trx erreichen.
Weiss keiner. Das macht die Sache interessant
Und wann geht das geld aus
Gekoppelt mit einer KE?
Wird mnkd in 2019
1000. Trx erreichen.
Weiss keiner. Das macht die Sache interessant
Und wann geht das geld aus
Gekoppelt mit einer KE?
Antwort auf Beitrag Nr.: 61.821.280 von price-of-success am 02.11.19 14:01:13Erstens, geht das Geld nicht aus durch die erfolgreiche Rekapitalisierung, und dann haben wir die Technosphere Technologie mir dem Megapartner UTHR, siehe Auszug aus dem letzten UTHR CC:
trial that we have going on with TreT and the MannKind product, you combine that with, hopefully, a successful unblinding increase and opening up a very small, easy-to-act, easy to -- drug-delivery device with a tenfold larger population of Group 3. And it seems to me that 10,000 patients on treprostinil is a very readily achievable, reasonable goal for our company to set out for ourselves, and we have done that.
So thanks so much for joining us this morning. And we look forward to seeing many of you certainly at J.P. Morgan in just a couple of months to come. Operator, you can wrap up the call.
--------------------------------------------------------------------------------
trial that we have going on with TreT and the MannKind product, you combine that with, hopefully, a successful unblinding increase and opening up a very small, easy-to-act, easy to -- drug-delivery device with a tenfold larger population of Group 3. And it seems to me that 10,000 patients on treprostinil is a very readily achievable, reasonable goal for our company to set out for ourselves, and we have done that.
So thanks so much for joining us this morning. And we look forward to seeing many of you certainly at J.P. Morgan in just a couple of months to come. Operator, you can wrap up the call.
--------------------------------------------------------------------------------
Durch ke gäbe es neue aktien gekoppelt mit evtl fallenden kursen
Ich drücke allen die daumen
Ich drücke allen die daumen
Die UTHR-Kooperation schreitet super voran, wieder 12,5 Millionen US Dollar Milestones:
MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics
GlobeNewswire•November 4, 2019
WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional milestone payments up to $25 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit www.mannkindcorp.com.
Company Contact:
818.661.5000
ir@mannkindcorp.com
MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics
GlobeNewswire•November 4, 2019
WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional milestone payments up to $25 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit www.mannkindcorp.com.
Company Contact:
818.661.5000
ir@mannkindcorp.com
schön..aber den Markt scheint es kaum zu beeindrucken.
Vielleicht kommt Mittwoch ja noch was
Vielleicht kommt Mittwoch ja noch was
Das ist eine super Meldung, d.h. das TrepT Progamm schreitet wie geplant voran, Zulassung nächstes Jahr möglich mit 40-50 Millionen US Dollar jährlichen revenues, die shorts versuchen die Meldung zu einem non event zu machen, zeitverzögert wird Mannkind sich vervielfachen, dank der Technosphere Technologie!
ich will ja nicht immer den Spielverderber spielen, jedoch was sind schon 12.5M in der Geschäftswelt und vorallem in der Pharmabranche? ein Fliegenschi**, ein Tropfen auf den heissen Stein...… das sollte zumind. 100 Mill sein... hier geht einfach mal gar nix vorwärts... und die Konkurrenz schläft ja schon mal gar nicht.
Hab mir gerade mal die Zahlen angeschaut auf der Homepage, erste Umsätze in brasilien---Finanzierung abgeschlossen---klingt doch insgesamt recht gut---mal sehen was die Telco bringt :-)
700.000. las ich toll kleiner anfang
Drücke allen die Daumen
Drücke allen die Daumen
700.000. las ich toll kleiner anfang
Drücke allen die Daumen
Brasilien hat ca 216 millionen einwohnet
Davon 21 mio diabetiker ( geraten von mir)
Drücke allen die Daumen
Brasilien hat ca 216 millionen einwohnet
Davon 21 mio diabetiker ( geraten von mir)
geht's hier eigentlich nur um das "Mürbe" machen der Kleinanleger oder ist die Firma wirklich nicht mehr wert? Ich kann es mir nicht vorstellen, dass so ein super Produkt so wenig Gebrauch findet.
Woran liegt es? Warten auf nächstes Jahr... ist ja nicht mehr lang.
Woran liegt es? Warten auf nächstes Jahr... ist ja nicht mehr lang.
Ich warte ab
Das muss jeder für sich entscheiden
Brasilien läuft an wer weiss was noch kommt
Dennoch. Enttäuschung ob der bislang geringen absatzzahlen
Dyor
Das muss jeder für sich entscheiden
Brasilien läuft an wer weiss was noch kommt
Dennoch. Enttäuschung ob der bislang geringen absatzzahlen
Dyor
Antwort auf Beitrag Nr.: 61.867.809 von price-of-success am 07.11.19 22:22:23Könnte mit den Problemen in US zu tun haben was generell Inhalationsprodukte betrifft---da ist wohl im Moment einiges an Verunsicherung unterwegs??? (E-Zigarette---Canabis usw.??)
moin
das kann durchaus sein
das kann durchaus sein
Antwort auf Beitrag Nr.: 61.869.717 von price-of-success am 08.11.19 09:00:31Man könnte also im Umkehrschluß auf zusätzlich positive Effekte hoffen, denn diese Probleme betreffen ja nicht das Produkt von Mannkind--- die Darreichungsform ist nur die gleiche oder?
Nrx = 332
Rrx = 406
Trx = 738
Total revenues = 1,260,000
Rrx = 406
Trx = 738
Total revenues = 1,260,000
GAP-Close bei 1,20$??
den Wert kann man wirklich nur traden, immer wieder rauf und runter, nichts für schwache Nerven.
SK über 1,30$???
Antwort auf Beitrag Nr.: 61.874.175 von questionmark am 08.11.19 16:08:10Schade das man vom Mangement nichts hört.....
...no communication from the Boardmanagers are they dead ??????
...no communication from the Boardmanagers are they dead ??????
Antwort auf Beitrag Nr.: 61.876.200 von sir1 am 08.11.19 18:53:01Ich glaub da gibt's gar keins
Antwort auf Beitrag Nr.: 61.876.335 von bernd1980 am 08.11.19 19:08:15..die inhallieren wohl was anderes
1o jahre mannkind for nothing
1o jahre mannkind for nothing
So heist es warten auf den kommenden Freitag
stets neu gefragt-wo liegt die wurzel der miesen performance-
und hoffe brazilien hilft uns mit positiven verkaufszaheln
und hoffe brazilien hilft uns mit positiven verkaufszaheln
Antwort auf Beitrag Nr.: 61.907.027 von price-of-success am 13.11.19 02:22:43Schau mer mal, bin schon sehr gespannt---vor allem wie sich diese Zahlen entwickeln ohne den aktuellen Hemmschuh bzw. Verunsicherung wie in den USA zu Inhalationsprodukten generell.
Das würde im Umkehrschluß eine neue US-Prognose ermöglichen, wenn die Verunsicherung verflogen ist
Meine Meinung.!
Das würde im Umkehrschluß eine neue US-Prognose ermöglichen, wenn die Verunsicherung verflogen ist
Meine Meinung.!
für mich.. ein guter Preis um mal wieder einzusteigen
n.m.M und keine Kaufempfehlung
n.m.M und keine Kaufempfehlung
Steigendes Volumen, Kurs hat gedreht heute die neuen Zahlen---könnte ein kleines Feuerwerk geben? :-)
TRx 785
NRx 378
Rrx407
1,33 Mio
NRx 378
Rrx407
1,33 Mio
Fast wieder über 800
Ich WILL jetzt 1000
Trx
Bitte
Ich WILL jetzt 1000
Trx
Bitte
Antwort auf Beitrag Nr.: 61.929.101 von pegasusorion am 15.11.19 08:31:13
Feuerwerk?
schreibt mir wenns so weit ist.wir schaffen nicht mal die 1000 zu überspringen für ne längere Zeit! Warum soll es hier ein Feuerwerk geben. das Management ist unfähig, oder die Patienten haben echt keine Lust auf was neues, es ist halt leider soo..das sich der Mensch bei was neuem immer schwer tut.... Jedoch bleib ich auch dabei , dass das Management völlig versagt hat. Keine Kommunikation in der heutigen Zeit ist halt tödlich..... und von diesen Leuten da bei MNKD hört man ja wirklich nie was..... ich frag mich für was die Kohle bekommen??????
Als Langzeit Invest kann man die Aktie vergessen. Ein überheblicher MC dem die Shareholder egal sind, Hauptsache sein Gehalt und Boni passen. BOD schaut sich das ganze gelangweilt an.
Ich denke demnächst kommt wieder so eine "Pillepalle Meldung" die den Kurs ein, zwei Tage treibt um dann wieder dem $ entgegen zu trudeln...
Über Wasser halten und noch so lange wie möglich kassieren ist deren Motto...
In der Zwischenzeit spiele ich zwischen 1,10 und 1,40 mit und verdiene ein paar Groschen hat dieses Jahr schon öfter funktioniert
n.m.M.
Ich denke demnächst kommt wieder so eine "Pillepalle Meldung" die den Kurs ein, zwei Tage treibt um dann wieder dem $ entgegen zu trudeln...
Über Wasser halten und noch so lange wie möglich kassieren ist deren Motto...
In der Zwischenzeit spiele ich zwischen 1,10 und 1,40 mit und verdiene ein paar Groschen hat dieses Jahr schon öfter funktioniert
n.m.M.
Antwort auf Beitrag Nr.: 61.952.186 von HHMania am 18.11.19 17:28:15Jeder hat halt so seine Strategie, andere reden und schreiben viel Müll---darüber regt man sich dann noch mehr auf.
Fazit: Wie man s macht ist es eh verkehrt oder?
Fazit: Wie man s macht ist es eh verkehrt oder?
Antwort auf Beitrag Nr.: 61.955.666 von pegasusorion am 19.11.19 06:37:30Da geb ich dir Recht.. Jeder wie er mag...
Vermutlich bin ich grad dann nicht investiert wenn die Übernahme kommt und ich schau dem Kurs hinterher... wäre typisch 🤣
Vermutlich bin ich grad dann nicht investiert wenn die Übernahme kommt und ich schau dem Kurs hinterher... wäre typisch 🤣
Antwort auf Beitrag Nr.: 61.952.594 von Kleingeldinvestor am 18.11.19 18:13:32...man soll den Vorstand komplett entlassen......kill the boardmanagement,
Prominenter Neuzugang, hoffentlich reißt der mal was:
MannKind Appoints Tony Hooper to Its Board of Directors
•November 21, 2019
WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020. Mr. Hooper will also serve as a member of the Audit Committee of the Board. Mr. Hooper brings 35 years of experience in the pharmaceutical industry to the MannKind Board of Directors.
“Tony will be a terrific addition to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation. “His commercial operations experience and his deep knowledge of the pharmaceutical industry will be invaluable to MannKind as we look to grow our company for the future.”
Mr. Hooper served as executive vice president of Global Commercial Operations for Amgen Inc. from Oct 2011 until August 2018. During his tenure, he led the transformation of Amgen's commercial organization, placing a relentless focus on putting patients at the center of all the company’s activities. Under his leadership, Amgen grew revenue by 50 percent, launched six new first-in-class medicines for serious diseases, more than doubled the global footprint by expanding into 50 new countries, and established a new biosimilars business. Prior to joining Amgen, Hooper spent more than 15 years at Bristol-Myers Squibb. His last role there was senior vice president, Global Commercial Operations and president of the company’s $15 billion pharmaceutical business in the Americas, Japan and Intercontinental regions. Previously, he was assistant vice president of Global Marketing for Wyeth Laboratories and led the international marketing group for Lederle International. Mr. Hooper earned law and MBA degrees from the University of South Africa.
The addition of Mr. Hooper will bring the total number of MannKind Board members to eight.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind’s ability to directly commercialize pharmaceutical products. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon the MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, MannKind’s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Company Contact:
818-661-5000
ir@mannkindcorp.com
MannKind Appoints Tony Hooper to Its Board of Directors
•November 21, 2019
WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020. Mr. Hooper will also serve as a member of the Audit Committee of the Board. Mr. Hooper brings 35 years of experience in the pharmaceutical industry to the MannKind Board of Directors.
“Tony will be a terrific addition to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation. “His commercial operations experience and his deep knowledge of the pharmaceutical industry will be invaluable to MannKind as we look to grow our company for the future.”
Mr. Hooper served as executive vice president of Global Commercial Operations for Amgen Inc. from Oct 2011 until August 2018. During his tenure, he led the transformation of Amgen's commercial organization, placing a relentless focus on putting patients at the center of all the company’s activities. Under his leadership, Amgen grew revenue by 50 percent, launched six new first-in-class medicines for serious diseases, more than doubled the global footprint by expanding into 50 new countries, and established a new biosimilars business. Prior to joining Amgen, Hooper spent more than 15 years at Bristol-Myers Squibb. His last role there was senior vice president, Global Commercial Operations and president of the company’s $15 billion pharmaceutical business in the Americas, Japan and Intercontinental regions. Previously, he was assistant vice president of Global Marketing for Wyeth Laboratories and led the international marketing group for Lederle International. Mr. Hooper earned law and MBA degrees from the University of South Africa.
The addition of Mr. Hooper will bring the total number of MannKind Board members to eight.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind’s ability to directly commercialize pharmaceutical products. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon the MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, MannKind’s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Company Contact:
818-661-5000
ir@mannkindcorp.com
Der kostet erstmal teuer Geld...
TRx 809
NRx 393
Refillls 416
1,408 m
NRx 393
Refillls 416
1,408 m
Die 800 haben wir wieder
Cool die refills sehen gut aus
Das wird noch!
Also , da könnte wirklich was am "köcheln" sein...
Ein Mann wie Mr. Hooper mit all seiner Erfahrung und Kompetenz wird sicherlich nicht ohne Plan oder blauäugig hier an Bord gegangen sein...….
Vor Wochen hätte ich mir noch nicht vorstellen können , das die wirklich versuchen die Warrents zum 26.12. verfallen zu lassen. Mittlerweile sind das nur noch 4 Wochen und ich glaube das gehört zum Plan.
Dann kommt Mr. Hooper zum 01.01.20, also erst danach. Warum nicht ab sofort oder zum 01.12. ??
Die Frage wäre nur : Was haben sie vor?
Ein Re-Split um dem drohenden Delisting zu entgehen und somit sich noch ein paar Jahre die Taschen voll zu machen ??? Denkbar und die schlechteste Variante für uns
Allerdings halte ich Mr. Hooper eher für einen Macher mit großem Ansehen in der Branche, ob er so seine letzten Jahre im Geschäft verbringen will??? Glaube ich nicht
Für wahrscheinlicher halte ich eine Amgen Übernahme, die bereits vorbereitet wird. Oder sie werden Mannkind im Alleingang nach vorne bringen. Es steckt ja noch einiges in der Pipeline mit großem Potential .
Jedenfalls werde ich definitiv Anfang 2020 nicht ohne Shares dastehen :-)
Ein Mann wie Mr. Hooper mit all seiner Erfahrung und Kompetenz wird sicherlich nicht ohne Plan oder blauäugig hier an Bord gegangen sein...….
Vor Wochen hätte ich mir noch nicht vorstellen können , das die wirklich versuchen die Warrents zum 26.12. verfallen zu lassen. Mittlerweile sind das nur noch 4 Wochen und ich glaube das gehört zum Plan.
Dann kommt Mr. Hooper zum 01.01.20, also erst danach. Warum nicht ab sofort oder zum 01.12. ??
Die Frage wäre nur : Was haben sie vor?
Ein Re-Split um dem drohenden Delisting zu entgehen und somit sich noch ein paar Jahre die Taschen voll zu machen ??? Denkbar und die schlechteste Variante für uns
Allerdings halte ich Mr. Hooper eher für einen Macher mit großem Ansehen in der Branche, ob er so seine letzten Jahre im Geschäft verbringen will??? Glaube ich nicht
Für wahrscheinlicher halte ich eine Amgen Übernahme, die bereits vorbereitet wird. Oder sie werden Mannkind im Alleingang nach vorne bringen. Es steckt ja noch einiges in der Pipeline mit großem Potential .
Jedenfalls werde ich definitiv Anfang 2020 nicht ohne Shares dastehen :-)
TRX 826 (last week 809)
NRX 403 (393)
Refills 423 (416)
TRX$ 1.461m (1.408m)
NRX 403 (393)
Refills 423 (416)
TRX$ 1.461m (1.408m)
Etwas besser aber reicht lang noch nicht. Dauert noch mit den 1000. Ich hab Zeit
Ich auch, wir haben jetzt fast 1,5 Millionen US Dollar Umsatz pro Woche und das mit einer Minimannschaft von 100 Reps, dazu den UTHR-Deal, Refinanzierung......., vor 5 US Dollar gebe ich kein Stück ab:
MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference
[GlobeNewswire]
GlobeNewswire•November 29, 2019
WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. (ET) at the Lotte New York Palace in New York City. Presenting from the Company will be its Chief Executive Officer, Michael Castagna.
The presentation will be webcast live. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
818-661-5000
ir@mannkindcorp.com
MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference
[GlobeNewswire]
GlobeNewswire•November 29, 2019
WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. (ET) at the Lotte New York Palace in New York City. Presenting from the Company will be its Chief Executive Officer, Michael Castagna.
The presentation will be webcast live. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
818-661-5000
ir@mannkindcorp.com
trx 687
three day week only
ergo theoretisch 1145 trx
dyor
three day week only
ergo theoretisch 1145 trx
dyor
Hat schon jemand die neuen Zahlen? VG und Vielen Dank vorab
Antwort auf Beitrag Nr.: 62.095.436 von pegasusorion am 06.12.19 12:26:57siehe oben
Antwort auf Beitrag Nr.: 62.044.976 von Magnetfeldfredy am 29.11.19 18:05:33hat jemand zugehört beim webcast??
Antwort auf Beitrag Nr.: 62.095.439 von price-of-success am 06.12.19 12:27:46Danke, das war wohl Gedankenübertragung---schau mal auf die Uhrzeiten
mich macht es wahnsinnig-der langsame anstieg
Antwort auf Beitrag Nr.: 62.095.481 von price-of-success am 06.12.19 12:31:09Geht mir genauso... aber besser als das hin und her wie vor Monaten
nur meine Meinung...momentan sind das für mich Kaufkurse.
Dieses Jahr sind es noch 2 volle und 2 halbe Wochen... erst Mitte Januar werden wir sehen ob der Anstieg schneller voran kommt. Bis dahin sind die Warrents raus , wird auch beflügeln ( bei Stockwits gibt's kaum ein anderes Thema). Dazu noch eine positive News und der Kurs steht nicht mehr hier unten.
nur meine Meinung...momentan sind das für mich Kaufkurse.
Dieses Jahr sind es noch 2 volle und 2 halbe Wochen... erst Mitte Januar werden wir sehen ob der Anstieg schneller voran kommt. Bis dahin sind die Warrents raus , wird auch beflügeln ( bei Stockwits gibt's kaum ein anderes Thema). Dazu noch eine positive News und der Kurs steht nicht mehr hier unten.
Kursanstieg heute wg. dieser Meldung?
https://www.wiwo.de/unternehmen/industrie/pharmakonzern-sano…
Tja, Sanofi hatte die Chance mit Afreeza...🙄
https://www.wiwo.de/unternehmen/industrie/pharmakonzern-sano…
Tja, Sanofi hatte die Chance mit Afreeza...🙄
Die wollten doch Afrezza nach dem überraschenden CEO Wechsel gar nicht mehr, selber schuld!
Was fällt mir dazu ein, Mannkind--Sanofi--Evotec??? Da könnten Evotec und Mannkind in Kooperation mit einem weiteren Big Pharma??? .... hab nur mal laut gedacht ... :-)
14195_20191211155354_Afrezza Preise Brasil[/uimg][/img]
Brasilien ist jetzt angeblich auf Afrezza!
Brasilien ist jetzt angeblich auf Afrezza!
Antwort auf Beitrag Nr.: 62.133.521 von Magnetfeldfredy am 11.12.19 15:54:18Schau ma mal auf die Freitagszahlen
Wird brazil separat ausgewiesen in den Freitagszahlen?
Der Preis ist sehr günstig in Brasilien, vielleicht kommt damit der Durchbruch wenn die "Masse" sich das leisten kann, wäre super!
Aktie steigt, Volumen auch---kommen heute etwa gute Verkaufszahlen??? :-)
Total 779.
nRx 323.
rRx 456.
Sales of $1.26m.
Happy Friday.
nRx 323.
rRx 456.
Sales of $1.26m.
Happy Friday.
Antwort auf Beitrag Nr.: 62.150.390 von Kleingeldinvestor am 13.12.19 10:51:16Also Zahlen ohne Brasilien, so wies aussieht :-)
Dann kommen trx über 900 eben zum Neujahr
Morgen wieder der Blick auf TRX
bin neugierig, was da kommt
GRuß- Daumen drücken- mehr geht für mich/ uns nicht
bin neugierig, was da kommt
GRuß- Daumen drücken- mehr geht für mich/ uns nicht
Guten Tag
jemand von euch die scripts evtl?
jemand von euch die scripts evtl?
unter Vorbehalt 779 aber 1,42 Mio
Antwort auf Beitrag Nr.: 62.205.081 von Kleingeldinvestor am 20.12.19 11:14:43Hört sich doch gut an, schau ma mal auf den Wochenausklang
auf über 900 dann wohl erst in 2020
mist
mist
"Best in class Insulin" für mich, keine Unterlegenheit und weniger Hypos, sehr wichtig diese Meldung da Mannkind sich in 2020 auch auf Diabetiker Typ 1 vertärkt richten will, mit dem richtigen Partner wären 5000 Scripts pro Woche drin und der Kurs bei 10 US Dollar:
Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes
Publication in DIABETICMedicine Now Available Online
WESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus has been published online in DIABETICMedicine.
This post-hoc analysis was designed to further evaluate the risk of hypoglycemia observed in adults with type 1 diabetes who were treated with inhaled Technosphere Insulin (Afrezza®) or subcutaneous insulin aspart. Specifically, the research controlled for the level of any HbA1c achieved on the incidence rates of hypoglycemia (low levels of sugar in the blood) in 375 adults with type 1 diabetes. The data demonstrated the following:
Participants treated with Afrezza experienced statistically significantly lower rates of level 1 (blood glucose ≤ 3.9 mmol/L or 70 mg/dL) and level 2 (blood glucose ≤ 3.0 mmol/L or 54 mg/dL) hypoglycemic events. There was also a trend towards lower rates of level 3 hypoglycemia (requiring external assistance for recovery) than participants treated with insulin aspart.
The lower rate of hypoglycemia with Afrezza was observed across the range of end-of-treatment A1c levels.
Due to its unique pharmacokinetic/pharmacodynamic profile, Afrezza was associated with higher rates of hypoglycemia 30–60 minutes after meals but significantly lower rates 2–6 hours after meals.
These data indicate that participants using Afrezza experienced clinically non-inferior glycemic control and lower hypoglycemia rates across a range of A1c levels compared with participants receiving insulin aspart.
Hypoglycemia and fear of hypoglycemia are barriers to effective insulin therapy and may prevent people with diabetes from achieving glycemic targets. Potential risks associated with hypoglycemia include, but are not limited to, treatment costs, limiting the individual patient’s capacity to intensify diabetes control, individual patient rates of productivity, as well as many other debilitating effects.
The published research can be found online at https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14202
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
MannKind Contact:
818-661-5000
ir@mannkindcorp.com
MannkindLogoStackedPreferd.jpg
Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes
Publication in DIABETICMedicine Now Available Online
WESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus has been published online in DIABETICMedicine.
This post-hoc analysis was designed to further evaluate the risk of hypoglycemia observed in adults with type 1 diabetes who were treated with inhaled Technosphere Insulin (Afrezza®) or subcutaneous insulin aspart. Specifically, the research controlled for the level of any HbA1c achieved on the incidence rates of hypoglycemia (low levels of sugar in the blood) in 375 adults with type 1 diabetes. The data demonstrated the following:
Participants treated with Afrezza experienced statistically significantly lower rates of level 1 (blood glucose ≤ 3.9 mmol/L or 70 mg/dL) and level 2 (blood glucose ≤ 3.0 mmol/L or 54 mg/dL) hypoglycemic events. There was also a trend towards lower rates of level 3 hypoglycemia (requiring external assistance for recovery) than participants treated with insulin aspart.
The lower rate of hypoglycemia with Afrezza was observed across the range of end-of-treatment A1c levels.
Due to its unique pharmacokinetic/pharmacodynamic profile, Afrezza was associated with higher rates of hypoglycemia 30–60 minutes after meals but significantly lower rates 2–6 hours after meals.
These data indicate that participants using Afrezza experienced clinically non-inferior glycemic control and lower hypoglycemia rates across a range of A1c levels compared with participants receiving insulin aspart.
Hypoglycemia and fear of hypoglycemia are barriers to effective insulin therapy and may prevent people with diabetes from achieving glycemic targets. Potential risks associated with hypoglycemia include, but are not limited to, treatment costs, limiting the individual patient’s capacity to intensify diabetes control, individual patient rates of productivity, as well as many other debilitating effects.
The published research can be found online at https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14202
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
MannKind Contact:
818-661-5000
ir@mannkindcorp.com
MannkindLogoStackedPreferd.jpg
"Best in Class Insulin" für mich, keine Unterlegenheit und weniger Hypos, sehr wichtig, da Mannkind sich im Jahr 2020 auch auf Diabetiker einstellt : Studie 171 zeigt, dass die Hypoglykämie durch die Verwendung von Afrezza® im Vergleich zu Insulin-Aspart bei Typ-1-Diabetes reduziert wird gab heute bekannt, dass Hypoglykämie durch die Anwendung von inhalativem Technosphere® Insulin im Vergleich zu Insulin-Aspart bei Typ-1-Diabetes mellitus reduziert wird. Dies wurde online in DIABETICMedicine veröffentlicht. Diese Post-hoc-Analyse wurde entwickelt, um das Risiko einer Hypoglykämie bei Erwachsenen mit Typ-1-Diabetes, die mit inhalativem Technosphere-Insulin (Afrezza®) oder subkutanem Insulin-Aspart behandelt wurden, weiter zu bewerten. Insbesondere kontrollierte die Forschung die Häufigkeit von Hypoglykämien (niedrige Zuckerspiegel im Blut) bei 375 Erwachsenen mit Typ-1-Diabetes. Die Daten zeigten Folgendes: Die mit Afrezza behandelten Teilnehmer zeigten statistisch signifikant niedrigere Raten von Level 1 (Blutglukose ≤ 3,9 mmol / l oder 70 mg / dl) und Level 2 (Blutglukose ≤ 3,0 mmol / l oder 54 mg / dl) als hypoglykämisch Veranstaltungen. Es gab auch einen Trend zu niedrigeren Raten von Hypoglykämien der Stufe 3 (die externe Hilfe zur Genesung benötigten) als Teilnehmer, die mit Insulinaspart behandelt wurden. Die niedrigere Hypoglykämierate bei Afrezza wurde über den Bereich der A1c-Spiegel am Ende der Behandlung beobachtet. Aufgrund seines einzigartigen pharmakokinetischen / pharmakodynamischen Profils war Afrezza 30 bis 60 Minuten nach den Mahlzeiten mit einer höheren Hypoglykämierate verbunden, 2 bis 6 Stunden nach den Mahlzeiten jedoch mit einer signifikant niedrigeren Rate. Diese Daten zeigen, dass Teilnehmer, die Afrezza verwendeten, eine klinisch nicht schlechtere Blutzuckerkontrolle und niedrigere Hypoglykämieraten über einen Bereich von A1c-Spiegeln erlebten, verglichen mit Teilnehmern, die Insulin-Aspart erhielten. Hypoglykämie und Angst vor Hypoglykämie sind Hindernisse für eine wirksame Insulintherapie und können Menschen mit Diabetes daran hindern, glykämische Ziele zu erreichen. Mögliche Risiken im Zusammenhang mit Hypoglykämie sind unter anderem die Behandlungskosten, die Einschränkung der Fähigkeit des einzelnen Patienten, die Diabetes-Kontrolle zu intensivieren, die Produktivität des einzelnen Patienten sowie viele andere schwächende Effekte.
Nächste Jahr ist das "make it" or "brake it" year für Mannkind, allen Diabetikern/innen und uns Investierten viel Glück!
kommen news aus Brasilien durch wg TRX?
Neues Coverage:
MannKind initiated with an Outperform at Oppenheimer Oppenheimer analyst Steven Lichtman initiated coverage of MannKind with an Outperform rating and $2.50 price target.
Read more at:
https://thefly.com/landingPageNews.php?id=3010564
Frohe Weihnachten all den gebeutelten Mannkind Aktionären mit der Hoffung, dass es 2020 endlich besser wird!😇💹
MannKind initiated with an Outperform at Oppenheimer Oppenheimer analyst Steven Lichtman initiated coverage of MannKind with an Outperform rating and $2.50 price target.
Read more at:
https://thefly.com/landingPageNews.php?id=3010564
Frohe Weihnachten all den gebeutelten Mannkind Aktionären mit der Hoffung, dass es 2020 endlich besser wird!😇💹
Antwort auf Beitrag Nr.: 62.226.530 von Magnetfeldfredy am 24.12.19 13:52:59Eben auf Stockwits…
TRX 932 (779)
NRX 413 (326)
Refills 519 (453)
1,51 Mio
die nächste Marke geknackt
TRX 932 (779)
NRX 413 (326)
Refills 519 (453)
1,51 Mio
die nächste Marke geknackt
Nicht schlecht und das mit einer Mini-Sales Truppe, fast 1000 Verschreibungen pro Woche, wartet mal ab wenn die Kinder Studie 2020 erfolgreich abgeschlossen ist, dann können wir von 2000 Verschreibungen pro Woche ausgehen und der Kurs sollte bei US Dollar 5 stehen!
Antwort auf Beitrag Nr.: 62.234.219 von Magnetfeldfredy am 27.12.19 10:53:43Irgendwo im US Chat hab ich irgendwas von Stellenangeboten zur Verstärkung des Sales-Team gelesen.
Sollten da noch ein paar Jungs dazu kommen, Brasilien endlich starten und eine längst fällige, positive News kommen..... anschnallen nicht vergessen
Sollten da noch ein paar Jungs dazu kommen, Brasilien endlich starten und eine längst fällige, positive News kommen..... anschnallen nicht vergessen
Ja, Mannkind sucht 19 neue Vertriebler:
Es werden 19 von 19 Stellenangeboten angezeigt
Territory Business Manager (Boston, MA)
23. Dez. 2019
Sales
TERRI01013
Vollzeit
Boston, MA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Boston, MA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Worcester, MA)
23. Dez. 2019
Sales
TERRI01014
Vollzeit
Worcester, MA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Worcester, MA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Hartford, CT)
23. Dez. 2019
Sales
TERRI01015
Vollzeit
Hartford, CT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Hartford, CT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Stamford, CT)
23. Dez. 2019
Sales
TERRI01016
Vollzeit
Stamford, CT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Stamford, CT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Norfolk, VA)
23. Dez. 2019
Sales
TERRI01017
Vollzeit
Norfolk, VA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Norfolk, VA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Richmond, VA)
23. Dez. 2019
Sales
TERRI01018
Vollzeit
Richmond, VA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Richmond, VA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Morgantown, WV)
23. Dez. 2019
Sales
TERRI01019
Vollzeit
Morgantown, WV, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Morgantown, WV. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Minneapolis, MN)
23. Dez. 2019
Sales
TERRI01020
Vollzeit
Minneapolis, MN, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Minneapolis, MN. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Jackson, MS)
23. Dez. 2019
Sales
TERRI01021
Vollzeit
Jackson, MS, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Jackson, MS. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (New Orleans/Baton Rouge, LA)
23. Dez. 2019
Sales
TERRI01022
Vollzeit
New Orleans, LA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in New Orleans/Baton Rouge, LA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Houston-Central, TX)
23. Dez. 2019
Sales
TERRI01023
Vollzeit
Houston, TX, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Houston-Central, TX. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Portland, OR)
23. Dez. 2019
Sales
TERRI01024
Vollzeit
Portland, OR, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Portland, OR. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Seattle, WA)
23. Dez. 2019
Sales
TERRI01025
Vollzeit
Seattle, WA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Seattle, WA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Oklahoma City, OK)
23. Dez. 2019
Sales
TERRI01026
Vollzeit
Oklahoma City, OK, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Oklahoma City, OK. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
District Business Manager (New England)
23. Dez. 2019
Sales
DISTR01027
Vollzeit
Remote
MannKind Corporation is currently seeking a District Business Manager for the New England area. In this position the incumbent will be responsible for development and management of a district with the goal of maximizing sales to achieving established revenue and profit goals. Strong people leadership and a commitment to developing people is key to the role. Lead, direct and manage the customer activities of sales representatives within a geographic area. Manage expenses in a fiscally responsible manner. Participate in national, regional, and local strategic meetings as well as lead meetings with respective team.
Territory Business Manager (Orlando/Melbourne, FL)
14. Okt. 2019
Sales
TERRI01010
Vollzeit
Melbourne, FL, USA
+1 weitere
We have an exciting opportunity available for a Territory Business Manager (TBM) in Orlando/Melbourne, FL. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Corporate Controller
10. Okt. 2019
Finance/Accounting
CORPO01009
Vollzeit
Westlake Village, CA, USA
The Corporate Controller reports to the Chief Financial Officer and plans, develops, and implements financial and accounting systems, controls, and standards for the entire company. This person will ensure timely production of financial and statistical reports for senior management use and will provide leadership and direction to the accounting department.
Territory Business Manager (Salt Lake City, UT)
19. Sep. 2019
Sales
TERRI01005
Vollzeit
Salt Lake City, UT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Salt Lake City, UT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Pittsburgh, PA)
19. Sep. 2019
Sales
TERRI01003
Vollzeit
Pittsburgh, PA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Pittsburgh, PA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Entdecken Sie Ihr Potenzial
Wir helfen Ihnen bei der Erstellung eines Profils, mit dem Sie Ihre Ergebnisse speichern und die relevantesten Stellen finden können.
1 Meine ideale Stellenbezeichnung ist...
2 Mein Ausbildungsniveau ist...
3 Ich besitze eine Lizenz oder Zertifizierung für...
MannKind Corp
Es werden 19 von 19 Stellenangeboten angezeigt
Territory Business Manager (Boston, MA)
23. Dez. 2019
Sales
TERRI01013
Vollzeit
Boston, MA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Boston, MA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Worcester, MA)
23. Dez. 2019
Sales
TERRI01014
Vollzeit
Worcester, MA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Worcester, MA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Hartford, CT)
23. Dez. 2019
Sales
TERRI01015
Vollzeit
Hartford, CT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Hartford, CT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Stamford, CT)
23. Dez. 2019
Sales
TERRI01016
Vollzeit
Stamford, CT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Stamford, CT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Norfolk, VA)
23. Dez. 2019
Sales
TERRI01017
Vollzeit
Norfolk, VA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Norfolk, VA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Richmond, VA)
23. Dez. 2019
Sales
TERRI01018
Vollzeit
Richmond, VA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Richmond, VA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Morgantown, WV)
23. Dez. 2019
Sales
TERRI01019
Vollzeit
Morgantown, WV, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Morgantown, WV. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Minneapolis, MN)
23. Dez. 2019
Sales
TERRI01020
Vollzeit
Minneapolis, MN, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Minneapolis, MN. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Jackson, MS)
23. Dez. 2019
Sales
TERRI01021
Vollzeit
Jackson, MS, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Jackson, MS. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (New Orleans/Baton Rouge, LA)
23. Dez. 2019
Sales
TERRI01022
Vollzeit
New Orleans, LA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in New Orleans/Baton Rouge, LA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Houston-Central, TX)
23. Dez. 2019
Sales
TERRI01023
Vollzeit
Houston, TX, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Houston-Central, TX. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Portland, OR)
23. Dez. 2019
Sales
TERRI01024
Vollzeit
Portland, OR, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Portland, OR. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Seattle, WA)
23. Dez. 2019
Sales
TERRI01025
Vollzeit
Seattle, WA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Seattle, WA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Oklahoma City, OK)
23. Dez. 2019
Sales
TERRI01026
Vollzeit
Oklahoma City, OK, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Oklahoma City, OK. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
District Business Manager (New England)
23. Dez. 2019
Sales
DISTR01027
Vollzeit
Remote
MannKind Corporation is currently seeking a District Business Manager for the New England area. In this position the incumbent will be responsible for development and management of a district with the goal of maximizing sales to achieving established revenue and profit goals. Strong people leadership and a commitment to developing people is key to the role. Lead, direct and manage the customer activities of sales representatives within a geographic area. Manage expenses in a fiscally responsible manner. Participate in national, regional, and local strategic meetings as well as lead meetings with respective team.
Territory Business Manager (Orlando/Melbourne, FL)
14. Okt. 2019
Sales
TERRI01010
Vollzeit
Melbourne, FL, USA
+1 weitere
We have an exciting opportunity available for a Territory Business Manager (TBM) in Orlando/Melbourne, FL. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Corporate Controller
10. Okt. 2019
Finance/Accounting
CORPO01009
Vollzeit
Westlake Village, CA, USA
The Corporate Controller reports to the Chief Financial Officer and plans, develops, and implements financial and accounting systems, controls, and standards for the entire company. This person will ensure timely production of financial and statistical reports for senior management use and will provide leadership and direction to the accounting department.
Territory Business Manager (Salt Lake City, UT)
19. Sep. 2019
Sales
TERRI01005
Vollzeit
Salt Lake City, UT, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Salt Lake City, UT. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Territory Business Manager (Pittsburgh, PA)
19. Sep. 2019
Sales
TERRI01003
Vollzeit
Pittsburgh, PA, USA
We have an exciting opportunity available for a Territory Business Manager (TBM) in Pittsburgh, PA. Reporting directly to the District Business Manager, this individual will maximize the sale of MannKind products within the geographic territory, and drive sales growth in line with our marketing/brand strategy.
Entdecken Sie Ihr Potenzial
Wir helfen Ihnen bei der Erstellung eines Profils, mit dem Sie Ihre Ergebnisse speichern und die relevantesten Stellen finden können.
1 Meine ideale Stellenbezeichnung ist...
2 Mein Ausbildungsniveau ist...
3 Ich besitze eine Lizenz oder Zertifizierung für...
MannKind Corp
Antwort auf Beitrag Nr.: 62.234.366 von Magnetfeldfredy am 27.12.19 11:21:45Danke fürs posten....
dann dürften die 1000 schnell Geschichte sein
dann dürften die 1000 schnell Geschichte sein
Das ist nicht so einfach, Anfang des Jahres werden die neu zu verhandelnden Versicherungsabdeckungen immer wieder für anfängliche Rückschläge führen, aber mittel bis langfristig wird sich Afrezza als schnelllstes und bestes Mealtime-Insulin durchsetzen, wenige Hypos damit weniger Komplikationen, und Kinder hassen Spritzen!
Daneben das tolle UTHR-Programm......., yes we hope!
Daneben das tolle UTHR-Programm......., yes we hope!
Antwort auf Beitrag Nr.: 62.234.141 von Kleingeldinvestor am 27.12.19 10:36:39Leute
mega geil- über 900 TRX.was hat das gedauert, diese Hürde zu nehmen
sehr gut
schönes neues Jahr 2020 allen
mega geil- über 900 TRX.was hat das gedauert, diese Hürde zu nehmen
sehr gut
schönes neues Jahr 2020 allen
Afrezza ist überhaupt gut für typ 2
Als zugabe statt der eckeligen spritzen
Als zugabe statt der eckeligen spritzen
Denke, nachdem das Ganze mit der E-Zigarette jetzt geklärt scheint sollte die Unsicherheit vorbei sein oder??
Week ending Dec 27th.
Trxs 673
Nrx 277
Rrx 396
Sales $1.22m
Trxs 673
Nrx 277
Rrx 396
Sales $1.22m
Für eine 3-tage und Feiertagswoche ok!
Prominente Empfehlungsliste mit Mannkind:
232 viewsJan 3, 2020, 09:20am
7 Hot Drug Stocks To Buy In 2020
MoneyShow Contributor
MoneyShow
Contributor Group
Markets
Each year, MoneyShow surveys the nation’s most respected and well-known newsletter advisors for their favorite investment ideas for the coming year. From conservative quality blue chips for safe and steady returns to high-growth stocks with massive potential upside, MoneyShow's Top Picks Report features 100+ investment ideas covering the best stocks and ETFs to buy for 2020.
Here are seven favorites from the pharmaceutical and biotechnology space.
Off The Charts M A
FILE- In this Jan. 3, 2019, file photo specialist Peter Giacchi, right, calls out prices for ... [+]ASSOCIATED PRESS
Mike Larson, Safe Money Report
The biotechnology company Amgen (AMGN) — my more speculative favorite for 2020 — sells several different medical treatments. The firms products include the infection-fighting drug Neulasta, migraine treatment Aimovig, cholesterol drug Repatha, rheumatoid arthritis drug Enbrel and kidney therapy Sensipar. Enbrel is its biggest seller, at approximately 25% of sales, followed by Neulasta at 13%.
Today In: Money
Amgen has also been active on the M&A front. It recently acquired the rights to Celgene’s Otezla psoriasis drug for $13.4 billion. That product generated around $1.6 billion in sales last year.
Plus, Amgen announced plans to invest $2.7 billion for a 20.5% stake in the Chinese biotechnology firm BeiGene (BGNE). The deal will give Amgen’s cancer drugs greater exposure to the Chinese market. This will also allow the firm to profit if BeiGene’s pipeline of molecularly targeted and immuno-oncology products prove to be effective and ready for commercialization.
PROMOTED
Civic Nation BrandVoice
| Paid Program
Not Another Student Loan Piece
UNICEF USA BrandVoice
| Paid Program
Want To Know What Matters Most To Kids? Ask The Experts.
Grads of Life BrandVoice
| Paid Program
5 Myths About High School Interns (And Why You Should Hire Them)
Amgen pays a generous quarterly dividend of $1.45 per share. That was good for an indicated yield of 2.7% in December 2019. Further, the shares broke out to a fresh all-time high on heavy volume late last year. And it goes without saying that biotechnology is not an industry affected by the vicissitudes of the U.S. economy. That makes this promising, relatively defensive pharma play a great addition to investor portfolios.
Kelley Wright, Investment Quality Trends
AbbVie, Inc. (ABBV) is a global, research-based biopharmaceutical company; its products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and HIV.
The company is also involved in neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.
The firm also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
In June 2019, AbbVie entered into a definitive transaction agreement to acquire Allergan plc (AGN). The transaction is expected to close in early 2020 and would create a massive biopharmaceutical company with about $48 billion in combined 2019 revenue.
Management expects that shareholders will see 10% EPS accretion in the first full year of the combination and that the company can achieve annual pre-tax synergies and other cost reductions of over $2 billion by year 3.
The company’s combined net debt of approximately $95 billion will be reduced by $15 to $18 billion by 2021-end, while continuing to support dividend growth and pipeline investment. Historically the shares offer good value when the dividend yield is 4.50%. Based on the current dividend of $4.72 per share, a 4.50% dividend is realized at $105 per share. Trading recently around $88 per share, the stock is about a 20% discount from its historically repetitive area of high yield.
Tom Bishop, BI Research
Anavex (AVXL) is a bio-pharmaceutical company that amazingly few know about, but those who do are passionate about. Its lead drug is Anavex 2-73 (A2-73), an orally available drug with a clean safety profile that gives every indication so far of being highly effective against Alzheimer’s disease.
I’ll explain. Though there are 4 drugs approved, none of them really works beyond 6 months. It is currently in a 1-year, 450-patient Phase 2b/3 Alzheimer’s trial that is halfway through enrollment. If successful the company will file for provisional approval.
In an earlier, smaller Phase 2 study, comparable patients in the ADNI data base not taking Anavex 2-73 saw 4 times the deterioration in their Activities of Daily Living (ADL) scores as those protected by the higher dosage of Anavex 2-73 after two years.
In Anavex’s Phase 2a trial the high dosage of A2-73 cohort saw only a 3-point decline in ADL score (a normal score is about 70 or better) as compared to a 25 point decline (8 times the decline) in the low dosage group (that basically did not work so was effectively a placebo) at 148 weeks.
Same story with the Mini Mental State Exam (MMSE) score (perfect is 30, in this realm scores run below 26) where those taking the higher dose of Anavex 2-73 saw a drop of 1.1 in the MMSE score over two years vs. a drop of 4.4 in untreated patients.
This is phenomenal. Nothing on the market today can come even close to this and if the company can prove this in the Australian trial it will be on track to become the lead Alzheimer’s drug in a market that is at least $10 billion worldwide.
Proof of the pudding, 94% of those who have completed the current 1-year trial period are voluntarily continuing to take A2-73, and some (from the earlier Phase 2a trial) have continued for as much as 3 to 4 more years now. Sometimes that speaks louder than the hard data.
In addition, Anavex is currently wrapping up a Phase 2, 120-patient study with A2-73 for Parkinson’s dementia and is working on three Phase 2 trials for Rett Syndrome, a devastating disease that strikes girls in infancy handicapping them severely in almost every function.
Data from these trials are expected in 2020. I could go on for pages. There are no guarantees on Wall Street, but I hope you will agree that the above at least stacks the odds in our favor.
Chuck Carlson, DRIP Investor
Bristol-Myers Squibb (BMY) is a shining example of value and a top pick for total return. Bristol-Myers Squibb has a number of factors in its favor, not the least of which is solid revenue and earnings growth potential over the next 12 months, an attractive dividend yield of nearly 3%, and a potential kicker in its recent acquisition of Celgene.
Bristol-Myers Squibb is a leading provider of pharmaceuticals. Leading brands include Opdivo, Eliquis, Plavix, Orencia, and Yervoy. Revenues will grow sharply with the addition of Celgene. The addition of Celgene will push annual revenues over $40 billion and give the combined company the number one position in oncology and cardiovascular drugs.
Bristol-Myers Squibb shares trade for just 10 times the 2020 earnings estimate, so investors aren’t paying much for the expected growth. The company is taking on a big chunk of debt to pay for the Celgene deal. Despite the increased debt load, the company just raised its dividend approximately 10%, indicating the firm is fairly confident in its future.
The stock traded in the low $70s in 2018 and was a $77 stock as recently as 2016. I think expected appreciation in the 10%-15% range plus a nearly 3% dividend yield sets up for a nice total return in 2020. I expect these shares to outperform the market over the next year. Please note Bristol-Myers Squibb offers a direct-purchase plan whereby any investor may buy the first share and every share directly from the company.
Mike Cintolo, Cabot Growth Investor
Vertex Pharmaceuticals (VRTX) is a great company, and after a couple of years of choppy action, it appears the buyers are finally beginning to flex their muscles. The company has made hay with cystic fibrosis (CF) treatments, with approvals of individual drugs (it has three on the market today) and combination therapies gradually expanding the share of the CF market it addresses—sales growth has been steady and earnings are following the same upward path.
But what’s brought in the buyers was news that the FDA approved (five months early) Vertex’s triple combination CF treatment — long story short, the combo will greatly expand the number of CF patients the company can serve, and the selling price it’s targeting was higher than many analysts expected.
Bottom line, management hiked revenue guidance after the approval (now looking for a 22% bump in revenues in 2019) and analysts are looking for a very solid 2020 (sales up 26%, earnings up 39%) as the triple combo product gains acceptance, with another round of excellent growth in 2021. All told, earnings are expected to basically double from 2019 to 2021.
The firm has some other early-stage research going on — it eventually wants to diversify away from just CF products — but there’s no question the cystic fibrosis business is going to drive perception in the quarters ahead. Technically, the stock broke out of a two-year dead period in October and looks like it is going to be one of the stock market’s liquid leaders for 2020.
Nate Pile, Nate's Notes
MannKind (MNKD) has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).
The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics. Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,
Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.
And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.
Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR). It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.
And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).
Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004. While it remains to be seen how things will actually play I do find it encouraging that all of those short sales represent pent up buying demand when short sellers eventually close out their trades.
Dr. Joe Duarte, In the Money Options
I’ve liked the action in "Big Pharma" for some time; in my view, pharmaceutical giant Pfizer (PFE) has very positive potential for the new year, New drugs are finally coming on line and hitting revenue and earnings streams and because there are more of them likely to come in what seem to be increasingly encouraging pipelines throughout the sector.
Pfizer lost patent exclusivity for its blockbuster nerve pain drug Lyrica and the stock tanked. But the stock has quietly made a comeback in late 2019 due to its market dominance for blood thinners with Eliquis, its blockbuster cancer drug Inlyta, a broadening set of indications for Xtandi, its prostate cancer treatment, and steady performance for its arthritis drug Xeljans which has recently won extended FDA approval for treatment indications in ulcerative colitis.
Moreover, Pfizer may be sitting on a couple of stealth blockbusters. One is Vyndaquel which treats what used to be considered a rare form of heart failure which may be a more common ailment than previously known and which insurance companies are actually paying for without too much trouble leading to initial sales being well above expectations.
The other potential blockbuster is in a partnership with Eli Lilly (LLY) has the potential to reduce opioid use significantly in the treatment of low back pain. The drug, Tanezumab, is a monoclonal antibody that blocks a substance called nerve growth factor, which has been found to be a key component in spine pain.
If this medication is approved, there is no major competition. And if it is effective, it will likely change the whole chronic pain industry. The drawback is related to a statistically significant potential for users to have damage to bones while under treatment.
There is still room for gains in the healthcare sector and I expect that barring a major market event, the stocks that have lagged in 2019 could be upside surprises in 2020. The Big Pharma stocks are starting to gather steam but there is still time to buy them before they take off.
Click here for access to MoneyShow's 100+ page Top Picks Report featuring the nation’s most respected and well-known newsletter advisors favorite investment ideas for 2020.
Follow me on Twitter or LinkedIn. Check out some of my other work here.
MoneyShow
MoneyShow
MoneyShow — an industry pioneer in investor education since 1981 — is a global, financial media company, operating the world's leading investment and trading conference...
Print
Site Feedback
Tips
Corrections
Reprints & Permissions
Terms
Privacy
©2020 Forbes Media LLC. All Rights Reserved.
AdChoices
Current Time 0:03
/
Duration 1:08
Google Cloud AI Solutions
Google Cloud AI Solutions
BRANDVOICE | Paid Program
Leadership
W
hile artificial intelligence (AI) has been around for many years, deployment has been picking up. Between 2017 and 2018, consulting firm McKinsey & Co. found the percentage of companies embedding at least one AI capability in their business processes more than doubled to 47 percent from 20 percent the year before.
Although companies are adopting it, they often lack a clear plan: A recent IDC survey found that of the companies already using AI, only 25 percent had an enterprise-wide strategy on how to implement it.
To help navigate that challenge, here’s how the four pillars of Google Cloud’s Deployed AI vision can reshape your business.
For AI to be deployed effectively, it must be focused on a new business problem or unrealized opportunity. To that end, there are several areas of business that the technology is well-suited to address.
One key problem is fixing aging processes, notes Ritu Jyoti, program vice president of Artificial Intelligence Strategies for research firm IDC.
“Companies that have been around for a long time will have a lot of archaic processes, and they need to be upgraded,” Jyoti says.
Bank fraud is one prominent example. Machine learning (ML), a subset of AI, provides an opportunity to solve this problem—by helping banks sort through large amounts of bank transactions to detect suspicious patterns of financial activity.
Customer relationships is another area AI can improve. Chatbots, for example, are enhancing customer service by providing support 24/7, Jyoti says. Furthermore, companies can also use AI to develop the right incentives for customers without losing money. Firms sometimes lose income due to lapsed contracts or “stuck deals” in which a transaction is started but unable to be completed, Jyoti notes.
“This feature helps organizations optimize early payment discount offers by using ML algorithms to find the right balance between incentivizing customers while ensuring profitability for the seller,” Jyoti says.
Another business problem in which AI can help is in document processing, including insurance claims, tax returns and mortgage applications, which can involve hundreds of pages of documents on income and assets, notes Vinod Valloppillil, Google’s head of product for Google Cloud Language AI, who spoke at Forbes’ CIO Next conference.
“[Document processing] is one of the few domains that actually brings in multiple parts of AI all simultaneously,” Valloppillil says. It incorporates computer vision, deep learning and natural language processing.
When deploying AI to solve a business problem, the technology should be central to that solution. Many examples across industries—including healthcare and energy—exemplify how innovative problem-solving can hinge on AI.
The medical industry, for instance, is turning to AI to build algorithms to detect pneumonia. With genomic data bringing insights on who will be susceptible to various disease conditions, disease prevention is one area that can’t be solved without AI. An AI platform can also become part of an end-to-end solution when hospitals need to connect medical data to cloud platforms.
AI can also help physicians determine whether a patient has diabetic retinopathy, Valloppillil says. An “Explainable AI” model would help determine if screening was necessary based on the appearance of various regions of the image.
“We’re getting to the point where AI can do quite a bit of engineering,” Valloppillil says.Meanwhile, the energy sector has found AI to be essential to keeping wind facilities “safer, faster, and more accurate,” according to Andrés Gluski, president and CEO of AES, a global power company. Drones and Cloud AutoML Vision, a platform that provides advanced visual intelligence and custom ML models, make these improvements in wind energy possible.
Once you’ve identified the business problem and decided to use AI in the solution, the next step is building customer trust and maintaining proper ethics. In a Deloitte survey of 1,100 IT and “line-of-business” executives, 32 percent placed ethical risks in the top three of AI-related concerns.
To build trust, ethics should come ahead of any productivity or financial gains from using AI. A crucial part of that is being transparent about how a company uses AI.Consulting firm Capgemini recommends using opt-in forms to help build transparency with customers regarding AI. Meanwhile, privacy laws like the European Union’s General Data Protection Regulation (GDPR) also contribute to the transparency requirements for AI.
Jyoti also recommends including fact sheets—similar to how food packaging includes nutrition information—about details like data sources and lineage. A set of AI Principles from Google help businesses ensure that they’re using AI in a responsible manner and that they understand the limits of the technology. Users of AI should maintain accountability to human direction, uphold standards set by scientists and test for safety.
“These are the principles we as a company orient around, things like ‘always optimize around the fairness of AI, and try to avoid any situation where AI can get abused,” Valloppillil says.
Finally, to ensure a cycle of improvement, companies should use clear, objective metrics to assess progress towards their business goals.
For example, if AI is used to assist with résumé screening in the hiring process, make sure the screening adheres to company policies on equal opportunity to maintain fairness. To form an objective metric, come up with representative numbers of candidates for various demographics and train ML algorithms accordingly.
“Avoid the blinders of the homogenous teams,” Jyoti says.Tools and frameworks like Explainable AI can help companies build inclusive systems that address bias, which involves the data not being representative of the decisions a business is trying to make. This makes the problem of “garbage in, garbage out” multiplied a hundredfold, Valloppillil says.
The concept of “explainability” helps provide insight into the decisions that AI helps deliver.
“With explainability we're now finally getting to the point where we go peek inside the box,” Valloppillil says. “We actually have a shot at understanding exactly why does AI make the call.”
looking ahead
As AI continues to evolve, there are increasing opportunities for the technology to meaningfully improve business operations. With ethical implications in mind and a clear focus on measurable metrics, Deployed AI is poised for growth.
Google Cloud AI Solutions
Google Cloud AI Solutions
Google Cloud is widely recognized as a global leader in delivering a secure, open, and intelligent enterprise cloud platform. We’re focused on building solutions in five...
Print
Site Feedback
Tips
Corrections
Reprints & Permissions
Terms
Privacy
©2020 Forbes Media LLC. All Rights Reserved.
AdChoices
Cookie Preference
232 viewsJan 3, 2020, 09:20am
7 Hot Drug Stocks To Buy In 2020
MoneyShow Contributor
MoneyShow
Contributor Group
Markets
Each year, MoneyShow surveys the nation’s most respected and well-known newsletter advisors for their favorite investment ideas for the coming year. From conservative quality blue chips for safe and steady returns to high-growth stocks with massive potential upside, MoneyShow's Top Picks Report features 100+ investment ideas covering the best stocks and ETFs to buy for 2020.
Here are seven favorites from the pharmaceutical and biotechnology space.
Off The Charts M A
FILE- In this Jan. 3, 2019, file photo specialist Peter Giacchi, right, calls out prices for ... [+]ASSOCIATED PRESS
Mike Larson, Safe Money Report
The biotechnology company Amgen (AMGN) — my more speculative favorite for 2020 — sells several different medical treatments. The firms products include the infection-fighting drug Neulasta, migraine treatment Aimovig, cholesterol drug Repatha, rheumatoid arthritis drug Enbrel and kidney therapy Sensipar. Enbrel is its biggest seller, at approximately 25% of sales, followed by Neulasta at 13%.
Today In: Money
Amgen has also been active on the M&A front. It recently acquired the rights to Celgene’s Otezla psoriasis drug for $13.4 billion. That product generated around $1.6 billion in sales last year.
Plus, Amgen announced plans to invest $2.7 billion for a 20.5% stake in the Chinese biotechnology firm BeiGene (BGNE). The deal will give Amgen’s cancer drugs greater exposure to the Chinese market. This will also allow the firm to profit if BeiGene’s pipeline of molecularly targeted and immuno-oncology products prove to be effective and ready for commercialization.
PROMOTED
Civic Nation BrandVoice
| Paid Program
Not Another Student Loan Piece
UNICEF USA BrandVoice
| Paid Program
Want To Know What Matters Most To Kids? Ask The Experts.
Grads of Life BrandVoice
| Paid Program
5 Myths About High School Interns (And Why You Should Hire Them)
Amgen pays a generous quarterly dividend of $1.45 per share. That was good for an indicated yield of 2.7% in December 2019. Further, the shares broke out to a fresh all-time high on heavy volume late last year. And it goes without saying that biotechnology is not an industry affected by the vicissitudes of the U.S. economy. That makes this promising, relatively defensive pharma play a great addition to investor portfolios.
Kelley Wright, Investment Quality Trends
AbbVie, Inc. (ABBV) is a global, research-based biopharmaceutical company; its products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and HIV.
The company is also involved in neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.
The firm also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
In June 2019, AbbVie entered into a definitive transaction agreement to acquire Allergan plc (AGN). The transaction is expected to close in early 2020 and would create a massive biopharmaceutical company with about $48 billion in combined 2019 revenue.
Management expects that shareholders will see 10% EPS accretion in the first full year of the combination and that the company can achieve annual pre-tax synergies and other cost reductions of over $2 billion by year 3.
The company’s combined net debt of approximately $95 billion will be reduced by $15 to $18 billion by 2021-end, while continuing to support dividend growth and pipeline investment. Historically the shares offer good value when the dividend yield is 4.50%. Based on the current dividend of $4.72 per share, a 4.50% dividend is realized at $105 per share. Trading recently around $88 per share, the stock is about a 20% discount from its historically repetitive area of high yield.
Tom Bishop, BI Research
Anavex (AVXL) is a bio-pharmaceutical company that amazingly few know about, but those who do are passionate about. Its lead drug is Anavex 2-73 (A2-73), an orally available drug with a clean safety profile that gives every indication so far of being highly effective against Alzheimer’s disease.
I’ll explain. Though there are 4 drugs approved, none of them really works beyond 6 months. It is currently in a 1-year, 450-patient Phase 2b/3 Alzheimer’s trial that is halfway through enrollment. If successful the company will file for provisional approval.
In an earlier, smaller Phase 2 study, comparable patients in the ADNI data base not taking Anavex 2-73 saw 4 times the deterioration in their Activities of Daily Living (ADL) scores as those protected by the higher dosage of Anavex 2-73 after two years.
In Anavex’s Phase 2a trial the high dosage of A2-73 cohort saw only a 3-point decline in ADL score (a normal score is about 70 or better) as compared to a 25 point decline (8 times the decline) in the low dosage group (that basically did not work so was effectively a placebo) at 148 weeks.
Same story with the Mini Mental State Exam (MMSE) score (perfect is 30, in this realm scores run below 26) where those taking the higher dose of Anavex 2-73 saw a drop of 1.1 in the MMSE score over two years vs. a drop of 4.4 in untreated patients.
This is phenomenal. Nothing on the market today can come even close to this and if the company can prove this in the Australian trial it will be on track to become the lead Alzheimer’s drug in a market that is at least $10 billion worldwide.
Proof of the pudding, 94% of those who have completed the current 1-year trial period are voluntarily continuing to take A2-73, and some (from the earlier Phase 2a trial) have continued for as much as 3 to 4 more years now. Sometimes that speaks louder than the hard data.
In addition, Anavex is currently wrapping up a Phase 2, 120-patient study with A2-73 for Parkinson’s dementia and is working on three Phase 2 trials for Rett Syndrome, a devastating disease that strikes girls in infancy handicapping them severely in almost every function.
Data from these trials are expected in 2020. I could go on for pages. There are no guarantees on Wall Street, but I hope you will agree that the above at least stacks the odds in our favor.
Chuck Carlson, DRIP Investor
Bristol-Myers Squibb (BMY) is a shining example of value and a top pick for total return. Bristol-Myers Squibb has a number of factors in its favor, not the least of which is solid revenue and earnings growth potential over the next 12 months, an attractive dividend yield of nearly 3%, and a potential kicker in its recent acquisition of Celgene.
Bristol-Myers Squibb is a leading provider of pharmaceuticals. Leading brands include Opdivo, Eliquis, Plavix, Orencia, and Yervoy. Revenues will grow sharply with the addition of Celgene. The addition of Celgene will push annual revenues over $40 billion and give the combined company the number one position in oncology and cardiovascular drugs.
Bristol-Myers Squibb shares trade for just 10 times the 2020 earnings estimate, so investors aren’t paying much for the expected growth. The company is taking on a big chunk of debt to pay for the Celgene deal. Despite the increased debt load, the company just raised its dividend approximately 10%, indicating the firm is fairly confident in its future.
The stock traded in the low $70s in 2018 and was a $77 stock as recently as 2016. I think expected appreciation in the 10%-15% range plus a nearly 3% dividend yield sets up for a nice total return in 2020. I expect these shares to outperform the market over the next year. Please note Bristol-Myers Squibb offers a direct-purchase plan whereby any investor may buy the first share and every share directly from the company.
Mike Cintolo, Cabot Growth Investor
Vertex Pharmaceuticals (VRTX) is a great company, and after a couple of years of choppy action, it appears the buyers are finally beginning to flex their muscles. The company has made hay with cystic fibrosis (CF) treatments, with approvals of individual drugs (it has three on the market today) and combination therapies gradually expanding the share of the CF market it addresses—sales growth has been steady and earnings are following the same upward path.
But what’s brought in the buyers was news that the FDA approved (five months early) Vertex’s triple combination CF treatment — long story short, the combo will greatly expand the number of CF patients the company can serve, and the selling price it’s targeting was higher than many analysts expected.
Bottom line, management hiked revenue guidance after the approval (now looking for a 22% bump in revenues in 2019) and analysts are looking for a very solid 2020 (sales up 26%, earnings up 39%) as the triple combo product gains acceptance, with another round of excellent growth in 2021. All told, earnings are expected to basically double from 2019 to 2021.
The firm has some other early-stage research going on — it eventually wants to diversify away from just CF products — but there’s no question the cystic fibrosis business is going to drive perception in the quarters ahead. Technically, the stock broke out of a two-year dead period in October and looks like it is going to be one of the stock market’s liquid leaders for 2020.
Nate Pile, Nate's Notes
MannKind (MNKD) has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).
The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics. Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,
Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.
And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.
Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR). It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.
And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).
Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004. While it remains to be seen how things will actually play I do find it encouraging that all of those short sales represent pent up buying demand when short sellers eventually close out their trades.
Dr. Joe Duarte, In the Money Options
I’ve liked the action in "Big Pharma" for some time; in my view, pharmaceutical giant Pfizer (PFE) has very positive potential for the new year, New drugs are finally coming on line and hitting revenue and earnings streams and because there are more of them likely to come in what seem to be increasingly encouraging pipelines throughout the sector.
Pfizer lost patent exclusivity for its blockbuster nerve pain drug Lyrica and the stock tanked. But the stock has quietly made a comeback in late 2019 due to its market dominance for blood thinners with Eliquis, its blockbuster cancer drug Inlyta, a broadening set of indications for Xtandi, its prostate cancer treatment, and steady performance for its arthritis drug Xeljans which has recently won extended FDA approval for treatment indications in ulcerative colitis.
Moreover, Pfizer may be sitting on a couple of stealth blockbusters. One is Vyndaquel which treats what used to be considered a rare form of heart failure which may be a more common ailment than previously known and which insurance companies are actually paying for without too much trouble leading to initial sales being well above expectations.
The other potential blockbuster is in a partnership with Eli Lilly (LLY) has the potential to reduce opioid use significantly in the treatment of low back pain. The drug, Tanezumab, is a monoclonal antibody that blocks a substance called nerve growth factor, which has been found to be a key component in spine pain.
If this medication is approved, there is no major competition. And if it is effective, it will likely change the whole chronic pain industry. The drawback is related to a statistically significant potential for users to have damage to bones while under treatment.
There is still room for gains in the healthcare sector and I expect that barring a major market event, the stocks that have lagged in 2019 could be upside surprises in 2020. The Big Pharma stocks are starting to gather steam but there is still time to buy them before they take off.
Click here for access to MoneyShow's 100+ page Top Picks Report featuring the nation’s most respected and well-known newsletter advisors favorite investment ideas for 2020.
Follow me on Twitter or LinkedIn. Check out some of my other work here.
MoneyShow
MoneyShow
MoneyShow — an industry pioneer in investor education since 1981 — is a global, financial media company, operating the world's leading investment and trading conference...
Site Feedback
Tips
Corrections
Reprints & Permissions
Terms
Privacy
©2020 Forbes Media LLC. All Rights Reserved.
AdChoices
Current Time 0:03
/
Duration 1:08
Google Cloud AI Solutions
Google Cloud AI Solutions
BRANDVOICE | Paid Program
Leadership
W
hile artificial intelligence (AI) has been around for many years, deployment has been picking up. Between 2017 and 2018, consulting firm McKinsey & Co. found the percentage of companies embedding at least one AI capability in their business processes more than doubled to 47 percent from 20 percent the year before.
Although companies are adopting it, they often lack a clear plan: A recent IDC survey found that of the companies already using AI, only 25 percent had an enterprise-wide strategy on how to implement it.
To help navigate that challenge, here’s how the four pillars of Google Cloud’s Deployed AI vision can reshape your business.
For AI to be deployed effectively, it must be focused on a new business problem or unrealized opportunity. To that end, there are several areas of business that the technology is well-suited to address.
One key problem is fixing aging processes, notes Ritu Jyoti, program vice president of Artificial Intelligence Strategies for research firm IDC.
“Companies that have been around for a long time will have a lot of archaic processes, and they need to be upgraded,” Jyoti says.
Bank fraud is one prominent example. Machine learning (ML), a subset of AI, provides an opportunity to solve this problem—by helping banks sort through large amounts of bank transactions to detect suspicious patterns of financial activity.
Customer relationships is another area AI can improve. Chatbots, for example, are enhancing customer service by providing support 24/7, Jyoti says. Furthermore, companies can also use AI to develop the right incentives for customers without losing money. Firms sometimes lose income due to lapsed contracts or “stuck deals” in which a transaction is started but unable to be completed, Jyoti notes.
“This feature helps organizations optimize early payment discount offers by using ML algorithms to find the right balance between incentivizing customers while ensuring profitability for the seller,” Jyoti says.
Another business problem in which AI can help is in document processing, including insurance claims, tax returns and mortgage applications, which can involve hundreds of pages of documents on income and assets, notes Vinod Valloppillil, Google’s head of product for Google Cloud Language AI, who spoke at Forbes’ CIO Next conference.
“[Document processing] is one of the few domains that actually brings in multiple parts of AI all simultaneously,” Valloppillil says. It incorporates computer vision, deep learning and natural language processing.
When deploying AI to solve a business problem, the technology should be central to that solution. Many examples across industries—including healthcare and energy—exemplify how innovative problem-solving can hinge on AI.
The medical industry, for instance, is turning to AI to build algorithms to detect pneumonia. With genomic data bringing insights on who will be susceptible to various disease conditions, disease prevention is one area that can’t be solved without AI. An AI platform can also become part of an end-to-end solution when hospitals need to connect medical data to cloud platforms.
AI can also help physicians determine whether a patient has diabetic retinopathy, Valloppillil says. An “Explainable AI” model would help determine if screening was necessary based on the appearance of various regions of the image.
“We’re getting to the point where AI can do quite a bit of engineering,” Valloppillil says.Meanwhile, the energy sector has found AI to be essential to keeping wind facilities “safer, faster, and more accurate,” according to Andrés Gluski, president and CEO of AES, a global power company. Drones and Cloud AutoML Vision, a platform that provides advanced visual intelligence and custom ML models, make these improvements in wind energy possible.
Once you’ve identified the business problem and decided to use AI in the solution, the next step is building customer trust and maintaining proper ethics. In a Deloitte survey of 1,100 IT and “line-of-business” executives, 32 percent placed ethical risks in the top three of AI-related concerns.
To build trust, ethics should come ahead of any productivity or financial gains from using AI. A crucial part of that is being transparent about how a company uses AI.Consulting firm Capgemini recommends using opt-in forms to help build transparency with customers regarding AI. Meanwhile, privacy laws like the European Union’s General Data Protection Regulation (GDPR) also contribute to the transparency requirements for AI.
Jyoti also recommends including fact sheets—similar to how food packaging includes nutrition information—about details like data sources and lineage. A set of AI Principles from Google help businesses ensure that they’re using AI in a responsible manner and that they understand the limits of the technology. Users of AI should maintain accountability to human direction, uphold standards set by scientists and test for safety.
“These are the principles we as a company orient around, things like ‘always optimize around the fairness of AI, and try to avoid any situation where AI can get abused,” Valloppillil says.
Finally, to ensure a cycle of improvement, companies should use clear, objective metrics to assess progress towards their business goals.
For example, if AI is used to assist with résumé screening in the hiring process, make sure the screening adheres to company policies on equal opportunity to maintain fairness. To form an objective metric, come up with representative numbers of candidates for various demographics and train ML algorithms accordingly.
“Avoid the blinders of the homogenous teams,” Jyoti says.Tools and frameworks like Explainable AI can help companies build inclusive systems that address bias, which involves the data not being representative of the decisions a business is trying to make. This makes the problem of “garbage in, garbage out” multiplied a hundredfold, Valloppillil says.
The concept of “explainability” helps provide insight into the decisions that AI helps deliver.
“With explainability we're now finally getting to the point where we go peek inside the box,” Valloppillil says. “We actually have a shot at understanding exactly why does AI make the call.”
looking ahead
As AI continues to evolve, there are increasing opportunities for the technology to meaningfully improve business operations. With ethical implications in mind and a clear focus on measurable metrics, Deployed AI is poised for growth.
Google Cloud AI Solutions
Google Cloud AI Solutions
Google Cloud is widely recognized as a global leader in delivering a secure, open, and intelligent enterprise cloud platform. We’re focused on building solutions in five...
Site Feedback
Tips
Corrections
Reprints & Permissions
Terms
Privacy
©2020 Forbes Media LLC. All Rights Reserved.
AdChoices
Cookie Preference
Gute Liste aus stocktwits.com was wir für Trigger-Points vor uns haben:
StupidShort
04:07 AM
$MNKD
Let me explain further, daily SP is not the main metric to gauge the approach and performance of the CEO. And here are the results of his strategy:
1) TRx - 2017-$15.1M, 2018-$36.4M, 2019 $56.5M increasing sales not decreasing
2) Restructure with reduced debt load
3) Launching of Afrezza in Brazil very soon
4) Partnerships with UTHR
5) Milestone payments from UTHR
6) Tre-T study completion 2H20
7) Pediatric trial completion 2H20
8) Filing of NDA for Tre-T 2H20
9) Upcoming Tre-T milestone payments from UTHR
10) Payments from Cipla
11) Approval in India and Australia 2020/2021
Focusing of SP for approach and performance? Wrong!!
StupidShort
04:07 AM
$MNKD
Let me explain further, daily SP is not the main metric to gauge the approach and performance of the CEO. And here are the results of his strategy:
1) TRx - 2017-$15.1M, 2018-$36.4M, 2019 $56.5M increasing sales not decreasing
2) Restructure with reduced debt load
3) Launching of Afrezza in Brazil very soon
4) Partnerships with UTHR
5) Milestone payments from UTHR
6) Tre-T study completion 2H20
7) Pediatric trial completion 2H20
8) Filing of NDA for Tre-T 2H20
9) Upcoming Tre-T milestone payments from UTHR
10) Payments from Cipla
11) Approval in India and Australia 2020/2021
Focusing of SP for approach and performance? Wrong!!
WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil. Biomm intends to commence marketing and distributing Afrezza throughout Brazil, beginning the week of January 13, 2020
Mal sehen ob die verkaufszahlen steigen. Wird ja langsam mal Zeit. Ab über die 1000
Damit wäre Punkt 3 in der heute von mir geposteten Liste abgearbeitet, wichtiger Schritt für einen evtl. Global Player der mehr Muskeln hat wie wir und uns übernimmt!
China und Indien im Zulassungsprozess??
Drücke die Daumen für alle
Drücke die Daumen für alle
Antwort auf Beitrag Nr.: 62.295.122 von price-of-success am 06.01.20 17:19:43dieses Jahr müssen die Umsatzzahlen anspringen, sonst wird Mannkind in der versunkung verschwinden.
stetig steigen wäre hilfreich
morgen, am 10.1 erste Zahlen aus der letzten woche 2019-wohl wenig aussagekraft- plus teile ex 2020
morgen, am 10.1 erste Zahlen aus der letzten woche 2019-wohl wenig aussagekraft- plus teile ex 2020
Antwort auf Beitrag Nr.: 62.295.122 von price-of-success am 06.01.20 17:19:43wenn Sie nicht bald durchstarten wird Mannkind wohl absaufen......10 Jahre Mannkind und nix verdient,
der alte würde sich im Grab umdrehen.🤢
der alte würde sich im Grab umdrehen.🤢
Antwort auf Beitrag Nr.: 62.329.256 von sir1 am 09.01.20 17:40:56Du meinst in der Versunkung versenkt verschwinden?? oder der Phönix mit der Lasche
Mit manchen Aktien ist es nötig ein gutes Jahrzehnt zu warten- ein Jahr gebe ich mir noch
GRuß
GRuß
Antwort auf Beitrag Nr.: 62.329.340 von price-of-success am 09.01.20 17:46:43würde mich net wundern wenn die Zahlen morgen besser als erwartet ausfallen..
Ende Q3 waren sie auch auffallend gut. Eine Theorie dafür war , das die Salesmen einige Aufträge zurück gehalten hatten und dann zum Q Ende glattgestellt haben.....
Wäre vllt auch eine Erklärung für die hohen Umsätze heute in US
Ende Q3 waren sie auch auffallend gut. Eine Theorie dafür war , das die Salesmen einige Aufträge zurück gehalten hatten und dann zum Q Ende glattgestellt haben.....
Wäre vllt auch eine Erklärung für die hohen Umsätze heute in US
Moin
Wer weiss. Bereits was zu den zahlen?
Wer weiss. Bereits was zu den zahlen?
voila from stocktwits
Week ending January 3rd
TRx 716 $1.17 million
NRx 249
RRx 467
Week ending January 3rd
TRx 716 $1.17 million
NRx 249
RRx 467
Antwort auf Beitrag Nr.: 62.329.457 von price-of-success am 09.01.20 17:54:30bin gespannt auf die Umsatzzahlen von dieser Woche
....its time to run
....its time to run
Week ending January 3rd
TRx 716 $1.17 million
NRx 249
RRx 467
TRx 716 $1.17 million
NRx 249
RRx 467
wollte sagen
über 1000. TRX wäre hilfreich!! 5 Tage Woche
über 1000. TRX wäre hilfreich!! 5 Tage Woche
War doch eine 3 tage Woche oder. Klasse Zahlen
ich meine: die 716 TRX für 3 Tage Woche sind prima
und in der neuen Woche hatten wir 5 Tage!!
und in der neuen Woche hatten wir 5 Tage!!
Denke das die 1000 in den nächsten 2-3 Monate fallen.
Mal sehen was Brasilien dann noch kommt da geht der Start glaube ich nächste Woche los, oder liege ich da falsch.
Mal sehen was Brasilien dann noch kommt da geht der Start glaube ich nächste Woche los, oder liege ich da falsch.
Brasilien
Start ab dem 13.1 2020
Start ab dem 13.1 2020
Top Picks 2020: MannKind (MNKD)
5 hours ago
Focus: HEALTHCARE
Nate Pile Image
Nate Pile
Editor, Nate’s Notes and The Wagmore Advisory Letter
Given how things are shaping up for MannKind (MNKD) as we begin 2020, it is once again my Top Pick for speculative investors in the coming year, suggests Nate Pile, editor of Nate's Notes.
For those not familiar with the company, MannKind has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).
The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics.
Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,
Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.
And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.
Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR).
It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.
And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).
Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004.
At that time, the company did not have an FDA approved product nor anywhere near as much data about the potential for Technosphere to revolutionize drug delivery in a number of different categories.
While it remains to be seen how things will actually play out (short squeezes are far less common than people like to believe they are), I do find it encouraging that all of those short sales represent pent up buying demand for roughly 40 million shares when those short sellers eventually close out their trades. MNKD is a strong buy under $5 and a buy under $10.
(Editor's note: Nate Pile's Top Pick for 2019, Catasys (CATS), has risen 71%. The company has developed a proprietary data analysis platform to help individuals in healthcare plans better manage chronic conditions. He The advisor says, "This is a rapidly growing field. I believe there is still plenty of upside ahead.)
5 hours ago
Focus: HEALTHCARE
Nate Pile Image
Nate Pile
Editor, Nate’s Notes and The Wagmore Advisory Letter
Given how things are shaping up for MannKind (MNKD) as we begin 2020, it is once again my Top Pick for speculative investors in the coming year, suggests Nate Pile, editor of Nate's Notes.
For those not familiar with the company, MannKind has a proprietary drug delivery platform called Technosphere that allows it to deliver a wide variety of drugs to the body through the lungs rather than via pills or injections (thus allowing for an often much faster onset of action).
The company's lead product is Afrezza (inhalable insulin), and it is already approved by the FDA for use by both type 1 and type 2 diabetics.
Though still quite small relative other mealtime insulins, sales of Afrezza have been growing steadily for the past couple of years,
Doctors need to see results in a small group of patients before they'll start expanding use of the new therapy into the rest of their practice, and the reality is that this "trial" period often takes 12-18 months when it comes to managing diabetes.
And, given the manner in which new ways of managing diabetes have been adopted in the past, I believe the odds are good that 2020 will be the year that Afrezza finally starts to gain some meaningful traction in the marketplace.
Along with Afrezza, MannKind is also developing a Technosphere-based version of treprostinil (along with another undisclosed molecule) with its partner United Therapeutics (UTHR).
It also has an agreement in place with privately-held Receptor Life Sciences (RLS) under which RLS is developing cannabis-based products utilizing the Technosphere platform.
And though they are not yet licensed to partners, MannKind is also working on inhalable versions of a number of interesting compounds, most notably epinephrine (for anaphylactic shock), sumatriptan (migraines), and tadalafil (erectile dysfunction).
Thanks to a very aggressive group of short sellers who have flooded the market with 40 million "extra" shares over the years, MannKind's market cap has been beaten down just over half of what it was when the company first came public back in 2004.
At that time, the company did not have an FDA approved product nor anywhere near as much data about the potential for Technosphere to revolutionize drug delivery in a number of different categories.
While it remains to be seen how things will actually play out (short squeezes are far less common than people like to believe they are), I do find it encouraging that all of those short sales represent pent up buying demand for roughly 40 million shares when those short sellers eventually close out their trades. MNKD is a strong buy under $5 and a buy under $10.
(Editor's note: Nate Pile's Top Pick for 2019, Catasys (CATS), has risen 71%. The company has developed a proprietary data analysis platform to help individuals in healthcare plans better manage chronic conditions. He The advisor says, "This is a rapidly growing field. I believe there is still plenty of upside ahead.)
auf deutsch
Top Picks 2020: MannKind (MNKD) vor 5 Stunden Fokus: GESUNDHEITSWESEN Nate Pile Image Nate Pile Editor, Nates Notizen und das Wagmore Advisory Letter Angesichts der Entwicklung von MannKind (MNKD) zu Beginn des Jahres 2020 ist es wieder mein Top Nate Pile, Herausgeber von Nate's Notes, schlägt vor, sich für spekulative Anleger im kommenden Jahr zu entscheiden. Für diejenigen, die mit dem Unternehmen nicht vertraut sind, bietet MannKind eine firmeneigene Plattform zur Medikamentenabgabe mit dem Namen Technosphere, mit der eine Vielzahl von Medikamenten nicht über Pillen oder Injektionen, sondern über die Lunge an den Körper abgegeben werden kann ). Das Hauptprodukt des Unternehmens ist Afrezza (inhalierbares Insulin) und es ist bereits von der FDA für die Anwendung bei Typ-1- und Typ-2-Diabetikern zugelassen. Obwohl der Umsatz von Afrezza im Vergleich zu anderen Insulinen für Mahlzeiten noch recht gering ist, ist er in den letzten Jahren stetig gestiegen. Ärzte müssen die Ergebnisse in einer kleinen Gruppe von Patienten sehen, bevor sie die Anwendung der neuen Therapie auf den Rest ihrer Patienten ausweiten können Praxis, und die Realität ist, dass diese "Probezeit" oft 12-18 Monate dauert, wenn es um die Behandlung von Diabetes geht. Angesichts der Art und Weise, in der in der Vergangenheit neue Wege zur Behandlung von Diabetes eingeschlagen wurden, stehen die Chancen gut, dass Afrezza im Jahr 2020 endlich eine bedeutende Marktposition einnimmt. Zusammen mit Afrezza entwickelt MannKind zusammen mit seinem Partner United Therapeutics (UTHR) eine auf Technosphere basierende Version von Treprostinil (zusammen mit einem anderen unbekannten Molekül). Darüber hinaus besteht eine Vereinbarung mit privat gehaltenen Receptor Life Sciences (RLS), in deren Rahmen RLS Cannabis-basierte Produkte unter Verwendung der Technosphere-Plattform entwickelt. Obwohl sie noch nicht an Partner lizenziert sind, arbeitet MannKind auch an inhalierbaren Versionen einer Reihe interessanter Substanzen, insbesondere Epinephrin (bei anaphylaktischem Schock), Sumatriptan (Migräne) und Tadalafil (erektile Dysfunktion). Dank einer sehr aggressiven Gruppe von Leerverkäufern, die den Markt im Laufe der Jahre mit 40 Millionen zusätzlichen Aktien überflutet haben, hat sich die Marktkapitalisierung von MannKind nur halb so stark verschlechtert wie zu dem Zeitpunkt, als das Unternehmen 2004 an die Börse kam Zu dieser Zeit verfügte das Unternehmen weder über ein von der FDA zugelassenes Produkt noch über annähernd so viele Daten über das Potenzial von Technosphere, die Arzneimittelabgabe in verschiedenen Kategorien zu revolutionieren. Es bleibt abzuwarten, wie sich die Dinge tatsächlich entwickeln werden (kurze Drücke sind weitaus seltener, als die Leute gerne glauben), aber ich finde es ermutigend, dass all diese Leerverkäufe einen Anstieg der Kaufnachfrage nach rund 40 Millionen Aktien darstellen, wenn Diese Leerverkäufer schließen schließlich ihre Geschäfte ab. MNKD ist ein starker Kauf unter 5 USD und ein Kauf unter 10 USD. (Anmerkung des Herausgebers: Catasys (CATS), Nate Pile's Top Pick für 2019, ist um 71% gestiegen. Das Unternehmen hat eine proprietäre Datenanalyseplattform entwickelt, die es Einzelpersonen in Krankenversicherungsplänen ermöglicht, mit chronischen Erkrankungen besser umzugehen schnell wachsendes Feld. Ich glaube, es gibt noch viel Aufwärtspotenzial.)
Mannkind, Game-Chancer in Sachen Diabetik? | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1162683-5751-576…
Top Picks 2020: MannKind (MNKD) vor 5 Stunden Fokus: GESUNDHEITSWESEN Nate Pile Image Nate Pile Editor, Nates Notizen und das Wagmore Advisory Letter Angesichts der Entwicklung von MannKind (MNKD) zu Beginn des Jahres 2020 ist es wieder mein Top Nate Pile, Herausgeber von Nate's Notes, schlägt vor, sich für spekulative Anleger im kommenden Jahr zu entscheiden. Für diejenigen, die mit dem Unternehmen nicht vertraut sind, bietet MannKind eine firmeneigene Plattform zur Medikamentenabgabe mit dem Namen Technosphere, mit der eine Vielzahl von Medikamenten nicht über Pillen oder Injektionen, sondern über die Lunge an den Körper abgegeben werden kann ). Das Hauptprodukt des Unternehmens ist Afrezza (inhalierbares Insulin) und es ist bereits von der FDA für die Anwendung bei Typ-1- und Typ-2-Diabetikern zugelassen. Obwohl der Umsatz von Afrezza im Vergleich zu anderen Insulinen für Mahlzeiten noch recht gering ist, ist er in den letzten Jahren stetig gestiegen. Ärzte müssen die Ergebnisse in einer kleinen Gruppe von Patienten sehen, bevor sie die Anwendung der neuen Therapie auf den Rest ihrer Patienten ausweiten können Praxis, und die Realität ist, dass diese "Probezeit" oft 12-18 Monate dauert, wenn es um die Behandlung von Diabetes geht. Angesichts der Art und Weise, in der in der Vergangenheit neue Wege zur Behandlung von Diabetes eingeschlagen wurden, stehen die Chancen gut, dass Afrezza im Jahr 2020 endlich eine bedeutende Marktposition einnimmt. Zusammen mit Afrezza entwickelt MannKind zusammen mit seinem Partner United Therapeutics (UTHR) eine auf Technosphere basierende Version von Treprostinil (zusammen mit einem anderen unbekannten Molekül). Darüber hinaus besteht eine Vereinbarung mit privat gehaltenen Receptor Life Sciences (RLS), in deren Rahmen RLS Cannabis-basierte Produkte unter Verwendung der Technosphere-Plattform entwickelt. Obwohl sie noch nicht an Partner lizenziert sind, arbeitet MannKind auch an inhalierbaren Versionen einer Reihe interessanter Substanzen, insbesondere Epinephrin (bei anaphylaktischem Schock), Sumatriptan (Migräne) und Tadalafil (erektile Dysfunktion). Dank einer sehr aggressiven Gruppe von Leerverkäufern, die den Markt im Laufe der Jahre mit 40 Millionen zusätzlichen Aktien überflutet haben, hat sich die Marktkapitalisierung von MannKind nur halb so stark verschlechtert wie zu dem Zeitpunkt, als das Unternehmen 2004 an die Börse kam Zu dieser Zeit verfügte das Unternehmen weder über ein von der FDA zugelassenes Produkt noch über annähernd so viele Daten über das Potenzial von Technosphere, die Arzneimittelabgabe in verschiedenen Kategorien zu revolutionieren. Es bleibt abzuwarten, wie sich die Dinge tatsächlich entwickeln werden (kurze Drücke sind weitaus seltener, als die Leute gerne glauben), aber ich finde es ermutigend, dass all diese Leerverkäufe einen Anstieg der Kaufnachfrage nach rund 40 Millionen Aktien darstellen, wenn Diese Leerverkäufer schließen schließlich ihre Geschäfte ab. MNKD ist ein starker Kauf unter 5 USD und ein Kauf unter 10 USD. (Anmerkung des Herausgebers: Catasys (CATS), Nate Pile's Top Pick für 2019, ist um 71% gestiegen. Das Unternehmen hat eine proprietäre Datenanalyseplattform entwickelt, die es Einzelpersonen in Krankenversicherungsplänen ermöglicht, mit chronischen Erkrankungen besser umzugehen schnell wachsendes Feld. Ich glaube, es gibt noch viel Aufwärtspotenzial.)
Mannkind, Game-Chancer in Sachen Diabetik? | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1162683-5751-576…
Antwort auf Beitrag Nr.: 62.342.183 von huetchen6 am 10.01.20 20:53:38.....wer hat die Umsatzzahlen von der Woche bitte mal reinstellen danke
Pfizer hatte schon mal ein inhalierbars Insulin auf dem Markt names Exubera und das 2007. Mangels Akzeptanz von Ärzten und Patienten wurde es eingestellt. Einer der größten "Flops" der Pharmageschichte. Afrezza wird es schwer haben. Es kann auch das Langzeitinsulin nicht ersetzen, sondern kann, lediglich vor den Mahlzeiten inhaliert werden. Es ist im Vergleich zur klassischen Insulintherapie in der Wirkung und Dosierung schlechter steuerbar, als die genau ausgerechneten und individuell benötigten Einheiten von Insulin aus der Spritze. Für die Typ 2 Diabetiker, gibt es eine Vielzahl neuer Therapiemöglichkeiten mit Tabletten. Aus diesen Gründen halte ich den Wert für wenig erfolgsvorsprechend und BigPharma hat ebenfalls nicht zugegriffen trotz FDA Zulassung.
Antwort auf Beitrag Nr.: 62.348.321 von Freedom2040 am 11.01.20 22:21:11VW hat Anfang der 90er auch schon einen Golf-SUV rausgebracht.. Der floppte
Siehe SUV‘s heute...
vielleicht Apfel mit Banane verglichen, aber so läuft es halt 😉
Siehe SUV‘s heute...
vielleicht Apfel mit Banane verglichen, aber so läuft es halt 😉
Antwort auf Beitrag Nr.: 62.348.555 von lobberland am 11.01.20 23:36:42Im Gegensatz zum SUV kommt das inhalierbare Insulin aber weiterhin nicht so gut an, die Zahlen sprechen für sich, bisher zumindest.
Hatte hier grosse Hoffnungen und denke aber zunehmend, dass hier irgendein Problem nicht gesehen wird.
Hatte hier grosse Hoffnungen und denke aber zunehmend, dass hier irgendein Problem nicht gesehen wird.
Das bietet einfach keinen Vorteil und ist deutlich teurer als Insulin. Mit den heutigen Pumpsystemen muss der Patient nichtmal mehr sich spritzen, er kann individuell sich einen Bolus verabreichen vor dem Essen. Für Raucher, Asthmatiker, COPD´ler kommt es nicht in Frage, die Mehrzahl der Typ 2 Diabetiker hat aber genau das Problem der multiplen anderweitigen Erkrankungen. Als Notfallmedikament auf dem Rettungswagen bei Ketoazidose ist es auch nicht geeignet. Pfizer hatte damals von Sanofi die Rechte gekauft für Exubera, jetzt kauft Sanofi die Rechte für die Vermarktung von Mannkind für ein bereits gescheitertes Produkt in der Vergangenheit. Das wird in naher Zukunft kein Blockbuster.
Zur Info
1 erstellte Diskussionen
Dyor
1 erstellte Diskussionen
Dyor
Antwort auf Beitrag Nr.: 62.349.380 von price-of-success am 12.01.20 09:26:37Jeder fängt mal an hier zu schreiben, und freedom2040 hat definitiv Ahnung von Pharma.
Warten wir mal auf die Entgegnungen von MF, unserem Threadersteller
Warten wir mal auf die Entgegnungen von MF, unserem Threadersteller
Antwort auf Beitrag Nr.: 62.349.236 von Freedom2040 am 12.01.20 08:55:13Blockbuster nicht aber wird sind dieses Jahr schon bei 55 Millionen revenues, nächstes Jahr 75 Millionen, und jetzt kommt Brasilien.....
Die Technosphere Technologie bringt Partner wie UTHR mit Fix-revenues bei Zulassung von bis zu 50 Millionen US Dollar pro Jahr, das wird!
Die Technosphere Technologie bringt Partner wie UTHR mit Fix-revenues bei Zulassung von bis zu 50 Millionen US Dollar pro Jahr, das wird!
Antwort auf Beitrag Nr.: 62.354.477 von Magnetfeldfredy am 13.01.20 08:26:38Das Produkt ist besser als sein Ruf, außerdem wer von den Mitbewerbern lobt schon das Produkt des Selbigen
IMO: longer term Invest.Und
wegen der Plattform- und dem Wunsch vieler nach Erleichertung vom Spritzen
wer will das- ich nicht.....
wenn ich als Patient sage- wenn ich unterzuckere mit dem Afrezza egal-ich will mehr Lebensqualität
und stelle die lästige Pickserein ein- warum nicht
leider ist das Insulin Molekül zu groß- so mein Stand-das es nicht subkutan verfügbat ist
Ich beilbe dabei- auch wenn kein Blockbuster gleich morgen.
DYOR
wegen der Plattform- und dem Wunsch vieler nach Erleichertung vom Spritzen
wer will das- ich nicht.....
wenn ich als Patient sage- wenn ich unterzuckere mit dem Afrezza egal-ich will mehr Lebensqualität
und stelle die lästige Pickserein ein- warum nicht
leider ist das Insulin Molekül zu groß- so mein Stand-das es nicht subkutan verfügbat ist
Ich beilbe dabei- auch wenn kein Blockbuster gleich morgen.
DYOR
1,50 & 1,60-Marke in einem Rutsch mit hohem Volumen durch...so kann‘s weiter gehen 💪
Bei ca.5$ liegt mein EK den will ich wieder sehen...☝️
Bei ca.5$ liegt mein EK den will ich wieder sehen...☝️
Moin- im wahresten Sinne des Wortes
steckt DER 13.1 ( BRASILIENVerkaufsbeginn Afrezza) hinter dem Kurs Anstieg?
steckt DER 13.1 ( BRASILIENVerkaufsbeginn Afrezza) hinter dem Kurs Anstieg?
Bin schon auf die heutigen Zahlen gespannt :-)
Ich glaube nicht das die verkaufszahlen so schnell hochgehen wegen Brasilien. Es sollten erstmal die 1000 bei den Amis übersteigen. Bin mal gespannt wann die ersten Zahlen aus Brasilien und wann die kommen
Jemand Trx der vergangenen Woche zufällig?
Antwort auf Beitrag Nr.: 62.405.099 von price-of-success am 17.01.20 12:09:03Eben auf stockwits.. wie immer ohne Gewähr
TRX - 693
NRX - 298
$1.3m
TRX - 693
NRX - 298
$1.3m
danke
wir nehmen keine Fahrt auf
dennoch: an meinen 1000 TRX halte ich fest für Ende 1.Quartal- mal so unreflektiert erwähnt
gruß
wir nehmen keine Fahrt auf
dennoch: an meinen 1000 TRX halte ich fest für Ende 1.Quartal- mal so unreflektiert erwähnt
gruß
zur Erinnerung:
aus google gefischt
While TRx tracks all prescriptions, NRx tracks new prescriptions—that is, all scripts written except refills. However, the NRx also includes renewals—the script patients get when they run out of refills.
aus google gefischt
While TRx tracks all prescriptions, NRx tracks new prescriptions—that is, all scripts written except refills. However, the NRx also includes renewals—the script patients get when they run out of refills.
Brasilien Information. 28.1.2020
now
$MNKD Biomm announces on January 28, at 10 am, in São Paulo (SP), the arrival of Afrezza inhalable insulin to the Brazilian market. The product of a partnership with the American pharmaceutical company Mannkind, it is a new treatment alternative for diabetics, with faster and more efficient action than the insulins available in the country.
After the United States, Brazil is the second country in the world to distribute the medicine to patients.
CEO Heraldo Marchezini will speak about the development of Afrezza and the creation of the exclusive sales channel for patients. The endocrinologist Márcio Krakauer, from the Brazilian Society of Endocrinology and Metabology, will discuss the performance of this innovative medicine and its benefits compared to traditional insulins.
now
$MNKD Biomm announces on January 28, at 10 am, in São Paulo (SP), the arrival of Afrezza inhalable insulin to the Brazilian market. The product of a partnership with the American pharmaceutical company Mannkind, it is a new treatment alternative for diabetics, with faster and more efficient action than the insulins available in the country.
After the United States, Brazil is the second country in the world to distribute the medicine to patients.
CEO Heraldo Marchezini will speak about the development of Afrezza and the creation of the exclusive sales channel for patients. The endocrinologist Márcio Krakauer, from the Brazilian Society of Endocrinology and Metabology, will discuss the performance of this innovative medicine and its benefits compared to traditional insulins.
Bin letzte Woche hier eingestiegen.........guter Start heute.
https://seekingalpha.com/article/4317907-mannkinds-afrezza-r…
https://seekingalpha.com/article/4317907-mannkinds-afrezza-r…
Guter Einstiegszeitpunkt 👍
Scheint so, daß die Aktie (mal wieder) Richtung 2$ marschiert...
Scheint so, daß die Aktie (mal wieder) Richtung 2$ marschiert...
bald- täglich grüßt das Murmeltier-am Freitag wieder neue TRX
ich hoffe stets auf gute TRX
so auch wieder am 24.1
Gruß
ich hoffe stets auf gute TRX
so auch wieder am 24.1
Gruß
sorry- wöchentlich natürlich
Chartechnisch ein brutaler Ausbruch.........eine kleine Korrektur könnte nich schaden.
Ein gute Ziel liegt bei 2,33 USD.......aber da sind noch ein paar Hindernisse z.B. bei 2 USD.
https://www.tradesignalonline.com/ext/edt.ashx/wo/4BA08E16-8…
Ein gute Ziel liegt bei 2,33 USD.......aber da sind noch ein paar Hindernisse z.B. bei 2 USD.
https://www.tradesignalonline.com/ext/edt.ashx/wo/4BA08E16-8…
zock oder ist etwas im Busche?
Antwort auf Beitrag Nr.: 62.455.206 von price-of-success am 22.01.20 18:39:01In verschiedenen US Foren wird von einen Cannabis Inhalator gesprochen den Mannkind entwickeln soll.
Ist hier irgendetwas bekannt?
https://finance.yahoo.com/quote/MNKD/community/
Ist hier irgendetwas bekannt?
https://finance.yahoo.com/quote/MNKD/community/
Das ist der kurstreiber
Klingt gut
Neben aftrezza ein weiteres produkt plus brasilien
Warum nicht wir kennen die amerikaner und deren lust zu übertreiben
10 usd fänden wir wohl gut
Klingt gut
Neben aftrezza ein weiteres produkt plus brasilien
Warum nicht wir kennen die amerikaner und deren lust zu übertreiben
10 usd fänden wir wohl gut
hoffentlich hat das Leiden bald ein Ende-für uns Investoren
Das ist der kurstreiber
Klingt gut
Neben aftrezza ein weiteres produkt plus brasilien
Warum nicht wir kennen die amerikaner und deren lust zu übertreiben
10 usd fänden wir wohl gut
Klingt gut
Neben aftrezza ein weiteres produkt plus brasilien
Warum nicht wir kennen die amerikaner und deren lust zu übertreiben
10 usd fänden wir wohl gut
Antwort auf Beitrag Nr.: 62.457.420 von price-of-success am 22.01.20 21:31:58Zustimmung 👍 mal schauen wie die Wochenzahlen heute ausfallen
Moin
Zahlen gegen mittag??
Zahlen gegen mittag??
Wie immer ohne Gewähr.....
$MNKD From georgethenight2 @ PB
Numbers for Week ending 1/17
Trx 798
Nrx 330
RRX 468
Total sales of $1.44m.
$MNKD From georgethenight2 @ PB
Numbers for Week ending 1/17
Trx 798
Nrx 330
RRX 468
Total sales of $1.44m.
Antwort auf Beitrag Nr.: 62.473.971 von Kleingeldinvestor am 24.01.20 10:53:34Danke fürs einstellen
Gerne doch
Antwort auf Beitrag Nr.: 62.473.971 von Kleingeldinvestor am 24.01.20 10:53:34prima -danke für die Zahlen hier ein Vergleich ex stocktwits
380 same week 2018
551 same week 2019
798 same week 2020 (+45% vs 2019)
dyor
380 same week 2018
551 same week 2019
798 same week 2020 (+45% vs 2019)
dyor
Vorbörslich ca. 5% über Pari...hier was im Busch?
Antwort auf Beitrag Nr.: 62.495.348 von Stoxtrayder am 27.01.20 11:19:05Hoffentlich und dann noch etwas ordentliches ich meine im Busch...
news aus brasilien evtl.?
Scripts jemand??
Gruss
Gruss
Alle GAP s zu, hat wer die Freitags-Zahlen?
TRx 716 $ 1.26M NRx 329 RRx 387
Antwort auf Beitrag Nr.: 62.543.507 von Muckimann66 am 31.01.20 13:00:00Danke
😁 Das zieht sich aber mit den 1000
Antwort auf Beitrag Nr.: 62.543.705 von Muckimann66 am 31.01.20 13:21:17und: es gab bereits TRX 932. im peak
muß mich wohl in Geduld fassen
Gruß
muß mich wohl in Geduld fassen
Gruß
www.mannkindcorp.com
Tolle neue Homepage, mit der Ankündigung: A new Mannkind brand coming spring 2020....
Schaut super aus und hört sich noch besser an, jetzt müssen nur noch Taten folgen, yes we hope!
Tolle neue Homepage, mit der Ankündigung: A new Mannkind brand coming spring 2020....
Schaut super aus und hört sich noch besser an, jetzt müssen nur noch Taten folgen, yes we hope!
Antwort auf Beitrag Nr.: 62.570.557 von Magnetfeldfredy am 03.02.20 22:19:45
WESTLAKE-DORF, Calif., 06. Januar 2020 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ: MNKD) gab heute bekannt, dass sein brasilianischer PartnerBiomm SAhat eine schriftliche Mitteilung der Regulierungskammer für den Arzneimittelmarkt (CMED) erhalten, in der der vorgeschlagene Preis von Afrezza im Jahr 2000 gebilligt wird Brasilien. Biomm beabsichtigt, Afrezza im gesamten Land zu vermarkten und zu vertreiben BrasilienBeginn der Woche vom 13. Januar 2020.
wann steigt der Umsatz ???????????????????????????????????ßß
Afrezza® (Insulin Human) Inhalationspulver erhält Preisregistrierung in Brasilien. Die kommerziellen Aktivitäten beginnen in diesem MonatWESTLAKE-DORF, Calif., 06. Januar 2020 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ: MNKD) gab heute bekannt, dass sein brasilianischer PartnerBiomm SAhat eine schriftliche Mitteilung der Regulierungskammer für den Arzneimittelmarkt (CMED) erhalten, in der der vorgeschlagene Preis von Afrezza im Jahr 2000 gebilligt wird Brasilien. Biomm beabsichtigt, Afrezza im gesamten Land zu vermarkten und zu vertreiben BrasilienBeginn der Woche vom 13. Januar 2020.
Männer morgen neue Hoffnung auf steigende Trx
Schönen Abend
Schönen Abend
Antwort auf Beitrag Nr.: 62.570.557 von Magnetfeldfredy am 03.02.20 22:19:45Neugierig auf die neue website
TRx 679
NRx 345
RRx 334
Schwach
NRx 345
RRx 334
Schwach
Männer morgen kommt das Ttx murmeltier wieder mit zahlen
Mag gar nicht mehr hinschaurn werde es trotzdem tun goog luck
Mag gar nicht mehr hinschaurn werde es trotzdem tun goog luck
Trx. Good luck
Antwort auf Beitrag Nr.: 62.674.879 von price-of-success am 13.02.20 20:45:08..... und bringt hoffentlich Murmeln Dir!
Mühsam nährt sich das Murmeltier
TRX 720
NRX 328
$1.22m
TRX 720
NRX 328
$1.22m
Danke könnte weinen
Verkaufen die nix in Brasilien. Man sieht das übel aus.
War doch klar. Das letzte "inhalierbare Insulin" ist auch gescheitert. Warum sollte es dieses schaffen???
Antwort auf Beitrag Nr.: 62.683.465 von Freedom2040 am 14.02.20 14:57:09Weil es besser ist 🤔
Super neue Afrezza Daten:
MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)
[GlobeNewswire]
GlobeNewswire•February 20, 2020
WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder and MannKind’s BluHale® technology system. These data are being presented in both oral and poster presentations during the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) in Madrid Spain, February 20-22, 2020.
“We are very pleased to have the opportunity to highlight these positive results during this year’s ATTD,” stated Dr. David Kendall, Chief Medical Officer of MannKind. “These presentations highlight original studies of Afrezza in individuals with both type 1 and type 2 diabetes, and include initial studies of Afrezza in pediatric patients. In addition to the results of clinical studies, we are pleased to disclose novel data on the use of BluHale, our Bluetooth-enabled technology for real-time profiling of inhalation effort and other parameters associated with the use of our inhaler. Collectively, these data further expand our understanding of the unique clinical profile of Afrezza, and highlight the potential use of Afrezza in children and adolescents, as well as advancing the opportunity to create connected technology for our drug delivery system.”
Highlights of the original scientific disclosures:
Preliminary data from an independent, investigator initiated study of Afrezza on the background of closed loop pump insulin delivery by means of an “artificial pancreas” system showed that pulmonary dosing allows for titration to higher unit doses in individuals with type 1 diabetes (presented by Alfonso Galderisi MD, PhD from Yale University).
Clinical use of Afrezza in adults with uncontrolled type 2 diabetes on two or more glucose lowering therapies resulted in a significant (1.6%) drop in A1c levels and a significant increase in time in range (presented by Dr. Philip Levin MD, Endocrinology, MODEL Clinical Research).
Pharmacokinetics (and pharmacodynamics) of Technosphere insulin in children and adolescents ages 8-17 with type 1 diabetes showed that the ultra rapid rise in insulin concentrations corresponded with early post-prandial glucose control within the first hour post-dose, similar to what has been observed in adult patients.
Two poster presentations highlighting the use of MannKind’s unique Bluetooth enabled technology for enhanced instruction on use of the Afrezza inhaler and as a tool to provide connected dose information on top of continuous glucose monitoring data.
Dr. Phillip Levin, Principal Investigator from MODEL Clinical Research in Baltimore, MD and lead author on the study of uncontrolled type 2 diabetes patients, noted that “the addition and rapid titration of Afrezza in patients with type 2 diabetes not currently at goal using two or more glucose lowering therapies, resulted in a 1.6% reduction in A1C and significantly increased time in range as measured by CGM. Our study provides additional clarity on both dose requirements and the clinical impact of adding ultra rapid-acting Afrezza therapy in uncontrolled type 2 diabetes.”
In addition to the original scientific disclosure presented at this year’s ATTD meeting, Dr. Kendall will participate as faculty in the “Ultra-rapid Insulin Analogues” session on Saturday, February 22, during which he will provide a current perspective on the clinical use of Afrezza, including evidence that ultra rapid-acting Afrezza can be safely and effectively titrated in fixed dose increments and that speed of insulin action may supersede dose precision for achieving post-prandial glucose control.
The full title of each of the presentations, presenting author, and the date and time of each disclosure are provided below.
ORAL PRESENTATION HIGHLIGHTS
Title: Technosphere® Insulin Provides Better Early Postprandial Glucose Control Than Subcutaneous Rapid-Acting Analogue
(ATTD 2020 - Saturday February 22, 2020; 8:50 – 9:00 a.m. – Berlin Room)
Presenter: David Kendall, MD, MannKind Corporation
ELECTRONIC POSTER PRESENTATION HIGHLIGHTS
Title: Patient Trainer Experience with BluHale® V1.0 for Proper Technosphere® Insulin Administration
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: Nadia Zaveri, PharmD, MannKind Corporation
Title: Safety and Pharmacokinetics of Technosphere® Insulin in Pediatric Patients
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: David Kendall, MD, MannKind Corporation
Title: Insights to Improve Use of Technosphere® Insulin Provided By BluHale®, a Digital Diabetes Tool
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: Benoit Adamo, MannKind Corporation
Title: Effective Treatment of Patients with Uncontrolled Type 2 Diabetes On Multiple Diabetes Medications By Adding Mealtime Ultra-rapid Technosphere® Insulin
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: Philip Levin, MD, Endocrinology, MODEL Clinical Research
Title: Afrezza® Pre-meal Bolus Reduces Early Glycemic Excursion During Hybrid Closed Loop Treatment
(ATTD 2020 – Saturday, February 22, 2020; 8:30 a.m.)
Presenter: Alfonso Galderisi, MD, PhD, Yale University
About ATTD Annual Meeting
The ATTD is a scientific program that brings leading international experts together to discuss breakthroughs in diabetes treatments, technological innovations and showcase the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and much more.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.
MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)
[GlobeNewswire]
GlobeNewswire•February 20, 2020
WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder and MannKind’s BluHale® technology system. These data are being presented in both oral and poster presentations during the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) in Madrid Spain, February 20-22, 2020.
“We are very pleased to have the opportunity to highlight these positive results during this year’s ATTD,” stated Dr. David Kendall, Chief Medical Officer of MannKind. “These presentations highlight original studies of Afrezza in individuals with both type 1 and type 2 diabetes, and include initial studies of Afrezza in pediatric patients. In addition to the results of clinical studies, we are pleased to disclose novel data on the use of BluHale, our Bluetooth-enabled technology for real-time profiling of inhalation effort and other parameters associated with the use of our inhaler. Collectively, these data further expand our understanding of the unique clinical profile of Afrezza, and highlight the potential use of Afrezza in children and adolescents, as well as advancing the opportunity to create connected technology for our drug delivery system.”
Highlights of the original scientific disclosures:
Preliminary data from an independent, investigator initiated study of Afrezza on the background of closed loop pump insulin delivery by means of an “artificial pancreas” system showed that pulmonary dosing allows for titration to higher unit doses in individuals with type 1 diabetes (presented by Alfonso Galderisi MD, PhD from Yale University).
Clinical use of Afrezza in adults with uncontrolled type 2 diabetes on two or more glucose lowering therapies resulted in a significant (1.6%) drop in A1c levels and a significant increase in time in range (presented by Dr. Philip Levin MD, Endocrinology, MODEL Clinical Research).
Pharmacokinetics (and pharmacodynamics) of Technosphere insulin in children and adolescents ages 8-17 with type 1 diabetes showed that the ultra rapid rise in insulin concentrations corresponded with early post-prandial glucose control within the first hour post-dose, similar to what has been observed in adult patients.
Two poster presentations highlighting the use of MannKind’s unique Bluetooth enabled technology for enhanced instruction on use of the Afrezza inhaler and as a tool to provide connected dose information on top of continuous glucose monitoring data.
Dr. Phillip Levin, Principal Investigator from MODEL Clinical Research in Baltimore, MD and lead author on the study of uncontrolled type 2 diabetes patients, noted that “the addition and rapid titration of Afrezza in patients with type 2 diabetes not currently at goal using two or more glucose lowering therapies, resulted in a 1.6% reduction in A1C and significantly increased time in range as measured by CGM. Our study provides additional clarity on both dose requirements and the clinical impact of adding ultra rapid-acting Afrezza therapy in uncontrolled type 2 diabetes.”
In addition to the original scientific disclosure presented at this year’s ATTD meeting, Dr. Kendall will participate as faculty in the “Ultra-rapid Insulin Analogues” session on Saturday, February 22, during which he will provide a current perspective on the clinical use of Afrezza, including evidence that ultra rapid-acting Afrezza can be safely and effectively titrated in fixed dose increments and that speed of insulin action may supersede dose precision for achieving post-prandial glucose control.
The full title of each of the presentations, presenting author, and the date and time of each disclosure are provided below.
ORAL PRESENTATION HIGHLIGHTS
Title: Technosphere® Insulin Provides Better Early Postprandial Glucose Control Than Subcutaneous Rapid-Acting Analogue
(ATTD 2020 - Saturday February 22, 2020; 8:50 – 9:00 a.m. – Berlin Room)
Presenter: David Kendall, MD, MannKind Corporation
ELECTRONIC POSTER PRESENTATION HIGHLIGHTS
Title: Patient Trainer Experience with BluHale® V1.0 for Proper Technosphere® Insulin Administration
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: Nadia Zaveri, PharmD, MannKind Corporation
Title: Safety and Pharmacokinetics of Technosphere® Insulin in Pediatric Patients
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: David Kendall, MD, MannKind Corporation
Title: Insights to Improve Use of Technosphere® Insulin Provided By BluHale®, a Digital Diabetes Tool
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: Benoit Adamo, MannKind Corporation
Title: Effective Treatment of Patients with Uncontrolled Type 2 Diabetes On Multiple Diabetes Medications By Adding Mealtime Ultra-rapid Technosphere® Insulin
(ATTD 2020 – Thursday, February 20, 2020; 8 a.m.)
Presenter: Philip Levin, MD, Endocrinology, MODEL Clinical Research
Title: Afrezza® Pre-meal Bolus Reduces Early Glycemic Excursion During Hybrid Closed Loop Treatment
(ATTD 2020 – Saturday, February 22, 2020; 8:30 a.m.)
Presenter: Alfonso Galderisi, MD, PhD, Yale University
About ATTD Annual Meeting
The ATTD is a scientific program that brings leading international experts together to discuss breakthroughs in diabetes treatments, technological innovations and showcase the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and much more.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.
Magnet gibt es irgendwo etwas zu Brasilien
Schaun wir mal auf die VK-Zahlen gegen Mittag :-)
from stocktwits today
TRx 782 $1.21 million
NRx 301
RRx 481For the week ending February 14th
TRx 782 $1.21 million
NRx 301
RRx 481For the week ending February 14th
Antwort auf Beitrag Nr.: 62.748.526 von price-of-success am 21.02.20 13:24:27aktie springt nicht an, obwohl gute Ergebnisse präsentiert wurden
MannKind (MNKD + 0,3%) gibt Ergebnisse aus mehreren klinischen Studien mit inhaliertem Insulin Afrezza (Insulin Human) und seinem BluHale-Zubehörgerät bekannt. Die Daten werden auf der Internationalen Konferenz über fortschrittliche Technologien und Behandlungen für Diabetes in Madrid vorgestellt.
Vorläufige Daten aus einer von Forschern initiierten Studie über Afrezza vor dem Hintergrund der Insulinabgabe über ein "künstliches Pankreas" -System zeigten, dass die Lungendosierung die Titration auf höhere Einheitsdosen bei Typ-1-Diabetikern ermöglichte.
Die Anwendung von Afrezza bei Erwachsenen mit unkontrolliertem Typ-2-Diabetes führte zu einer signifikanten Verringerung der HbA1C-Spiegel um 1,6% mit einer signifikanten Verlängerung der Zeitspanne.
MannKind (MNKD + 0,3%) gibt Ergebnisse aus mehreren klinischen Studien mit inhaliertem Insulin Afrezza (Insulin Human) und seinem BluHale-Zubehörgerät bekannt. Die Daten werden auf der Internationalen Konferenz über fortschrittliche Technologien und Behandlungen für Diabetes in Madrid vorgestellt.
Vorläufige Daten aus einer von Forschern initiierten Studie über Afrezza vor dem Hintergrund der Insulinabgabe über ein "künstliches Pankreas" -System zeigten, dass die Lungendosierung die Titration auf höhere Einheitsdosen bei Typ-1-Diabetikern ermöglichte.
Die Anwendung von Afrezza bei Erwachsenen mit unkontrolliertem Typ-2-Diabetes führte zu einer signifikanten Verringerung der HbA1C-Spiegel um 1,6% mit einer signifikanten Verlängerung der Zeitspanne.
Antwort auf Beitrag Nr.: 62.750.968 von sir1 am 21.02.20 16:57:39Doch jetzt 😁👍🏻
Antwort auf Beitrag Nr.: 62.751.346 von lobberland am 21.02.20 17:28:24War ja auch schlecht zu sehen, der Kurs hat sich gut versteckt
Schönes WE
Ps.: Beim Optiker soll s auch Brillen geben gegen Kurssehschwäche 🤠
Schönes WE
Ps.: Beim Optiker soll s auch Brillen geben gegen Kurssehschwäche 🤠
MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results
[GlobeNewswire]
GlobeNewswire•February 25, 2020
Conference Call to Begin Today at 9:00 AM ET
2019 Total Revenue of $63.0 million
° 2019 Afrezza Net Revenue of $25.3 million; +46% vs. 2018
° 2019 Collaborations and Services Revenue of $37.7 million; +257% vs. 2018
4Q 2019 Total Revenue of $16.0 million
° 4Q 2019 Afrezza Net Revenue of $7.8 million; +35% vs. 4Q 2018
▪ 4Q 2019 Afrezza Net Revenue grew 22% vs. 3Q 2019
▪ 4Q 2019 Afrezza Gross Profit $3.1 million; 40% Gross Margin
° 4Q 2019 Collaborations and Services Revenue of $8.2 million; -20% vs. 4Q 2018
$50.2 million of Cash, Cash Equivalents, Restricted Cash, and Short-term Investments at December 31, 2019
WESTLAKE VILLAGE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2019.
“We ended 2019 on a strong note with fourth quarter 2019 Afrezza net revenue of $7.8 million, our best quarter to date,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. He also noted, “Our collaboration with United Therapeutics on TreT continues to make progress along the clinical and commercial pathways that are expected to set up a filing with the FDA within 12 months.”
Fourth Quarter 2019 Results
Total revenues were $16.0 million for the fourth quarter of 2019, reflecting Afrezza net revenue of $7.8 million and collaborations and services revenue of $8.2 million. Afrezza net revenue increased 35% compared to $5.7 million in the fourth quarter of 2018, primarily driven by higher product demand and price. Collaborations and services revenue decreased $2.1 million compared to the fourth quarter of 2018, primarily due to lower revenue from the United Therapeutics research agreement, which was substantially completed by the second quarter of 2019.
On a GAAP basis, Afrezza gross profit was $3.1 million for the fourth quarter of 2019 compared to $0.7 million in the same period in 2018. Afrezza cost of goods sold for the fourth quarter of 2018 included a fee of $2.0 million recorded in connection with the amendment of our insulin supply agreement with Amphastar. As a result, on a non-GAAP basis, gross profit was $2.7 million or 48% gross margin for the fourth quarter of 2018, compared to a GAAP basis gross margin of 40% for the fourth quarter of 2019.
Research and development (R&D) expenses for the fourth quarter of 2019 were $2.0 million compared to $1.1 million for the fourth quarter of 2018. This 82% increase was primarily attributable to an increase of $0.6 million in personnel costs associated with the United Therapeutics research agreement, which was classified as a cost of collaborations and services revenue in 2018, and to an increase of $0.3 million in maintenance costs for our research facility in Danbury, Connecticut.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2019 were $15.7 million compared to $18.0 million for the fourth quarter of 2018. This decrease of $2.3 million, or 13%, was primarily attributable to a $1.7 million decrease in personnel related costs and a $1.1 million decrease in Afrezza marketing costs, partially offset by an increase of $0.5 million in consulting and professional services costs.
Interest expense on debt for the fourth quarter of 2019 was $2.3 million compared to $1.7 million for the fourth quarter of 2018. This $0.6 million increase, or 35%, was primarily attributable to the net increase in our debt balance as a result of our debt restructuring in the third quarter of 2019.
The net loss for the fourth quarter of 2019 was $14.3 million, or $0.07 per share compared to a $9.8 million net loss in the fourth quarter of 2018 or $0.06 per share. The increase in the net loss of $4.5 million was primarily the result of an increased loss on foreign currency translation of $4.0 million associated with our insulin supply agreement denominated in Euros and of an increase of $0.6 million in interest expense.
Twelve Months Ended December 31, 2019
Total revenues were $63.0 million for the year ended December 31, 2019, reflecting Afrezza net revenue of $25.3 million and collaborations and services revenue of $37.7 million. Afrezza net revenue increased 46% compared to $17.3 million for the year ended December 31, 2018, primarily due to higher product demand, the first sale of Afrezza to our marketing partner in Brazil (Biomm), price increases as well as a more favorable mix of Afrezza cartridges. Collaborations and services revenue increased $27.2 million compared to the full year ended December 31, 2018, which was primarily attributed to the licensing and research agreements with United Therapeutics, both of which began in the fourth quarter of 2018.
On a GAAP basis, Afrezza gross profit was $5.2 million for the year ended December 31, 2019, an improvement of $7.3 million or 347% compared to a gross loss of $2.1 million in the same period in 2018, primarily due to an increase of $8.0 million in net revenue and a $2.2 million decrease in inventory write-offs, partially offset by increased costs due to higher sales and an increase of $0.8 million in fees paid to Amphastar for amendments to our insulin supply agreement. As a result, on a non-GAAP basis, gross profit was $8.0 million, or 32%, for the year ended December 31, 2019 compared to a gross loss of $0.1 million, or 1%, for the full year ended December 31, 2018.
R&D expenses for the year ended December 31, 2019 were $6.9 million compared to $8.7 million for the year ended December 31, 2018. This decrease of $1.8 million, or 21%, was primarily attributable to a $1.7 million decrease in personnel related costs and a $0.9 million decrease in clinical trial spending, partially offset by increased expenses of $0.2 million related to the development of our BluHale inhalation profiling apparatus and increased facility maintenance and equipment repair costs of $0.5 million.
SG&A expenses for the year ended December 31, 2019 were $74.7 million compared to $79.7 million for the year ended December 31, 2018. This decrease of $5.0 million, or 6%, was primarily attributable to a $6.6 million decrease in personnel and employee related costs, decreased consulting costs of $2.5 million and a $1.2 million decrease in stock-based compensation costs, which was partially offset by a $5.6 million increase in costs for television advertising for Afrezza.
Interest income increased by $0.5 million, or 99%, for the year ended December 31, 2019 compared to the year ended December 31, 2018, primarily due to a higher average balance on money market funds and short-term investments.
Interest expense on debt for the year ended December 31, 2019 was $10.9 million compared to $9.4 million for the year ended December 31, 2018. This $1.5 million increase was primarily attributable to a $3.4 million charge realized as a result of achieving a sales milestone in the third quarter of 2019 under our milestone agreement with Deerfield, partially offset by lower interest as a result of the repayment of the Deerfield credit facility.
The net loss for the year ended December 31, 2019 was $51.9 million, or $0.27 per share, compared to $87.0 million net loss for the year ended December 31, 2018, or $0.60 per share. The lower net loss was mainly attributable to a $35.2 million increase in total revenues.
Cash, Cash Equivalents, Restricted Cash and Short Term Investments
Cash, cash equivalents, restricted cash, and short-term investments at December 31, 2019 was $50.2 million compared to $71.7 million at December 31, 2018.
Non-GAAP Measures
Certain financial information contained in this press release is presented on both a reported basis (GAAP) and a non-GAAP basis. Reported results were prepared in accordance with GAAP whereas non-GAAP measures exclude items described in the reconciliation tables below. Non-GAAP financial information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current and past periods. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
Three Months Ended December 31,
2019 2018 $ Change % Change
Net revenue — Afrezza $ 7,761 $ 5,734 $ 2,027 35 %
Less cost of goods sold (4,632 ) (4,986 ) $ (354 ) (7 %)
GAAP gross profit — Afrezza 3,129 748 $ 2,381 318 %
Exclude Amphastar amendment fee — 2,000 $ (2,000 ) (100 %)
Non-GAAP gross profit — Afrezza $ 3,129 $ 2,748 $ 381 14 %
Non-GAAP gross margin 40 % 48 %
Twelve Months Ended December 31,
2019 2018 $ Change % Change
Net revenue — Afrezza $ 25,304 $ 17,276 $ 8,028 46 %
Less cost of goods sold (20,078 ) (19,392 ) $ 686 4 %
GAAP gross profit (loss) — Afrezza 5,226 (2,116 ) $ 7,342 347 %
Exclude Amphastar amendment fee 2,750 2,000 $ 750 38 %
Non-GAAP gross profit (loss) — Afrezza $ 7,976 $ (116 ) $ 8,092 6,976 %
Non-GAAP gross margin 32 % (1 %)
Conference Call
MannKind will host a conference call and presentation webcast to discuss these results today at 9:00 a.m. Eastern Time. To participate in the live call by telephone, please dial (800) 289-0438 or (323) 794-2423 and use the participant passcode: 1233728. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 1233728. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
[GlobeNewswire]
GlobeNewswire•February 25, 2020
Conference Call to Begin Today at 9:00 AM ET
2019 Total Revenue of $63.0 million
° 2019 Afrezza Net Revenue of $25.3 million; +46% vs. 2018
° 2019 Collaborations and Services Revenue of $37.7 million; +257% vs. 2018
4Q 2019 Total Revenue of $16.0 million
° 4Q 2019 Afrezza Net Revenue of $7.8 million; +35% vs. 4Q 2018
▪ 4Q 2019 Afrezza Net Revenue grew 22% vs. 3Q 2019
▪ 4Q 2019 Afrezza Gross Profit $3.1 million; 40% Gross Margin
° 4Q 2019 Collaborations and Services Revenue of $8.2 million; -20% vs. 4Q 2018
$50.2 million of Cash, Cash Equivalents, Restricted Cash, and Short-term Investments at December 31, 2019
WESTLAKE VILLAGE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2019.
“We ended 2019 on a strong note with fourth quarter 2019 Afrezza net revenue of $7.8 million, our best quarter to date,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. He also noted, “Our collaboration with United Therapeutics on TreT continues to make progress along the clinical and commercial pathways that are expected to set up a filing with the FDA within 12 months.”
Fourth Quarter 2019 Results
Total revenues were $16.0 million for the fourth quarter of 2019, reflecting Afrezza net revenue of $7.8 million and collaborations and services revenue of $8.2 million. Afrezza net revenue increased 35% compared to $5.7 million in the fourth quarter of 2018, primarily driven by higher product demand and price. Collaborations and services revenue decreased $2.1 million compared to the fourth quarter of 2018, primarily due to lower revenue from the United Therapeutics research agreement, which was substantially completed by the second quarter of 2019.
On a GAAP basis, Afrezza gross profit was $3.1 million for the fourth quarter of 2019 compared to $0.7 million in the same period in 2018. Afrezza cost of goods sold for the fourth quarter of 2018 included a fee of $2.0 million recorded in connection with the amendment of our insulin supply agreement with Amphastar. As a result, on a non-GAAP basis, gross profit was $2.7 million or 48% gross margin for the fourth quarter of 2018, compared to a GAAP basis gross margin of 40% for the fourth quarter of 2019.
Research and development (R&D) expenses for the fourth quarter of 2019 were $2.0 million compared to $1.1 million for the fourth quarter of 2018. This 82% increase was primarily attributable to an increase of $0.6 million in personnel costs associated with the United Therapeutics research agreement, which was classified as a cost of collaborations and services revenue in 2018, and to an increase of $0.3 million in maintenance costs for our research facility in Danbury, Connecticut.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2019 were $15.7 million compared to $18.0 million for the fourth quarter of 2018. This decrease of $2.3 million, or 13%, was primarily attributable to a $1.7 million decrease in personnel related costs and a $1.1 million decrease in Afrezza marketing costs, partially offset by an increase of $0.5 million in consulting and professional services costs.
Interest expense on debt for the fourth quarter of 2019 was $2.3 million compared to $1.7 million for the fourth quarter of 2018. This $0.6 million increase, or 35%, was primarily attributable to the net increase in our debt balance as a result of our debt restructuring in the third quarter of 2019.
The net loss for the fourth quarter of 2019 was $14.3 million, or $0.07 per share compared to a $9.8 million net loss in the fourth quarter of 2018 or $0.06 per share. The increase in the net loss of $4.5 million was primarily the result of an increased loss on foreign currency translation of $4.0 million associated with our insulin supply agreement denominated in Euros and of an increase of $0.6 million in interest expense.
Twelve Months Ended December 31, 2019
Total revenues were $63.0 million for the year ended December 31, 2019, reflecting Afrezza net revenue of $25.3 million and collaborations and services revenue of $37.7 million. Afrezza net revenue increased 46% compared to $17.3 million for the year ended December 31, 2018, primarily due to higher product demand, the first sale of Afrezza to our marketing partner in Brazil (Biomm), price increases as well as a more favorable mix of Afrezza cartridges. Collaborations and services revenue increased $27.2 million compared to the full year ended December 31, 2018, which was primarily attributed to the licensing and research agreements with United Therapeutics, both of which began in the fourth quarter of 2018.
On a GAAP basis, Afrezza gross profit was $5.2 million for the year ended December 31, 2019, an improvement of $7.3 million or 347% compared to a gross loss of $2.1 million in the same period in 2018, primarily due to an increase of $8.0 million in net revenue and a $2.2 million decrease in inventory write-offs, partially offset by increased costs due to higher sales and an increase of $0.8 million in fees paid to Amphastar for amendments to our insulin supply agreement. As a result, on a non-GAAP basis, gross profit was $8.0 million, or 32%, for the year ended December 31, 2019 compared to a gross loss of $0.1 million, or 1%, for the full year ended December 31, 2018.
R&D expenses for the year ended December 31, 2019 were $6.9 million compared to $8.7 million for the year ended December 31, 2018. This decrease of $1.8 million, or 21%, was primarily attributable to a $1.7 million decrease in personnel related costs and a $0.9 million decrease in clinical trial spending, partially offset by increased expenses of $0.2 million related to the development of our BluHale inhalation profiling apparatus and increased facility maintenance and equipment repair costs of $0.5 million.
SG&A expenses for the year ended December 31, 2019 were $74.7 million compared to $79.7 million for the year ended December 31, 2018. This decrease of $5.0 million, or 6%, was primarily attributable to a $6.6 million decrease in personnel and employee related costs, decreased consulting costs of $2.5 million and a $1.2 million decrease in stock-based compensation costs, which was partially offset by a $5.6 million increase in costs for television advertising for Afrezza.
Interest income increased by $0.5 million, or 99%, for the year ended December 31, 2019 compared to the year ended December 31, 2018, primarily due to a higher average balance on money market funds and short-term investments.
Interest expense on debt for the year ended December 31, 2019 was $10.9 million compared to $9.4 million for the year ended December 31, 2018. This $1.5 million increase was primarily attributable to a $3.4 million charge realized as a result of achieving a sales milestone in the third quarter of 2019 under our milestone agreement with Deerfield, partially offset by lower interest as a result of the repayment of the Deerfield credit facility.
The net loss for the year ended December 31, 2019 was $51.9 million, or $0.27 per share, compared to $87.0 million net loss for the year ended December 31, 2018, or $0.60 per share. The lower net loss was mainly attributable to a $35.2 million increase in total revenues.
Cash, Cash Equivalents, Restricted Cash and Short Term Investments
Cash, cash equivalents, restricted cash, and short-term investments at December 31, 2019 was $50.2 million compared to $71.7 million at December 31, 2018.
Non-GAAP Measures
Certain financial information contained in this press release is presented on both a reported basis (GAAP) and a non-GAAP basis. Reported results were prepared in accordance with GAAP whereas non-GAAP measures exclude items described in the reconciliation tables below. Non-GAAP financial information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current and past periods. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
Three Months Ended December 31,
2019 2018 $ Change % Change
Net revenue — Afrezza $ 7,761 $ 5,734 $ 2,027 35 %
Less cost of goods sold (4,632 ) (4,986 ) $ (354 ) (7 %)
GAAP gross profit — Afrezza 3,129 748 $ 2,381 318 %
Exclude Amphastar amendment fee — 2,000 $ (2,000 ) (100 %)
Non-GAAP gross profit — Afrezza $ 3,129 $ 2,748 $ 381 14 %
Non-GAAP gross margin 40 % 48 %
Twelve Months Ended December 31,
2019 2018 $ Change % Change
Net revenue — Afrezza $ 25,304 $ 17,276 $ 8,028 46 %
Less cost of goods sold (20,078 ) (19,392 ) $ 686 4 %
GAAP gross profit (loss) — Afrezza 5,226 (2,116 ) $ 7,342 347 %
Exclude Amphastar amendment fee 2,750 2,000 $ 750 38 %
Non-GAAP gross profit (loss) — Afrezza $ 7,976 $ (116 ) $ 8,092 6,976 %
Non-GAAP gross margin 32 % (1 %)
Conference Call
MannKind will host a conference call and presentation webcast to discuss these results today at 9:00 a.m. Eastern Time. To participate in the live call by telephone, please dial (800) 289-0438 or (323) 794-2423 and use the participant passcode: 1233728. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 1233728. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Imo positiv jedoch lsngsames Wachstum
Ich las nichts zu Brasilien möglich dass ich es überlesen habe??
!
Dieser Beitrag wurde von MODelfin moderiert. Grund: Bitte argumentieren Sie sachlich und achten Sie bitte auf Ihre Wortwahl, Danke.
Hoffe auf hohe TRX
Das hoffe ich dann auch, glaub aber nicht dran....
hier wird's auch noch durchsacken
hier wird's auch noch durchsacken
Trx. 770. laut stocktwits
Am 17.2 war presidents day
Also 4 tage woche
Trx über 1000??? Oder wieder nicht
749 trx shit
oh je... wieder nix
TRX 749
NRX 353
TRX $ 1.27
TRX 749
NRX 353
TRX $ 1.27
Antwort auf Beitrag Nr.: 62.906.682 von Kleingeldinvestor am 06.03.20 13:51:14reicht nur für einen Kleingeldinvestor
ich wüsste gerne mal, warum das so schlecht läuft mit dem Vertrieb
ich wüsste gerne mal, warum das so schlecht läuft mit dem Vertrieb
Antwort auf Beitrag Nr.: 62.906.793 von questionmark am 06.03.20 14:00:41😂😂 aber wirklich...da war ja die kurze vorletzte Woche noch besser....wirklich enttäuschend
Hallo Leute,
könnte mich jemand mal in aller Kürze in einem Satz schlau machen, was
TRX und NRX bedeutet?
Schon mal vielen Dank
könnte mich jemand mal in aller Kürze in einem Satz schlau machen, was
TRX und NRX bedeutet?
Schon mal vielen Dank
Klar hier ein link
Antwort auf Beitrag Nr.: 62.954.312 von price-of-success am 10.03.20 20:25:39Perfekt, thx a lot
jetzt hoffen wir auf TRX über 1.000 am Freitag
Trx 817. ex stocktwits
UD Dollar 1,47 Millionen pro Woche, nicht schlecht, Schnäppchenkurse!
Die 1000 sollten endlich kommem
Antwort auf Beitrag Nr.: 62.999.477 von Magnetfeldfredy am 13.03.20 17:02:03
Die sollten sich mal nach oben drehen. Klar, jetzt gerade sehr schwierig, aber mir dauert das hier schon zu lang. Die Ausgangsposition ist seit Jahren super, das ist dann aber auch schon Alles. 😕
Schnäppchen...
... stimmt, doch was bringen mir die Schnäppchen, wenn diese immer nur Schnäppchen bleiben.Die sollten sich mal nach oben drehen. Klar, jetzt gerade sehr schwierig, aber mir dauert das hier schon zu lang. Die Ausgangsposition ist seit Jahren super, das ist dann aber auch schon Alles. 😕
Antwort auf Beitrag Nr.: 63.009.722 von bernd1980 am 14.03.20 19:36:41...da kann ich mich nur anschließen......jetzt ist endlich mal MANNKIND dran den Aktionären auch die entsprechenden Zahlen zu liefern, damit schafft man Vertrauen, was im meinen Augen allerdings hier die Manager noch nie berücksichtigt haben...schade
Jetzt muss mannkind endlich liefetn
Bravo Mannkind: Die Behandlung zielt auf die Lungenerkrankung in der tiefen Lunge an, erreichbar mit der Technosphere Technologie und dem Dreamline-Inhalator:
MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic
Stocks mentioned: MNKD
Share
Listen
Save
WESTLAKE VILLAGE, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its pipeline of investigational products for treating serious lung diseases, with the goal of prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19.
Specifically, MannKind has initiated a collaboration with Immix Biopharma, Inc. to prepare a dry powder formulation of a compound with the potential to treat acute respiratory distress syndrome, a complication of COVID-19. The immediate focus of this effort is to rapidly develop prototype powders, which will then be assessed for their potential to be used therapeutically. Other collaborations are being actively explored at this time.
MannKind is committed to joining the global effort to overcome the COVID-19 crisis. MannKind’s formulation and drug development expertise as well as its excess manufacturing capacity will be deployed as necessary to help protect humankind from this global health crisis.
Formulations for Pulmonary Delivery
MannKind’s Technosphere® technology is an innovative, dry-powder formulation technology that allows medication to be delivered to the lungs. MannKind has successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides and small molecules. Technosphere powders are based on a proprietary excipient, fumaryl diketopiperazine (FDKP), which is a pH-sensitive organic molecule that self-assembles into small particles under acidic conditions. Active pharmaceutical ingredients can be loaded onto these particles, which are then dried to powder form. The resulting powder has a consistent and narrow range of particle sizes with good aerodynamic properties that enable efficient delivery deep into the lungs. Technosphere powders dissolve quickly when the particles contact the moist lung surface with its neutral pH, releasing the drug molecules to diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to provide excellent systemic exposure.
Drug Delivery Devices
MannKind has also created an innovative line of breath-powered, dry powder inhalers. Its inhalers are easy to use, cost-effective and can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. Both the reusable and single-use inhaler formats use the same internal air-flow design. Being breath-powered, our inhalers require only the patient’s inhalation effort to deliver the powder. The inhalers are engineered to produce an aggressive airstream that de-agglomerates the powder while keeping the powder moving relatively slowly. This slow-moving powder effectively navigates the patient’s airways to reach the deep lung with minimal deposition at the back of the throat. MannKind’s inhalers show very little change in performance (i.e., efficient cartridge emptying) over a wide range of inhalation efforts.
Manufacturing Capability
MannKind’s 328,000 square foot R&D and manufacturing facility is located in Danbury, Connecticut and has a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. The facility houses two 61 square meter lyophilizers and has sufficient filling capacity to produce more than 300 million cartridges of inhaled drug annually. The quality management systems of the facility have been certified to be in conformance with the ISO 13485 and MD-SAP standards and was inspected most recently by the U.S. Food and Drug Administration in June 2018, at which time there were no inspectional observations.
About Immix Biopharma
Immix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix is focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit www.immixbio.com.
About MannKind
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contacts:
Investor Relations
818-661-5000
ir@mannkindcorp.com
Collaborations
(818) 661-5001
MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic
Stocks mentioned: MNKD
Share
Listen
Save
WESTLAKE VILLAGE, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its pipeline of investigational products for treating serious lung diseases, with the goal of prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19.
Specifically, MannKind has initiated a collaboration with Immix Biopharma, Inc. to prepare a dry powder formulation of a compound with the potential to treat acute respiratory distress syndrome, a complication of COVID-19. The immediate focus of this effort is to rapidly develop prototype powders, which will then be assessed for their potential to be used therapeutically. Other collaborations are being actively explored at this time.
MannKind is committed to joining the global effort to overcome the COVID-19 crisis. MannKind’s formulation and drug development expertise as well as its excess manufacturing capacity will be deployed as necessary to help protect humankind from this global health crisis.
Formulations for Pulmonary Delivery
MannKind’s Technosphere® technology is an innovative, dry-powder formulation technology that allows medication to be delivered to the lungs. MannKind has successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides and small molecules. Technosphere powders are based on a proprietary excipient, fumaryl diketopiperazine (FDKP), which is a pH-sensitive organic molecule that self-assembles into small particles under acidic conditions. Active pharmaceutical ingredients can be loaded onto these particles, which are then dried to powder form. The resulting powder has a consistent and narrow range of particle sizes with good aerodynamic properties that enable efficient delivery deep into the lungs. Technosphere powders dissolve quickly when the particles contact the moist lung surface with its neutral pH, releasing the drug molecules to diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to provide excellent systemic exposure.
Drug Delivery Devices
MannKind has also created an innovative line of breath-powered, dry powder inhalers. Its inhalers are easy to use, cost-effective and can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. Both the reusable and single-use inhaler formats use the same internal air-flow design. Being breath-powered, our inhalers require only the patient’s inhalation effort to deliver the powder. The inhalers are engineered to produce an aggressive airstream that de-agglomerates the powder while keeping the powder moving relatively slowly. This slow-moving powder effectively navigates the patient’s airways to reach the deep lung with minimal deposition at the back of the throat. MannKind’s inhalers show very little change in performance (i.e., efficient cartridge emptying) over a wide range of inhalation efforts.
Manufacturing Capability
MannKind’s 328,000 square foot R&D and manufacturing facility is located in Danbury, Connecticut and has a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. The facility houses two 61 square meter lyophilizers and has sufficient filling capacity to produce more than 300 million cartridges of inhaled drug annually. The quality management systems of the facility have been certified to be in conformance with the ISO 13485 and MD-SAP standards and was inspected most recently by the U.S. Food and Drug Administration in June 2018, at which time there were no inspectional observations.
About Immix Biopharma
Immix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix is focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit www.immixbio.com.
About MannKind
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contacts:
Investor Relations
818-661-5000
ir@mannkindcorp.com
Collaborations
(818) 661-5001
Na da bin ich mal gespannt, wie hoch uns die Corona-Fantasie bringt...
Antwort auf Beitrag Nr.: 63.037.345 von Magnetfeldfredy am 17.03.20 14:08:26Das war schon immer eine Idee, es handelt sich um Inhalation wäre also bestens geeignet, deshalb hab ich auch aufgestockt
Das soll mit dem Mannkind Inhalator und dem neuen Mittel behandelt werden:
When coronavirus kills, the lung condition ARDS can be the culprit. Here’s what you need to know.
by Stacey Burling, Updated: 13 minutes ago
When coronavirus kills, the lung condition ARDS can be the culprit. Here’s what you need to know.
Zhang Yuwei / AP
Email
LinkedIn
When she was 33, Eileen Rubin learned firsthand what it’s like to have acute respiratory distress syndrome or ARDS, a life-threatening condition she had never heard of.
It’s about to become more widely known.
ARDS is one of the most severe complications caused by the new coronavirus, and early estimates are it could affect perhaps 1 in 100 people with the virus. ARDS kills 30 to 40 percent of the people who get it. Survivors require weeks of mechanical ventilation in the hospital and lots of help in recovery. Many say they’re still functioning below par a year later, even though their lungs appear to have recovered.
Rubin, a lawyer who founded and is now president of the ARDS Foundation, said ARDS can start in many ways: with a virus like the flu or coronavirus, vaping, smoke inhalation, a gunshot wound to the lungs, pancreatitis. She first became sick in 1995 with pain in her lower back that spread to her chest. Soon she was in the emergency room with kidney failure. She was on a ventilator for eight weeks, the first four in an induced coma. Her spleen was damaged. Her lungs collapsed. She had delirium.
Advertisement
When she began feeling better, she was helpless. “I was unable to lift even a finger,” she said. “I had no muscle tone, no small motor skills, no large muscle skills.”
It was eight months before she could go back to work.
The Inquirer Coronavirus Newsletter
Science-based coverage sent daily to your inbox — all facts, no panic
Rubin said cases of ARDS like hers that are caused by sepsis are among the worst, but recovery from the syndrome is a hard for everybody.
Eileen Rubin is president of the ARDS Foundation.
Courtesy of Eileen Rubin
Eileen Rubin is president of the ARDS Foundation.
About 200,000 Americans get ARDS each year. There are no medicines for it. Mechanical ventilation helps spread oxygen to tissues and remove carbon dioxide until the lungs can recover. Doctors treat other stressed organs as best they can. Patients are often given physical therapy to maintain some muscle strength. Antibiotics are meant to prevent further infection, and patients are fed through tubes. “You’re essentially doing everything for the patient at this point,” said Reynold A. Panettieri J., vice chancellor, clinical and translational science at Rutgers University.
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4 percent had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical care medicine doctor at University of California San Francisco, said he estimates that 1 to 3% of COVID-19 patients will get ARDS. Because some people have very mild or no symptoms and have not come to the attention of doctors, many rates currently cited for aspects of the disease may come down.
Advertisement
People over 60, smokers, and those with chronic conditions like diabetes and heart disease are at highest risk for COVID-19 complications and death, but Matthay said there also have been cases of ARDS among healthy people in their 30s, 40s and 50s.
Most people who get COVID-19 have relatively mild flu- or cold-like symptoms such as fever and cough, Panettieri said. They’re sick no more than two weeks. Some are better within 72 to 96 hours. Shortness of breath may show up two to three days into the disease and it is a warning sign. “Then you’re really concerned about pneumonia,” he said.
Pneumonia, a lung infection, is the big killer in patients with flu and other respiratory infections. It causes the tiny air sacs in lungs to fill with fluid, reducing their ability to supply oxygen to the body. This can be caused by bacteria or viruses. In flu, it is often caused by bacteria that move in after the initial viral infection. In COVID-19, the virus itself usually causes the pneumonia. An intense reaction from the immune system can add to lung inflammation, doctors said.
Nuala Meyer, pulmonary and critical care medicine doctor at Penn Medicine, said a strong immune response is necessary to kill the virus. Sometimes, some parts of the immune system are functioning properly while others are not. The fact that the elderly, who tend to have weaker immune systems, are most vulnerable to COVID-19 implies that over-reaction of the immune system is not the primary problem, she said.
When pneumonia spreads to both lungs, blood oxygen levels are well below normal and patients require assisted ventilation, such as high-flow oxygen or a breathing machine, the diagnosis shifts to ARDS. A small percentage of ARDS patients may also need an ECMO, extracorporeal membrane oxygenation, machine, which oxygenates blood outside the body.
Meyer said early reports are showing a high percentage of hospitalized patients with COVID-19 developing ARDS. They often have “profound hypoxia” or low oxygen levels in their tissues. Some also have low blood pressure and, later in the course of the disease, heart problems.
Meyer said that Italy’s experience with COVID-19 shows demand is likely to be higher for ventilators than ECMO machines. Many patients will need the machines for 10 to 14 days and some will need them longer. Matthay said patients spend an average of 25 days in an intensive care unit.
Rubin and Matthay said there is an urgent need for better treatments and any medications ARDS. Matthay said there are some antiviral drugs in the early phase of testing. High-dose vitamin C is also being tested for ARDS in general.
Advertisement
For now, Rubin said, “we have nothing.”
Patients who survive the devastating syndrome generally have almost normal lung function a year later, Meyer said. But weeks of hospitalization take a toll on muscles. Many say they are not as strong as they were before hospitalization. Even five years later, they function at lower levels physically than peers. Panettieri said younger people and those who were in better shape before they got sick tend to recover more muscle strength.
» READ MORE: Doctors study postintensive care syndrome
Rubin, who is now doing well now, said about one-third of ARDS patients never go back to work. Another third work reduced hours. Rates of depression, anxiety and post-traumatic stress disorder are high.
While there is no data on how COVID-19 affects ARDS survivors, Rubin said she’s been getting many calls and messages from people who are worried they are at high risk. “They are terrified,” she said.
by Stacey Burling
Posted: March 17, 2020 - 9:56 AM
Stacey Burling | @StaceyABurling | sburling@inquirer.com
We Recommend
Small businesses worry about coronavirus shutdown: ‘In this line of work you can’t make up two weeks’
Ellie Silverman, Staff Writer
How to stock your pantry in case of coronavirus or quarantine
Jenn Ladd, Staff Writer
Post offices, banks, water: How the coronavirus is affecting essential services across the region
Grace Dickinson, Staff Writer
How to keep your immune system healthy during the coronavirus pandemic, according to experts
Stacey Burling, Staff Writer
Chris Matthews’ shocking MSNBC exit prompts a Fox News host to defend the Philly native
Rob Tornoe, Staff Writer
On the market: A Main Line classic for $799,900
Paul Jablow, For The Inquirer, For The Inquirer
Advert
When coronavirus kills, the lung condition ARDS can be the culprit. Here’s what you need to know.
by Stacey Burling, Updated: 13 minutes ago
When coronavirus kills, the lung condition ARDS can be the culprit. Here’s what you need to know.
Zhang Yuwei / AP
When she was 33, Eileen Rubin learned firsthand what it’s like to have acute respiratory distress syndrome or ARDS, a life-threatening condition she had never heard of.
It’s about to become more widely known.
ARDS is one of the most severe complications caused by the new coronavirus, and early estimates are it could affect perhaps 1 in 100 people with the virus. ARDS kills 30 to 40 percent of the people who get it. Survivors require weeks of mechanical ventilation in the hospital and lots of help in recovery. Many say they’re still functioning below par a year later, even though their lungs appear to have recovered.
Rubin, a lawyer who founded and is now president of the ARDS Foundation, said ARDS can start in many ways: with a virus like the flu or coronavirus, vaping, smoke inhalation, a gunshot wound to the lungs, pancreatitis. She first became sick in 1995 with pain in her lower back that spread to her chest. Soon she was in the emergency room with kidney failure. She was on a ventilator for eight weeks, the first four in an induced coma. Her spleen was damaged. Her lungs collapsed. She had delirium.
Advertisement
When she began feeling better, she was helpless. “I was unable to lift even a finger,” she said. “I had no muscle tone, no small motor skills, no large muscle skills.”
It was eight months before she could go back to work.
The Inquirer Coronavirus Newsletter
Science-based coverage sent daily to your inbox — all facts, no panic
Rubin said cases of ARDS like hers that are caused by sepsis are among the worst, but recovery from the syndrome is a hard for everybody.
Eileen Rubin is president of the ARDS Foundation.
Courtesy of Eileen Rubin
Eileen Rubin is president of the ARDS Foundation.
About 200,000 Americans get ARDS each year. There are no medicines for it. Mechanical ventilation helps spread oxygen to tissues and remove carbon dioxide until the lungs can recover. Doctors treat other stressed organs as best they can. Patients are often given physical therapy to maintain some muscle strength. Antibiotics are meant to prevent further infection, and patients are fed through tubes. “You’re essentially doing everything for the patient at this point,” said Reynold A. Panettieri J., vice chancellor, clinical and translational science at Rutgers University.
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4 percent had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical care medicine doctor at University of California San Francisco, said he estimates that 1 to 3% of COVID-19 patients will get ARDS. Because some people have very mild or no symptoms and have not come to the attention of doctors, many rates currently cited for aspects of the disease may come down.
Advertisement
People over 60, smokers, and those with chronic conditions like diabetes and heart disease are at highest risk for COVID-19 complications and death, but Matthay said there also have been cases of ARDS among healthy people in their 30s, 40s and 50s.
Most people who get COVID-19 have relatively mild flu- or cold-like symptoms such as fever and cough, Panettieri said. They’re sick no more than two weeks. Some are better within 72 to 96 hours. Shortness of breath may show up two to three days into the disease and it is a warning sign. “Then you’re really concerned about pneumonia,” he said.
Pneumonia, a lung infection, is the big killer in patients with flu and other respiratory infections. It causes the tiny air sacs in lungs to fill with fluid, reducing their ability to supply oxygen to the body. This can be caused by bacteria or viruses. In flu, it is often caused by bacteria that move in after the initial viral infection. In COVID-19, the virus itself usually causes the pneumonia. An intense reaction from the immune system can add to lung inflammation, doctors said.
Nuala Meyer, pulmonary and critical care medicine doctor at Penn Medicine, said a strong immune response is necessary to kill the virus. Sometimes, some parts of the immune system are functioning properly while others are not. The fact that the elderly, who tend to have weaker immune systems, are most vulnerable to COVID-19 implies that over-reaction of the immune system is not the primary problem, she said.
When pneumonia spreads to both lungs, blood oxygen levels are well below normal and patients require assisted ventilation, such as high-flow oxygen or a breathing machine, the diagnosis shifts to ARDS. A small percentage of ARDS patients may also need an ECMO, extracorporeal membrane oxygenation, machine, which oxygenates blood outside the body.
Meyer said early reports are showing a high percentage of hospitalized patients with COVID-19 developing ARDS. They often have “profound hypoxia” or low oxygen levels in their tissues. Some also have low blood pressure and, later in the course of the disease, heart problems.
Meyer said that Italy’s experience with COVID-19 shows demand is likely to be higher for ventilators than ECMO machines. Many patients will need the machines for 10 to 14 days and some will need them longer. Matthay said patients spend an average of 25 days in an intensive care unit.
Rubin and Matthay said there is an urgent need for better treatments and any medications ARDS. Matthay said there are some antiviral drugs in the early phase of testing. High-dose vitamin C is also being tested for ARDS in general.
Advertisement
For now, Rubin said, “we have nothing.”
Patients who survive the devastating syndrome generally have almost normal lung function a year later, Meyer said. But weeks of hospitalization take a toll on muscles. Many say they are not as strong as they were before hospitalization. Even five years later, they function at lower levels physically than peers. Panettieri said younger people and those who were in better shape before they got sick tend to recover more muscle strength.
» READ MORE: Doctors study postintensive care syndrome
Rubin, who is now doing well now, said about one-third of ARDS patients never go back to work. Another third work reduced hours. Rates of depression, anxiety and post-traumatic stress disorder are high.
While there is no data on how COVID-19 affects ARDS survivors, Rubin said she’s been getting many calls and messages from people who are worried they are at high risk. “They are terrified,” she said.
by Stacey Burling
Posted: March 17, 2020 - 9:56 AM
Stacey Burling | @StaceyABurling | sburling@inquirer.com
We Recommend
Small businesses worry about coronavirus shutdown: ‘In this line of work you can’t make up two weeks’
Ellie Silverman, Staff Writer
How to stock your pantry in case of coronavirus or quarantine
Jenn Ladd, Staff Writer
Post offices, banks, water: How the coronavirus is affecting essential services across the region
Grace Dickinson, Staff Writer
How to keep your immune system healthy during the coronavirus pandemic, according to experts
Stacey Burling, Staff Writer
Chris Matthews’ shocking MSNBC exit prompts a Fox News host to defend the Philly native
Rob Tornoe, Staff Writer
On the market: A Main Line classic for $799,900
Paul Jablow, For The Inquirer, For The Inquirer
Advert
Antwort auf Beitrag Nr.: 63.038.404 von Magnetfeldfredy am 17.03.20 15:15:48Wäre toll für alle Betroffenen, wenn es klappt!
Ja können wir gut gebrauchen
Morgen gibt es Trx
Hat einer schon die Wochenzahlen??? Vielen Dank vorab :-)
Moment bittr
Keine TRX bislang
Trx ex stockteits 832
Antwort auf Beitrag Nr.: 63.078.259 von price-of-success am 20.03.20 14:45:29$MNKD Data taken from bloomberg BI
week ending 3/13/2020
TRx count 832 vs 817
TRx $ $1.37m vs $1.47m
week ending 3/13/2020
TRx count 832 vs 817
TRx $ $1.37m vs $1.47m
Haben wir schon VK Zahlen für die aktuelle Woche?? VG
TRX - 896 NRX - 352 (vs 376, vs 389) $1.53m
Langsam aber steigend
Antwort auf Beitrag Nr.: 63.151.720 von Muckimann66 am 27.03.20 12:26:59Sehr gut
Morgen wird es etwas geben 🤪
Antwort auf Beitrag Nr.: 63.213.048 von price-of-success am 02.04.20 12:49:25Schon Infos zu den Zahlen?? VG
Gegen Mittag
3/20/20: 896, 352(NRX)
Antwort auf Beitrag Nr.: 63.229.377 von Muckimann66 am 03.04.20 15:47:36Oh das waren die alten
Jetzt bitte ueber 900. Nzw 1000
Leichte steigerung
??????????
So zahlen 3/27 sind noch nicht raus lt stocktwits
Antwort auf Beitrag Nr.: 63.229.899 von price-of-success am 03.04.20 16:23:05Kamen die Zahlen schonmal sooo spät?
Neun gutes Zeichen ??
Antwort auf Beitrag Nr.: 63.231.294 von price-of-success am 03.04.20 18:00:36Hoffentlich
könnten aber auch miserabel sein....because of Corona...wäre dann wohl die Entschuldigung
könnten aber auch miserabel sein....because of Corona...wäre dann wohl die Entschuldigung
Trx 773 lt stocktwits 3/27
Ist das zäh. Liegt es Mike ?!
Scripts ? Sorry heute ist es erst Donnerstag !!
Heute ist Freitag gibt es scripts trotz Good Friday
Trx 670. wenig wenig
Woher rührt denn Euer Optimismus dass das hier noch eine Erfolgsstory wird ?
Die Zukunft in der Diabetes-Behandlung gehört den Closed-Loop-Systemen. Nachdem sich Afrezza nun jahrelang nicht am Markt etablierte wird die Luft für dieses Produkt in Zukunft immer dünner.
Die Corona-Geschichte kann m.E. als Trittbrett-Fahrerei einstufen.
Bleibt TreT. Hier fällt es mir schwer das Potential einzuschätzen.
Über eine fundierte Begründung warum man hier investieren sollte würde ich mich freuen.
Die Zukunft in der Diabetes-Behandlung gehört den Closed-Loop-Systemen. Nachdem sich Afrezza nun jahrelang nicht am Markt etablierte wird die Luft für dieses Produkt in Zukunft immer dünner.
Die Corona-Geschichte kann m.E. als Trittbrett-Fahrerei einstufen.
Bleibt TreT. Hier fällt es mir schwer das Potential einzuschätzen.
Über eine fundierte Begründung warum man hier investieren sollte würde ich mich freuen.
Du wärst nicht hier ohne Interesse an oral applizierten Arzneimitteln
Antwort auf Beitrag Nr.: 63.301.270 von price-of-success am 11.04.20 11:39:11
Richtig. Durch einen Typ 1 im engsten Familienkreis interesse ich mich grundsätzlich für alles in Sachen Diabetes. Aber wenn Dein Umkehrschluss ist, dass alles wofür ich mich interessiere auch ein Börsenerfolg ist muss ich Dich enttäuschen.
Die beste BZ-Einstellung hat man im Zusammenspiel zwischen kontinuiierlicher Blutzucker-Messung und Insulinabgabe, das wird Dir jeder Diabetologe und Arzt bestätigen. Closed-Loop wird mit einem Spray nicht funktionieren.
Dann würde für Afrezza eigentlich nur die "Ich brauche ab und zu mal Insulin"-Nische bleiben. Und da bleibt die Frage warum das Produkt, welches jetzt ja auch schon einige Jahre auf dem Markt ist, auch für diesen Anwendungsfall nur sehr wenig Akzeptanz findet
Zitat von price-of-success: Du wärst nicht hier ohne Interesse an oral applizierten Arzneimitteln
Richtig. Durch einen Typ 1 im engsten Familienkreis interesse ich mich grundsätzlich für alles in Sachen Diabetes. Aber wenn Dein Umkehrschluss ist, dass alles wofür ich mich interessiere auch ein Börsenerfolg ist muss ich Dich enttäuschen.
Die beste BZ-Einstellung hat man im Zusammenspiel zwischen kontinuiierlicher Blutzucker-Messung und Insulinabgabe, das wird Dir jeder Diabetologe und Arzt bestätigen. Closed-Loop wird mit einem Spray nicht funktionieren.
Dann würde für Afrezza eigentlich nur die "Ich brauche ab und zu mal Insulin"-Nische bleiben. Und da bleibt die Frage warum das Produkt, welches jetzt ja auch schon einige Jahre auf dem Markt ist, auch für diesen Anwendungsfall nur sehr wenig Akzeptanz findet
Hi Maigret . Denke die Zielgruppe ist eher Typ 2 so wie ich aber hier nicht offiziell erhältlich ja der Erfolg ist bislang kläglich. Leider.
Antwort auf Beitrag Nr.: 63.301.729 von price-of-success am 11.04.20 13:16:22
Bei Typ 2 sehe ich aber nur auch diejenigen als Zielgruppe die nur unregelmäßig Insulin benötigen. Gut, das ist wahrscheinlich immer noch eine recht große Anzahl von Menschen.
Aber ich stelle mir halt die Frage warum das Produkt trotz jahrelanger Promotion nicht einschlägt und warum große Partner abwinken. Anders formuliert: Was weiss der deutsche Kleininvestor was Sanofi nicht weiß ?
Zitat von price-of-success: Hi Maigret . Denke die Zielgruppe ist eher Typ 2 so wie ich aber hier nicht offiziell erhältlich ja der Erfolg ist bislang kläglich. Leider.
Bei Typ 2 sehe ich aber nur auch diejenigen als Zielgruppe die nur unregelmäßig Insulin benötigen. Gut, das ist wahrscheinlich immer noch eine recht große Anzahl von Menschen.
Aber ich stelle mir halt die Frage warum das Produkt trotz jahrelanger Promotion nicht einschlägt und warum große Partner abwinken. Anders formuliert: Was weiss der deutsche Kleininvestor was Sanofi nicht weiß ?
Antwort auf Beitrag Nr.: 63.307.957 von Maigret am 12.04.20 19:56:57Deine Frage sitzt mitten in der Zielscheibe.
fragen wir uns alle.
Vermutlich kennt nur Mike C. die Antwort
ist es die Versicherung?
Ist der Vertrieb zu klein?
ist der Einzugsberech zu klein?
Interessant wird der Einzug in Brasilien
Läuft es da besser?
Ich hoffe und wünsche es mir
Gruß
fragen wir uns alle.
Vermutlich kennt nur Mike C. die Antwort
ist es die Versicherung?
Ist der Vertrieb zu klein?
ist der Einzugsberech zu klein?
Interessant wird der Einzug in Brasilien
Läuft es da besser?
Ich hoffe und wünsche es mir
Gruß
eines noch: der Umsatz steigt trotzdem- nur eben nur in mini Schritten
interessanter wird es - hoffentlich- bei über 1000 TRX/ Monat- und auch das ist wenig
interessanter wird es - hoffentlich- bei über 1000 TRX/ Monat- und auch das ist wenig
Oder wollen die Endos Afrezza nicht berschreiben ??
Guten Abend es heisst natürlich ‚ verschreiben‘
Dennoch was erklärt den Anstieg von Mannkind?
Droht eine K E ??
Droht eine K E ??
Guten Morgen hier die Erklärung
Ultra rapid reacting Insulin auf dem label so scheint es dyor bitte
Guten Morgen auf Stockwits Aufregung wg des neuen labels . Was denkt die community hier?
Scheint, dass die Zahl der shot Aktien sinkt wer wird da nervös??
Short. Short sorry
Falls das stimmen sollte wärs nicht schlecht für ne kurze Woche
$1.44m
TRX 781
NRX 315 (290,333)
$1.44m
TRX 781
NRX 315 (290,333)
Nicht schlecht. 4 Tage Woche
Männer. Was hält mnkd davon ab über usd 1,30 zu steigen welcher Widerstand sitzt da?
Können warrants der grund sein warum mnkd
An der usd 1.30 abprallt
An der usd 1.30 abprallt
$MNKD it’s hard to believe that shorts covered over 10 million shares yet we are still in penny land. I imagine that as we move through this year we will see more short covering due to 2 United milestone payments, expiration of warrants, continued increase in revenues including Brazil, India Clinical trials completed, and potential added molecule(s). Not certain if added manufacturing capacity will be feasible this year and I doubt Pediatrics trials will be completed.
Von stocktwits kopiert dyor
Gibt es Trx ?
Trx. 761. from stocktwits
Antwort auf Beitrag Nr.: 63.443.513 von price-of-success am 24.04.20 15:38:18Es wird einfach net besser...bzw zu langsam
🤮🤮🤮🤮🤮🤮🤮
Männer geht hier was??
Sieht so aus, da geht man nur mal schnell ein paar Wände verputzen und dann das ... :-)
Was läuft da im hintergrund??
UTHR-Deal mit TreTgeht gut voran:
kevinmik
24m
$MNKD a question about TreT just came up from a Jefferies Analyst and United stated the trial is 1/3 enrolled and currently is not enrolling new patients due to COVID. United went on to say as clinical trial sites begin to open, they will add additional new sites to make up for lost time and expect the trial to complete during the original time line guidance. United also stated a second trial in healthy patients for TreT required by the FDA was started in March. Looks like TreT is a major focus at United and they are putting the time and resources into the program to get an approval asap. Good news.
kevinmik
24m
$MNKD a question about TreT just came up from a Jefferies Analyst and United stated the trial is 1/3 enrolled and currently is not enrolling new patients due to COVID. United went on to say as clinical trial sites begin to open, they will add additional new sites to make up for lost time and expect the trial to complete during the original time line guidance. United also stated a second trial in healthy patients for TreT required by the FDA was started in March. Looks like TreT is a major focus at United and they are putting the time and resources into the program to get an approval asap. Good news.
Netter Sprung heute nach oben
Pharma läuft sogar bei mnkd??
Moin hat jemand scripts?
4/21/20 trx. 739
Ein fröhliches hallo in die Runde,
hat schon jemand die Freitagszahlen??
VG und vielen Dank
hat schon jemand die Freitagszahlen??
VG und vielen Dank
Trx 649. stocktwits
🤮🙏🙊🙈
Die Scripts sind nicht gut aber beim CoronaKnock Down kannst Du nicht mehr erwarten, die Zahlen werden zurückkommen.
Viel wichtiger ist nach lesen des CC-transcripts, dass mit TreT-Programm der real-game changer bevorsteht, 400 Millionen-1 Milliarde Umsatz bei UTHR und Mannkind erhält nach Zuzlassung mindestens 10 % revenues, das wären 40-100 Millionen pro Jahr und damit Mannkind aller Sorgen los!
Das wird innerhalb von 12-15 Monaten kommen und der Kurs bei US Dollar 5 stehen:
Michael E. Castagna, MannKind Corporation - CEO & Director [32]
--------------------------------------------------------------------------------
Yes, Bert. Look, when we entered a deal with United, we knew that trial was coming. Obviously it was early. Wouldn't know the readout was. And having a positive readout, I think it was in WHO III criteria, literally expanded the market dramatically for Tyvaso. And we would expect our TreT program to be able to participate in that market expansion. In fact, it'll probably help penetrate that market because of the easier delivery platform that we have and the administration time and backup supplies you need, et cetera. So, we're very excited. We went into this expecting Tyvaso and PAH, and we felt that alone was a good enough partnership to make this a worthwhile endeavor for both companies. And now this is all upside. And we've got to think through that forecast. We have to think through that as a manufacturing capacity. Think about that in our packaging. So it definitely changes, and we're working closely every week to make sure we continue to supply patients in BREEZE, but also think about the interstitial lung disease indication and how we prepare for that with TreT. So we're very excited about treprostinil. We think that will ride the future capital of the company to ensure continued acceleration of growth as we get out there. And just to remind investors, we will receive double digit royalties upon approval. So this -- Tyvaso today does a little over $400 million. So these are significant when you look out and see where Afrezza revenues will be and Tyvaso on top of it. So, we're excited. Other questions, Bert? You missed our record revenue.
--------------------------------------------------------------------------------
Robert Cummins Hazlett, BTIG, LLC, Research Division - MD & Biotechnology Equity Research Analyst [33]
--------------------------------------------------------------------------------
Sorry. I'm muted. Are you contemplating additional -- are you additional expansion even beyond the TreT patients in your manufacturing plants? Again, they're talking fairly substantial, even about beyond the most recent data. So I'm just kind of curious as to what extent that's being contemplated in MannKind.
--------------------------------------------------------------------------------
Michael E. Castagna, MannKind Corporation - CEO & Director [34]
--------------------------------------------------------------------------------
Yes. We are the CMO for treprostinil DPI, so obviously we're in discussions with them. We'll work accordingly. We have time on our side to scale up where we need to. So we think about a filing within in the next I'll call it 12 months or sooner, plus the FDA review time, that gives you plenty of time to continue to figure out what you need to scale up manufacturing to supply the market. But if I recall, Martine -- maybe it was JPMorgan or investor meeting in the fall, but she sees Tyvaso being a billion dollar product. That gets us very excited as we think about our future. So we always thought this was a great program, a great opportunity to help patients. And I think the patients in the BREEZE study are demonstrating the success of this product as we know there's a rollover phase, and we're seeing what people are doing in the rollover phase and they're staying on the product and they're happy. So I'm excited to help more patients with our technology, and I think it just continues to help demonstrate the platform, what else it can do for other diseases beyond PAH, ILD, diabetes, migraine, et cetera. So Bert, if anything, it just reinforces we got to continue with this pipeline and the company forward and find additional partners to move the company down the road and expand the technology.
--------------------------------------------------------------------------------
Viel wichtiger ist nach lesen des CC-transcripts, dass mit TreT-Programm der real-game changer bevorsteht, 400 Millionen-1 Milliarde Umsatz bei UTHR und Mannkind erhält nach Zuzlassung mindestens 10 % revenues, das wären 40-100 Millionen pro Jahr und damit Mannkind aller Sorgen los!
Das wird innerhalb von 12-15 Monaten kommen und der Kurs bei US Dollar 5 stehen:
Michael E. Castagna, MannKind Corporation - CEO & Director [32]
--------------------------------------------------------------------------------
Yes, Bert. Look, when we entered a deal with United, we knew that trial was coming. Obviously it was early. Wouldn't know the readout was. And having a positive readout, I think it was in WHO III criteria, literally expanded the market dramatically for Tyvaso. And we would expect our TreT program to be able to participate in that market expansion. In fact, it'll probably help penetrate that market because of the easier delivery platform that we have and the administration time and backup supplies you need, et cetera. So, we're very excited. We went into this expecting Tyvaso and PAH, and we felt that alone was a good enough partnership to make this a worthwhile endeavor for both companies. And now this is all upside. And we've got to think through that forecast. We have to think through that as a manufacturing capacity. Think about that in our packaging. So it definitely changes, and we're working closely every week to make sure we continue to supply patients in BREEZE, but also think about the interstitial lung disease indication and how we prepare for that with TreT. So we're very excited about treprostinil. We think that will ride the future capital of the company to ensure continued acceleration of growth as we get out there. And just to remind investors, we will receive double digit royalties upon approval. So this -- Tyvaso today does a little over $400 million. So these are significant when you look out and see where Afrezza revenues will be and Tyvaso on top of it. So, we're excited. Other questions, Bert? You missed our record revenue.
--------------------------------------------------------------------------------
Robert Cummins Hazlett, BTIG, LLC, Research Division - MD & Biotechnology Equity Research Analyst [33]
--------------------------------------------------------------------------------
Sorry. I'm muted. Are you contemplating additional -- are you additional expansion even beyond the TreT patients in your manufacturing plants? Again, they're talking fairly substantial, even about beyond the most recent data. So I'm just kind of curious as to what extent that's being contemplated in MannKind.
--------------------------------------------------------------------------------
Michael E. Castagna, MannKind Corporation - CEO & Director [34]
--------------------------------------------------------------------------------
Yes. We are the CMO for treprostinil DPI, so obviously we're in discussions with them. We'll work accordingly. We have time on our side to scale up where we need to. So we think about a filing within in the next I'll call it 12 months or sooner, plus the FDA review time, that gives you plenty of time to continue to figure out what you need to scale up manufacturing to supply the market. But if I recall, Martine -- maybe it was JPMorgan or investor meeting in the fall, but she sees Tyvaso being a billion dollar product. That gets us very excited as we think about our future. So we always thought this was a great program, a great opportunity to help patients. And I think the patients in the BREEZE study are demonstrating the success of this product as we know there's a rollover phase, and we're seeing what people are doing in the rollover phase and they're staying on the product and they're happy. So I'm excited to help more patients with our technology, and I think it just continues to help demonstrate the platform, what else it can do for other diseases beyond PAH, ILD, diabetes, migraine, et cetera. So Bert, if anything, it just reinforces we got to continue with this pipeline and the company forward and find additional partners to move the company down the road and expand the technology.
--------------------------------------------------------------------------------
Trx 721. kleine Steigerung zur Vorwoche from stocktwits
Antwort auf Beitrag Nr.: 63.694.438 von price-of-success am 15.05.20 14:21:36nicht nur dass die neuen Verschribungen nicht mehr werden, die "Kunden" bleiben auch nicht lange, wie es scheint, da die refills auch nicht signifikant zunehmen.
Schon komisch, dass da wenig geht ...
Schon komisch, dass da wenig geht ...
Antwort auf Beitrag Nr.: 63.694.660 von questionmark am 15.05.20 14:33:20Darin sehe ich das Problem
Warum bleiben die nicht 🤔
Warum bleiben die nicht 🤔
Sehr gute Frage . Warum bloss nicht?
Ich würde stets inhalieren . Spritzen könnte ich niemals
Ich würde stets inhalieren . Spritzen könnte ich niemals
In den USA gabs doch das Problem mit den plötzlich vielen Toten durch Inhalation von E-Zigaretten.
Ich denke das könnte 1 ner der Gründe sein, Sippenhaft?? wobei Inhalation deutlich besser ist als Spritzen---alleine schon das nicht vorhandene Infektion s Risiko durch die fehlende Nadel.
Ich denke das könnte 1 ner der Gründe sein, Sippenhaft?? wobei Inhalation deutlich besser ist als Spritzen---alleine schon das nicht vorhandene Infektion s Risiko durch die fehlende Nadel.
Hat jemand schon die neuen Zahlen zu den Wochenumsätzen?
Vielen Dank vorab :-)
Vielen Dank vorab :-)
Jedoch dies von stocktwits zum gestrigen update durch Mike
Combined Positives Part 1
💥 Pediatric Clinical Trial
💥 Dexcom Clinical Trial
💥 United Therapeutics / MannKind Treprostinil Technosphere Clinical Trial
💥 India Clinical Trial
💥 BluHale Pro Launch
💥 Australia Regulatory Filing Approval
💥 FDA Approval on Advanced Expiration Dating
💥 United Therapeutics Second Molecule
💥 United Therapeutics Milestone Payments
💥 Pipeline Partnership(s)
💥 Pipeline Expansion
💥 Further Debt Reduction
💥 Increased International Expansion
💥 Brazil Afrezza Sales
💥 Receptor Life Sciences
💥 COVID-19 Pipe Program with Immix
💥 Continued Expansion of Vdex Clinics around the country = increased scripts, increased sales, increased cash Bullish
Combined Positives Part 1
💥 Pediatric Clinical Trial
💥 Dexcom Clinical Trial
💥 United Therapeutics / MannKind Treprostinil Technosphere Clinical Trial
💥 India Clinical Trial
💥 BluHale Pro Launch
💥 Australia Regulatory Filing Approval
💥 FDA Approval on Advanced Expiration Dating
💥 United Therapeutics Second Molecule
💥 United Therapeutics Milestone Payments
💥 Pipeline Partnership(s)
💥 Pipeline Expansion
💥 Further Debt Reduction
💥 Increased International Expansion
💥 Brazil Afrezza Sales
💥 Receptor Life Sciences
💥 COVID-19 Pipe Program with Immix
💥 Continued Expansion of Vdex Clinics around the country = increased scripts, increased sales, increased cash Bullish
Combined Positives Part 2
✅ $UTHR $12.5M milestone due this week.
✅ UTHR relationship is “growing”.
✅ UTHR and MNKD executives are meeting next week.
✅ Mike: “TreT royalties will be worth more than our current market cap”.
✅ TreT is as close of a sure bet as exists in biotech.
✅ MNKD did not request or need the $10M tranche from mid-cap. Hmm...
✅ MNKD and DXCM study results will be presented at the ADA next month. Doc Kendall is excited.
✅ 18 Afrezza publications in 2020. Veins of gold.
✅ CGMs do nothing without an Afrezza to improve results.
✅ No need to use shares for dilution.
✅ Countless inquiries from interested potential partners.
✅ From Mike’s post ASM email. This is BIG: “Our new board members have been active and I think you will see they bring an incredible amount of value and experience to our board.” Bullish
✅ $UTHR $12.5M milestone due this week.
✅ UTHR relationship is “growing”.
✅ UTHR and MNKD executives are meeting next week.
✅ Mike: “TreT royalties will be worth more than our current market cap”.
✅ TreT is as close of a sure bet as exists in biotech.
✅ MNKD did not request or need the $10M tranche from mid-cap. Hmm...
✅ MNKD and DXCM study results will be presented at the ADA next month. Doc Kendall is excited.
✅ 18 Afrezza publications in 2020. Veins of gold.
✅ CGMs do nothing without an Afrezza to improve results.
✅ No need to use shares for dilution.
✅ Countless inquiries from interested potential partners.
✅ From Mike’s post ASM email. This is BIG: “Our new board members have been active and I think you will see they bring an incredible amount of value and experience to our board.” Bullish
Wird unser Mannkind doch noch steigen?
Antwort auf Beitrag Nr.: 63.770.008 von price-of-success am 22.05.20 12:21:47Ich denke doch mal ja, alles andere wäre Blödsinn oder?
Stimmt schönes WE
Was geht hier ab omg
TGIF. Us closed on Monday
Hörte TRX 758
Antwort auf Beitrag Nr.: 63.776.305 von price-of-success am 22.05.20 22:51:49Besten Dank, ich würde sagen für Freitag sieht der Kurs doch gar nicht so schlecht aus oder???
Schönes Wochenende
Schönes Wochenende
Die boys drüben sind ganz happy die erwarten mehr
Sh den post unten
Sh den post unten
Short interest ex nasdaq
Shorts kaufen zu. Dyor
Ich würde sagen das ist ein gutes Zeichen :-)
Bin neugierig darauf , wie die Zahlen der shorts bei der nächsten Meldung aussehen
Antwort auf Beitrag Nr.: 63.780.364 von price-of-success am 23.05.20 17:12:00Ich glaube das ganze verpufft hier eh wieder... wiederholt sich halt immer mal...
🙈🙊😱
Antwort auf Beitrag Nr.: 63.781.894 von lobberland am 23.05.20 22:55:05Dann kannste prima traden, billig rein teurer raus....😎
Lobberland
Morgen wissen wir mehr
Morgen wissen wir mehr
Steigt heute früh
Heute leichter Anstieg
Ditto. Was im Busche??
Geruechte in den USA auf stocktwits
Ich weiß auch nicht.Seit 2011 halte ich das Teil.Mal gings aufwärts, langfristig aber nach unten.So langsam glaube ich hier nicht mehr an einen Erfolg.
Verfolgt jemand hier die coop mit UTHR?
Ja . Leider kommt Mnkd nicht in die Gänge
Und: was hatte ich mir gewünscht. Win win für alle
Mnkd, Investoren und Kunden
Egal . Ich lass das laufen
Und: was hatte ich mir gewünscht. Win win für alle
Mnkd, Investoren und Kunden
Egal . Ich lass das laufen
Antwort auf Beitrag Nr.: 63.960.792 von price-of-success am 09.06.20 19:18:05Was wir die ganze Zeit schon vermutet haben, das könnte der wirkliche "Game Changer" werden 😎
Es gibt ebenso die Coop mit UTHR
Covid macht den Weg frei für Inhallationsprodukte, die bis dato leider ein wenig beachtetes Dasein führen :-)
Wäre ja nicht schlecht, wenn sich hier mal der Erfolg einstellen würde. Ob die Zusammenarbeit mit UTHR was bringt werden wir ja sehen, schlechter kann es eigentlich nicht mehr kommen denke ich.
Shortsqueeze ? - war schon so oft in den Vermutungen der Teilnehmer. Das einzige mal wo die Post so richtig abging war im April 2014 - lange ist es her.
Ich selbst halte schon ein ganz paar Aktien, aber eben mit gehörigem Verlust. das hat man davon, wenn man wirklich an eine gute Sache glaubt, welche innovativ erscheint.
Jetzt bleibe ich aber auch drin. Unter Umständen geht ja doch noch was.
Allen Beteiligten viel Erfolg.
Shortsqueeze ? - war schon so oft in den Vermutungen der Teilnehmer. Das einzige mal wo die Post so richtig abging war im April 2014 - lange ist es her.
Ich selbst halte schon ein ganz paar Aktien, aber eben mit gehörigem Verlust. das hat man davon, wenn man wirklich an eine gute Sache glaubt, welche innovativ erscheint.
Jetzt bleibe ich aber auch drin. Unter Umständen geht ja doch noch was.
Allen Beteiligten viel Erfolg.
Heute wieder scripts.
Bin schon gespannt :-)
Sorry doppelpost
From Stocktwits
774 (658)
295 (248)
1.43mm (1.27mm)
774 (658)
295 (248)
1.43mm (1.27mm)
Letzte woche
Top news, Afrezzastudie:
Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
[GlobeNewswire]
GlobeNewswire•June 13, 2020
WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.
The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational “switch” study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed.
Study subjects experienced a significant (0.8%) reduction in A1C levels at the end of the 14-week treatment period after switching from their injected mealtime insulin to Afrezza. Subjects maintained 66-69% “time in range” (time with glucose values in the range of 70-180 mg/dL) and reduced the time spent with glucose <90 mg/dL. Afrezza therapy resulted in a significant improvement in diabetes quality of life scores.
“This study shows that Afrezza treatment—combined with the use of continuous glucose monitoring—can improve overall glucose control while maintaining time in range. Importantly, the study also demonstrates a reduction in blood glucose levels without additional hypoglycemia,” stated Dr. Kipnes. “In addition, after switching to Afrezza, these individuals reported an improvement in quality of life measures. This study demonstrates that by rapidly adjusting Afrezza doses, improved clinical outcomes were possible, and patients reported less burden from their diabetes treatment.”
Die Verkaufszahlen müssten das 10 fache sein, bei solchen Meldungen, big pharma könnte wenn sie wollte, aber big pharma versucht lieber die kleine Mannkind zu zerstören, in welcher perversen Welt leben wir?
MannKind provided financial support and study product for use in this study.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
[GlobeNewswire]
GlobeNewswire•June 13, 2020
WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.
The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational “switch” study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed.
Study subjects experienced a significant (0.8%) reduction in A1C levels at the end of the 14-week treatment period after switching from their injected mealtime insulin to Afrezza. Subjects maintained 66-69% “time in range” (time with glucose values in the range of 70-180 mg/dL) and reduced the time spent with glucose <90 mg/dL. Afrezza therapy resulted in a significant improvement in diabetes quality of life scores.
“This study shows that Afrezza treatment—combined with the use of continuous glucose monitoring—can improve overall glucose control while maintaining time in range. Importantly, the study also demonstrates a reduction in blood glucose levels without additional hypoglycemia,” stated Dr. Kipnes. “In addition, after switching to Afrezza, these individuals reported an improvement in quality of life measures. This study demonstrates that by rapidly adjusting Afrezza doses, improved clinical outcomes were possible, and patients reported less burden from their diabetes treatment.”
Die Verkaufszahlen müssten das 10 fache sein, bei solchen Meldungen, big pharma könnte wenn sie wollte, aber big pharma versucht lieber die kleine Mannkind zu zerstören, in welcher perversen Welt leben wir?
MannKind provided financial support and study product for use in this study.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions
[GlobeNewswire]
GlobeNewswire•June 15, 2020
WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.
The data presented includes:
A comprehensive post hoc analysis of four unique studies assessing the safe and effective dosing of Afrezza in patients with type 1 diabetes1 (Poster 1023)
An analysis demonstrating treatment with Afrezza is associated with weight loss in patients with type 2 diabetes, compared to weight gain with injected mealtime insulin2 (Poster 1024)
An evaluation of a comprehensive two year safety study showing that significant changes in FEV1 (as a measure of pulmonary function) during treatment with Afrezza are both uncommon and generally transient in nature3 (Oral Abstract 235)
”We are pleased to present these clinical studies detailing the safe and effective use of Afrezza at this year’s virtual ADA Scientific Sessions,” stated David Kendall, MD, Chief Medical Officer MannKind. “These studies provide further support of the effectiveness and clinical safety of Afrezza therapy and offer important insights on effective dosing of Afrezza, the favorable effect of Afrezza on body weight, and the improvement in clinical outcomes possible when converting patients to Afrezza therapy.”
Highlights of the presentations are described below. See the appendix for presentation details.
Poster 1023: Dose Titration and Clinical Effects of Inhaled Technosphere® Insulin Compared with Mealtime Subcutaneous (SC) Analog Insulin Therapy in Type 1 Diabetes (T1D)
Ultra rapid-acting Afrezza can be safely and effectively dosed at 1.5 to 2.0 times that of injected mealtime insulin
This dosing ratio appears to be consistent across a range of A1C responses
Afrezza’s ultra rapid-acting profile may supersede the perceived precision of injected mealtime insulin dosing and provides patients the ability to flexibly dose based on glycemic response
Poster 1024: Technosphere® Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (aspart) 70/30 Mixture in Type 2 DM
Patients with type 2 diabetes treated with Afrezza showed modest weight loss while those treated with insulin aspart or insulin aspart mix resulted in weight gain
The weight difference estimate between Afrezza and insulin aspart was 1.83 pounds
The weight difference estimate between Afrezza and biaspart insulin was 3.17 pounds
The effect on body weight was independent of the magnitude of improvement in glucose control
Oral Abstract 235: Incidence of Significant Changes in Pulmonary Function during A 2-year Study with Inhaled Technosphere® Insulin
Prior clinical studies have shown a modest (~40 ml) difference in mean change in FEV1 over two years when comparing treatment with Afrezza to other diabetes therapies
The majority (88%) of individuals treated with Afrezza had no significant change in FEV1 measured at any time
Overall, 98% of patients on Afrezza (vs. 99% of usual care) had either no significant change (≥15%) or were observed to have only a transient change in FEV1 over the two years of study
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
[GlobeNewswire]
GlobeNewswire•June 15, 2020
WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020.
The data presented includes:
A comprehensive post hoc analysis of four unique studies assessing the safe and effective dosing of Afrezza in patients with type 1 diabetes1 (Poster 1023)
An analysis demonstrating treatment with Afrezza is associated with weight loss in patients with type 2 diabetes, compared to weight gain with injected mealtime insulin2 (Poster 1024)
An evaluation of a comprehensive two year safety study showing that significant changes in FEV1 (as a measure of pulmonary function) during treatment with Afrezza are both uncommon and generally transient in nature3 (Oral Abstract 235)
”We are pleased to present these clinical studies detailing the safe and effective use of Afrezza at this year’s virtual ADA Scientific Sessions,” stated David Kendall, MD, Chief Medical Officer MannKind. “These studies provide further support of the effectiveness and clinical safety of Afrezza therapy and offer important insights on effective dosing of Afrezza, the favorable effect of Afrezza on body weight, and the improvement in clinical outcomes possible when converting patients to Afrezza therapy.”
Highlights of the presentations are described below. See the appendix for presentation details.
Poster 1023: Dose Titration and Clinical Effects of Inhaled Technosphere® Insulin Compared with Mealtime Subcutaneous (SC) Analog Insulin Therapy in Type 1 Diabetes (T1D)
Ultra rapid-acting Afrezza can be safely and effectively dosed at 1.5 to 2.0 times that of injected mealtime insulin
This dosing ratio appears to be consistent across a range of A1C responses
Afrezza’s ultra rapid-acting profile may supersede the perceived precision of injected mealtime insulin dosing and provides patients the ability to flexibly dose based on glycemic response
Poster 1024: Technosphere® Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (aspart) 70/30 Mixture in Type 2 DM
Patients with type 2 diabetes treated with Afrezza showed modest weight loss while those treated with insulin aspart or insulin aspart mix resulted in weight gain
The weight difference estimate between Afrezza and insulin aspart was 1.83 pounds
The weight difference estimate between Afrezza and biaspart insulin was 3.17 pounds
The effect on body weight was independent of the magnitude of improvement in glucose control
Oral Abstract 235: Incidence of Significant Changes in Pulmonary Function during A 2-year Study with Inhaled Technosphere® Insulin
Prior clinical studies have shown a modest (~40 ml) difference in mean change in FEV1 over two years when comparing treatment with Afrezza to other diabetes therapies
The majority (88%) of individuals treated with Afrezza had no significant change in FEV1 measured at any time
Overall, 98% of patients on Afrezza (vs. 99% of usual care) had either no significant change (≥15%) or were observed to have only a transient change in FEV1 over the two years of study
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.
Es müsste 12.5 mio geben von Technosphere
USD aktuell. 1,54
Mnkd. Jetzt 1,64
Wer weiss warum??
Antwort auf Beitrag Nr.: 64.024.536 von price-of-success am 15.06.20 19:41:10Keine Ahnung schau gerade rein nachdem ich den ganzen Tag draußen gearbeitet habe.
Könnte mit Covid zu tun haben?? warten wirs mal ab und schauen ob wir was finden 😎
Könnte mit Covid zu tun haben?? warten wirs mal ab und schauen ob wir was finden 😎
Antwort auf Beitrag Nr.: 64.024.536 von price-of-success am 15.06.20 19:41:10Gefunden:
https://www.globenewswire.com/news-release/2020/06/15/204812…
Hammer News einfach mal lesen, das is wirklich klasse!!!!
https://www.globenewswire.com/news-release/2020/06/15/204812…
Hammer News einfach mal lesen, das is wirklich klasse!!!!
Bitte den Gewichtsverlust der Patienten beachten, der hat ne Menge positiver Nebeneffekte für Herz Kreislauferkrankungen---super Nachrichten wie ich finde :-)
Drüben galten die 1,64 Usd
https://investors.mannkindcorp.com/news-releases/news-releas…
Jetzt wird mir auch klar, warum die Verschreibungszahlen nicht stark gestiegen sind. Man hatte wohl Bedenken das durch die Einnahme die Lungenfunktion eingeschränkt werden könnte. Wenn ich das richtig lese, konnte in den Studien dazu nichts negatives festgestellt werden. :-)
Jetzt bin ich echt gespannt wie Afrezzar weiter geht, + die Phantasie neuer Inhallationsprodukte die ggf.als Ansatz zur Behandlung von Covid 19 Patienten dienen könnten???
VG
Jetzt wird mir auch klar, warum die Verschreibungszahlen nicht stark gestiegen sind. Man hatte wohl Bedenken das durch die Einnahme die Lungenfunktion eingeschränkt werden könnte. Wenn ich das richtig lese, konnte in den Studien dazu nichts negatives festgestellt werden. :-)
Jetzt bin ich echt gespannt wie Afrezzar weiter geht, + die Phantasie neuer Inhallationsprodukte die ggf.als Ansatz zur Behandlung von Covid 19 Patienten dienen könnten???
VG
Sehe auch wieder etwas optimistischer in die Zukunft. Trotzdem ist es noch ein weiter Weg.
Kein Big Player kommt hier aus der Deckung um unterstützend zu wirken.Andere Bio Pharma Firmen werden ruckzuck geschluckt, hier aber kommt nichts.Trotzdem denke ich, dass Fortschritt sich auf Dauer nicht aufhalten lässt.
Schaumer mal was noch so kommt.
Grüße.
Kein Big Player kommt hier aus der Deckung um unterstützend zu wirken.Andere Bio Pharma Firmen werden ruckzuck geschluckt, hier aber kommt nichts.Trotzdem denke ich, dass Fortschritt sich auf Dauer nicht aufhalten lässt.
Schaumer mal was noch so kommt.
Grüße.
wenn das "Teil" heute wieder runter geht, bin ich erst mal raus. Was soll den groß passieren?
Die Zahlen sind seit ewigen Zeiten gleich und gute Nachrichten scheint die Investoren nicht zu interessieren
Die Zahlen sind seit ewigen Zeiten gleich und gute Nachrichten scheint die Investoren nicht zu interessieren
Antwort auf Beitrag Nr.: 64.035.201 von Signal999 am 16.06.20 16:18:25Den Hype um Covid 19 hatte vorher keiner auf dem Schirm, das ändert die Regeln gewaltig und auch die Möglichkeiten von Inhallationsprodukten werden komplett neu bewertet.
Was vorher 0 Interesse einbrachte kommt jetzt in den Fokus---so ist das manchmal
Das dürfte auch Begehrlichkeiten in Sachen möglicher Übernahme wecken?? 😎
Was vorher 0 Interesse einbrachte kommt jetzt in den Fokus---so ist das manchmal
Das dürfte auch Begehrlichkeiten in Sachen möglicher Übernahme wecken?? 😎
Hier gehts um ganz was Anderes, unser Partner UTHR präsentiert das inhalierbare TreT von Mannkind, das wird ein Superdeal:
UNITED THERAPEUTICS ANNOUNCES INCREASE DATA PRESENTATION AT AN AMERICAN THORACIC SOCIETY VIRTUAL SESSION
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Wednesday, June 17, 2020: United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at a Breaking News Session hosted by the American Thoracic Society (ATS) on June 24, 2020.
The virtual presentation, entitled “Inhaled Treprostinil in Interstitial Lung Disease Associated Pulmonary Hypertension: The INCREASE Study” will be given by Dr. Steven D. Nathan, M.D., Director of the Advanced Lung Disease Program and Director of the Lung Transplant Program at Inova Fairfax Hospital. The presentation will take place on Wednesday, June 24, 2020 from 2:53 to 3:18 p.m., Eastern Daylight Time. Additional information about the ATS session, entitled “Breaking News: Clinical Trial Results in Pulmonary Medicine,” including participant registration information, can be found on the ATS International Conference website at https://conference.thoracic.org/program/virtual-clinical-tri… Those interested in viewing the presentation should register free of charge in advance as a replay of the presentation will not be immediately available.
As previously announced on February 24, 2020, Tyvaso increased six-minute walk distance (6MWD) by 21 meters versus placebo (p=0.0043, Hodges-Lehmann estimate) after 16 weeks of treatment. Benefits of Tyvaso were observed across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and dose.
Significant improvements were also observed in each of the study’s secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at Week 12, and change in trough 6MWD at week 15. Treatment with Tyvaso of up to 12 breaths per session, four times daily, in the INCREASE study was well tolerated and the safety profile was consistent with previous Tyvaso studies in pulmonary arterial hypertension and known prostacyclin-related adverse events (see the Important Safety Information below under “About Tyvaso”).
United Therapeutics recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration seeking to revise the Tyvaso label to reflect the outcome of the INCREASE study.
About INCREASE
INCREASE was a phase III, multicenter, randomized, double-blinded, placebo-controlled, 16-week, parallel group study of Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease. Enrollment into the study was completed in August 2019 with a total of 326 patients. Patients were randomized in a 1:1 Tyvaso (n=163) or placebo (n=163).
The primary endpoint was to evaluate the change in 6MWD measured at peak exposure from Baseline to Week 16.
Secondary objectives of the study included:
• Change in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) from Baseline to Week 16
• Time to clinical worsening calculated as the time from randomization until one of the following criteria are met:
o Hospitalization due to a cardiopulmonary indication
o Decrease in 6MWD >15% from Baseline directly related to disease under study, at two consecutive visits, and at least 24 hours apart
o Death (all causes)
o Lung transplantation
• Change in peak 6MWD from Baseline to Week 12
• Change in trough 6MWD from Baseline to Week 15
Exploratory objectives of the study evaluated changes in peak 6MWD at Week 4 and Week 8, changes in quality of life as measured by the St. George’s Respiratory Questionnaire (SGRQ), and change in distance saturation product (DSP). Further exploratory analysis will also be performed on biomarkers and pharmacogenomics from this study.
Additional study results will be made available through scientific disclosure in upcoming peer-reviewed publications.
About TYVASO® (treprostinil) Inhalation Solution
For the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
UNITED THERAPEUTICS ANNOUNCES INCREASE DATA PRESENTATION AT AN AMERICAN THORACIC SOCIETY VIRTUAL SESSION
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Wednesday, June 17, 2020: United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at a Breaking News Session hosted by the American Thoracic Society (ATS) on June 24, 2020.
The virtual presentation, entitled “Inhaled Treprostinil in Interstitial Lung Disease Associated Pulmonary Hypertension: The INCREASE Study” will be given by Dr. Steven D. Nathan, M.D., Director of the Advanced Lung Disease Program and Director of the Lung Transplant Program at Inova Fairfax Hospital. The presentation will take place on Wednesday, June 24, 2020 from 2:53 to 3:18 p.m., Eastern Daylight Time. Additional information about the ATS session, entitled “Breaking News: Clinical Trial Results in Pulmonary Medicine,” including participant registration information, can be found on the ATS International Conference website at https://conference.thoracic.org/program/virtual-clinical-tri… Those interested in viewing the presentation should register free of charge in advance as a replay of the presentation will not be immediately available.
As previously announced on February 24, 2020, Tyvaso increased six-minute walk distance (6MWD) by 21 meters versus placebo (p=0.0043, Hodges-Lehmann estimate) after 16 weeks of treatment. Benefits of Tyvaso were observed across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and dose.
Significant improvements were also observed in each of the study’s secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at Week 12, and change in trough 6MWD at week 15. Treatment with Tyvaso of up to 12 breaths per session, four times daily, in the INCREASE study was well tolerated and the safety profile was consistent with previous Tyvaso studies in pulmonary arterial hypertension and known prostacyclin-related adverse events (see the Important Safety Information below under “About Tyvaso”).
United Therapeutics recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration seeking to revise the Tyvaso label to reflect the outcome of the INCREASE study.
About INCREASE
INCREASE was a phase III, multicenter, randomized, double-blinded, placebo-controlled, 16-week, parallel group study of Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease. Enrollment into the study was completed in August 2019 with a total of 326 patients. Patients were randomized in a 1:1 Tyvaso (n=163) or placebo (n=163).
The primary endpoint was to evaluate the change in 6MWD measured at peak exposure from Baseline to Week 16.
Secondary objectives of the study included:
• Change in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) from Baseline to Week 16
• Time to clinical worsening calculated as the time from randomization until one of the following criteria are met:
o Hospitalization due to a cardiopulmonary indication
o Decrease in 6MWD >15% from Baseline directly related to disease under study, at two consecutive visits, and at least 24 hours apart
o Death (all causes)
o Lung transplantation
• Change in peak 6MWD from Baseline to Week 12
• Change in trough 6MWD from Baseline to Week 15
Exploratory objectives of the study evaluated changes in peak 6MWD at Week 4 and Week 8, changes in quality of life as measured by the St. George’s Respiratory Questionnaire (SGRQ), and change in distance saturation product (DSP). Further exploratory analysis will also be performed on biomarkers and pharmacogenomics from this study.
Additional study results will be made available through scientific disclosure in upcoming peer-reviewed publications.
About TYVASO® (treprostinil) Inhalation Solution
For the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
Wir haben es uns verdient
Auch als Kunden
Es geht Richtung 52-Wochen-Hoch...
Bin hier seit Jahren mit EK 5$ investiert, wenn’s so weiter geht mit den positiven News, bin ich optimistisch wieder +/- 0 zu sein...
Bin hier seit Jahren mit EK 5$ investiert, wenn’s so weiter geht mit den positiven News, bin ich optimistisch wieder +/- 0 zu sein...
*noch in diesem Jahr 😉
Antwort auf Beitrag Nr.: 64.049.124 von Stoxtrayder am 17.06.20 16:52:13Sieht gut aus, daran könnte man sich gewöhnen 😎
Antwort auf Beitrag Nr.: 64.049.115 von Stoxtrayder am 17.06.20 16:51:40
dann kauf nach und mach gewinn
Zitat von Stoxtrayder: Es geht Richtung 52-Wochen-Hoch...
Bin hier seit Jahren mit EK 5$ investiert, wenn’s so weiter geht mit den positiven News, bin ich optimistisch wieder +/- 0 zu sein...
dann kauf nach und mach gewinn
Immer wenn ich gedacht habe es geht voran, kam dann bisher stets der Abwärtstrend.
Mein EK ist 4,85 Dollar und das mit sehr vielen Stücken.Wenn ich an die letzten Jahre denke mit dem Aktiensplit, die "Flucht" an die Börse von Tel Aviv , die Finanzprobleme usw.,da wirds einem gruselig.Schade, dass Alfred Mann damals also 2014 schon sehr alt war.10 Jahre jünger und ein fähigeres Management als wie damals, wer weiß was und wie es gekommen wäre.
Auch wie damals S....i aus Frankreich sich hat aufgeführt war nicht anständig. Hoffen wir mal das Beste.✌
Mein EK ist 4,85 Dollar und das mit sehr vielen Stücken.Wenn ich an die letzten Jahre denke mit dem Aktiensplit, die "Flucht" an die Börse von Tel Aviv , die Finanzprobleme usw.,da wirds einem gruselig.Schade, dass Alfred Mann damals also 2014 schon sehr alt war.10 Jahre jünger und ein fähigeres Management als wie damals, wer weiß was und wie es gekommen wäre.
Auch wie damals S....i aus Frankreich sich hat aufgeführt war nicht anständig. Hoffen wir mal das Beste.✌
15 Mio Aktien bereits gehandelt, war schon lange nicht mehr der Fall...
Btw. 30 Mio Aktien waren Ende Mai noch leerverkauft:
https://www.nasdaq.com/market-activity/stocks/mnkd/short-int…
Btw. 30 Mio Aktien waren Ende Mai noch leerverkauft:
https://www.nasdaq.com/market-activity/stocks/mnkd/short-int…
Antwort auf Beitrag Nr.: 64.051.809 von Signal999 am 17.06.20 19:59:52👍 Richtig, zur Strafe haben die jetzt einen Amerikaner als Chef bekommen, na wenns hilft???
Hat einer schon die Wochenzahlen gefunden??? VG und vielen Dank fürs einstellen :-)
Mannkind hat am 24. Juni 2020 eine Präsentation und UTHR stellt am selben Tag die Ergebnisse von unserem inhalierbaren Treprostinil vor, ich glaube kein Zufall, yes we hope:
MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
[GlobeNewswire]
GlobeNewswire•June 17, 2020
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.
A webcast of the presentation will be posted under the investors section of MannKind’s website under events & presentations or can be accessed at www.lythampartners.com/virtual. A replay of the presentation will be available following the event.
Management will also be participating in virtual one-on-one meetings with institutional investors on June 24, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at blum@lythampartners.com or visit www.lythampartners.com/virtual.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Phone: (818) 661-5000
Email: ir@mannkindcorp.com
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at a Breaking News Session hosted by the American Thoracic Society (ATS) on June 24, 2020.
MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
[GlobeNewswire]
GlobeNewswire•June 17, 2020
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.
A webcast of the presentation will be posted under the investors section of MannKind’s website under events & presentations or can be accessed at www.lythampartners.com/virtual. A replay of the presentation will be available following the event.
Management will also be participating in virtual one-on-one meetings with institutional investors on June 24, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at blum@lythampartners.com or visit www.lythampartners.com/virtual.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Phone: (818) 661-5000
Email: ir@mannkindcorp.com
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at a Breaking News Session hosted by the American Thoracic Society (ATS) on June 24, 2020.
Antwort auf Beitrag Nr.: 64.089.837 von Magnetfeldfredy am 19.06.20 15:29:09Na dann, Wochenende genießen und mit Hoffnung in die neue Woche starten.🙂✌
Antwort auf Beitrag Nr.: 64.089.885 von Signal999 am 19.06.20 15:32:31...kann mal einer posten, wie die Wochenzahlen letzte Woche waren
danke
danke
Antwort auf Beitrag Nr.: 61.067.143 von Magnetfeldfredy am 19.07.19 18:56:51sorry, waren schon gepostet.....steigen ja sehr langsam an
Neues Ziel: 3 Usd. Nach dem 24.6?
Antwort auf Beitrag Nr.: 64.129.159 von price-of-success am 22.06.20 16:40:56Als Zwischenhoch ja, dann Richtung 5$ würde ich sagen
Bitte 5 und höher.
Antwort auf Beitrag Nr.: 64.129.525 von price-of-success am 22.06.20 17:00:34Je nach News, halte ich s locker für möglich 👍
Weiter so.
Heute 12Uhr MEP sollen die News kommen wenn ich richtig gelesen habe? :-)
Antwort auf Beitrag Nr.: 64.152.904 von pegasusorion am 24.06.20 07:19:16Ich denke 12 pm et (Eastern Time) ist bei uns dann 18 Uhr heute. Bin auch gespannt und frage mich warum der Kurs gestern so stark wieder zurückgekommen ist. Schau mer mal.
Beitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+0,27 | |
-0,52 | |
-0,07 | |
-4,02 | |
0,00 | |
+1,80 | |
-0,04 | |
-3,45 | |
-4,35 | |
+1,99 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
223 | ||
99 | ||
91 | ||
80 | ||
53 | ||
47 | ||
45 | ||
42 | ||
41 | ||
32 |
Mannkind, Game-Chancer in Sachen Diabetik?